Vitamin D during pregnancy, lactation, and childhood: Vitamin D deficiency rickets in New Zealand children and
Vitamin D supplementation during exclusive lactation to improve both infant and maternal 25 hydroxyvitamin D status by Wheeler, Benjamin John
i 
 
Vitamin D during pregnancy, lactation, 
and childhood
 
Vitamin D deficiency rickets in New Zealand children  
And 
Vitamin D supplementation during exclusive lactation to improve both 
infant and maternal 25-hydroxyvitamin D status 
 
Benjamin John Wheeler 
 
 
A thesis submitted for the degree of: 
Doctor of Philosophy 
Otago School of Medicine 






Vitamin D is essential for calcium homeostasis and mineralisation of the skeleton.  Vitamin D 
deficiency during pregnancy, infancy and childhood is common, and severe deficiency can lead 
to rickets.  Rickets is a mineralisation defect at the epiphyseal growth plates specific to growing 
children.  However, currently there are no national statistics on vitamin D deficiency rickets in 
New Zealand children, nor any data on longitudinal vitamin D status during pregnancy and 
lactation for the southern hemisphere.  To prevent rickets and severe vitamin D deficiency, 
many countries use dietary fortification and recommend daily vitamin D supplementation to 
expectant mothers during pregnancy and infants during exclusive breastfeeding.  This is not 
currently the case in New Zealand. 
Aims 
1) To prospectively determine the annual incidence and characteristics of vitamin D deficiency 
rickets in New Zealand children 
2) To determine the effect of two different intermittent monthly doses of maternal 
cholecalciferol on infant and maternal vitamin D status 
3) To describe longitudinal vitamin D status during pregnancy and lactation in healthy women 
and their infants in Dunedin, New Zealand (latitude 45°S)    
Methods 
The New Zealand Paediatric Surveillance Unit (NZPSU) was utilised to prospectively collect cases 
of vitamin D deficiency rickets (defined by serum 25-hydroxyvitamin D <50nmol/L and elevated 
alkaline phosphatase levels, and/or radiological rickets) in New Zealand for 36 months between 
July 2010 and June 2013 inclusive.  Concurrently, a three arm, randomised, double-blind, 
placebo-controlled trial recruited women from Dunedin (45°S) who were planning to exclusively 
breastfed. Women (n=90) were randomly assigned to receive either cholecalciferol (50,000 IU 
or 100,000 IU) or placebo monthly from week 4 to week 20 postpartum.  The treatment effects 
relative to placebo were then estimated using a linear fixed-effects regression model.  In 
addition, longitudinal data (3 antenatal and 2 postnatal time points) on vitamin D status during 
pregnancy and lactation (out to week 20 postpartum) was analysed (total n=126).  Participants 
were the n=90 from the aforementioned trial, in combination with a further n=36 similarly 
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recruited historical control mother-infant pairs.  Data at the final postnatal time point week 20 
was included only for those in the placebo and historical control groups.    
Results 
Fifty-eight children with confirmed vitamin D deficiency rickets were identified using the NZPSU.  
Median age was 1.4 years (range 0.3-11), and 95% were born in New Zealand; however the 
majority of mothers (68%) were not.  The overall annual incidence of rickets in New Zealand 
children aged < 15 years was 2.2/100,000 (95%CI 1.4-3.5); with the incidence in those aged <3 
years greater at 10.5/100,000 (95%CI 6.7-16.6).  Key risk factors identified were: darker skin 
colour, Indian and African ethnicity, age <3 years, exclusive breastfeeding, southern latitude, 
and season (winter/spring).   
In the intervention trial, after 16 weeks of supplementation, maternal vitamin D status was 
significantly higher in both the 50,000 IU/month and 100,000 IU/month groups.  For infants, the 
unadjusted mean changes in vitamin D status were not significantly different from the placebo 
group.  However, after adjustment for season of birth, vitamin D-fortified formula intake, and 
skin colour the mean effect size for the 100,000IU/month group was 19.1nmol/L (95%CI 2.5-
35.6; P=0.025).     
Analysis of the longitudinal pregnancy and lactation data for 126 maternal and infant pairs 
revealed high rates of both maternal and infant vitamin D deficiency during pregnancy and the 
first 20 weeks postnatal (71% still exclusively breastfeeding).  Maternal vitamin D deficiency 
(25OHD < 50nmol/L) was seen at one or more time points (in those with data at all time points) 
during the full longitudinal study in 65% (52/80).  Infant vitamin D deficiency was more common, 
seen in 76% at one or more time points.  Deficiency at birth was found in 68% of infants, mean 
cord blood of 41nmol/L.  At 20 weeks postpartum three infants with severe deficiency had 
developed secondary hyperparathyroidism (serum PTH values between 120 and 281pg/ml - 
Upper limit normal ≤65pg/ml).  Season was the main variable affecting vitamin D status, with 
considerable variation in longitudinal status when examined by season of conception.  In 
addition, stage of pregnancy also appears to exert an independent effect on vitamin D status 
once all other variables in the model were accounted for.   
Conclusions 
This thesis has demonstrated that in New Zealand, vitamin D deficiency during pregnancy, 
lactation and childhood remains an important health concern.  In Dunedin, at 45°S, both infant 
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and maternal deficiency during pregnancy and lactation is very common, and sometimes 
severe.  Vitamin D deficiency rickets, the most severe manifestation of vitamin D deficiency is 
still occurring in New Zealand, with a higher incidence in children with mothers from India and 
Africa, and in children younger than three years who are currently or previously breastfed.  
While infancy and breastfeeding are risk factors for rickets, high-dose monthly maternal 
supplementation may also hold promise as an alternative dual maternal and infant 
supplementation strategy.  Further research is now required to expand on the findings of the 
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The broad aim of this thesis is to investigate aspects of the role of vitamin D during pregnancy, 
lactation, and childhood.  More specifically, my thesis contributes to describing the incidence 
and clinical characteristics of vitamin D deficiency rickets in New Zealand children, explores a 
potential option for dual maternal and neonatal supplementation during exclusive lactation, 
and examines vitamin D status longitudinally spanning pregnancy and the first 5 months of 
lactation.  These are questions that, in the New Zealand setting, have hitherto scarcely been 
addressed.     
The concept for this thesis developed out of my clinical experience in paediatrics and paediatric 
endocrinology, in particular through my patients over the past 15 years who I have diagnosed 
and treated for childhood vitamin D deficiency rickets.  My Master’s thesis (which subsequently 
converted to this PhD thesis) commenced with the New Zealand Paediatric surveillance unit 
study detailed in chapter 2, which investigates the characteristics and incidence of vitamin D 
deficiency rickets in New Zealand children.  This project gave me a deeper understanding of 
rickets and vitamin D deficiency in the New Zealand context, and it was therefore logical to 
progress to an intervention study, which at its core seeks to test an intervention aimed at 
improving infant vitamin D status and thus potentially preventing rickets.  In doing so, I also 
intentionally commenced recruiting early in pregnancy to assemble a longitudinal pregnancy 
cohort from which detailed descriptive data on vitamin D status in pregnancy and lactation 
could be derived – a first for the southern hemisphere, and one of the largest such studies to 
date.   
The following literature review covers the background to these studies, in particular with a focus 
on vitamin D, rickets, and factors in pregnancy, lactation, and childhood that may contribute to 







1.1 Literature review search strategy 
For the following section a review of the literature was undertaken using various search 
strategies.  As this thesis spanned multiple years of part time work, this has been a fluid process 
and has required updating on a regular basis.  PubMed (National Library of Medicine, Bethesda, 
MD, USA) was used to perform initial and ongoing literature searches.  The initial search strategy 
was similar to that used for the excellent and very thorough Institute of Medicine review on this 
topic (IOM, now known as the National Academy of Medicine)(A. Catharine Ross & Institute of 
Medicine (U. S.). Committee to Review Dietary Reference Intakes for Vitamin D and Calcium., 
2011), and was as follows: first general searches on vitamin D, bone health and calcium.  Articles 
were then screened by title, followed by abstract and full text as needed.  This helped establish 
the primary literature.  Secondary searches of this literature were then conducted focusing 
separately on vitamin D status and epidemiology, rickets, pregnancy, and lactation.  The 
Cochrane library was also used.  Additional hand searches were performed on reference lists of 
relevant papers and systematic reviews such as the IOM report (above).  A less structured 
literature search related to more general aspects of bone health and development was also 
performed.  All searches were limited to English language material (although relevant historical 
non-English papers were identified in reference list searches), but no time limits were placed 
on publication date, in order to identify evolution in the nature of the field over time, this was 











1.2 Vitamin D  
With currently over 50,000 Ovid® Medline articles mentioning vitamin D as a key word, Vitamin 
D remains one of the most talked about and controversial vitamins of the last 100 years.  This 
interest stems from its importance to bone health, the ease of with which it is measured 
clinically (and the expense generated from this), and the ongoing debate about possible roles 
outside of bone health. 
Vitamin D is unique among vitamins in that its principle source in humans (and most other living 
plants and terrestrial animals (Wagner, Taylor, Dawodu, Johnson, & Hollis, 2012)) is not dietary 
but comes from endogenous production following ultraviolet B (UVB) exposure from sunlight.  
The Oxford English dictionary defines a vitamin as:  
“Any of a diverse group of organic compounds of which small quantities 
are needed in the diet because they have a distinct biochemical role, often 
as coenzymes, and cannot be adequately synthesized by the body, so that 
in most cases a deficiency produces characteristic symptoms or disease.” 
(Oxford English Dictionary)  
Therefore, following this classic definition, vitamin D is not in fact a “vitamin”, and a more 
accurate name might be a steroid prohormone.  On the other hand, given that many humans 
now struggle to achieve the appropriate UVB exposure to ensure adequate vitamin D status, 
dietary vitamin supplementation remains vital, and thus using the word vitamin – as I shall 
continue to do in this document – is not inappropriate, not to mention the weight of history in 
favour of its use.   
 
1.2.1 Structure, Synthesis, and metabolism 
There are two main forms of vitamin D of relevance to humans.  These are Cholecalciferol 
(vitamin D3) and ergocalciferol (vitamin D2) (Figure 1).  These combined with a number of other 
metabolites I will henceforth collectively refer to as vitamin D unless otherwise specified.  
Cholecalciferol, the most commonly used form of vitamin D supplement in New Zealand, is 
pharmaceutically manufactured by the ultraviolet irradiation of 7-dehydrocholesterol obtained 
from Lanolin (a wax obtained from the wool of sheep, and other wool producing animals), 
whereas vitamin D2 is produced via irradiation of ergosterol from yeast (M. F. Holick, 2007, 
2009).   
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Cholecalciferol is also the form produced endogenously in humans and other vertebrates.  It is 
a secosteroid (based on four carbon rings like all steroids, but with the B ring broken) (Hochberg, 
2003).  This process occurs following skin exposure of 7-dehydrocholesterol (found in the 
epidermis and dermis) to UVB radiation from the sun (wavelength 290 – 315 nm) (Elder & 
Bishop, 2014; M. F. Holick, 2007).  Pre-vitamin D3 is first formed, and then when combined with 
heat is rapidly converted to cholecalciferol.  Excess pre-vitamin D3 is however broken down to 
inactive photoproducts (lumisterol and tachysterol) with ongoing UVB exposure (M. F. Holick, 
1987), which is the explanation for why too much sunlight exposure does not causing vitamin D 
toxicity.   
Cholecalciferol is biologically inert and must undergo two separate hydroxylation steps, similar 
to ergocalciferol, to reach the biologically active hormone 1,25-dihydroxyvitamin D3 
(1,25(OH)2D).  Vitamin D is transported to the liver in the venous circulation bound to the 
vitamin D binding protein (DeLuca, 2004; Elder & Bishop, 2014).  Here (in the liver) the first 
hydroxylation step [catalysed by the enzyme vitamin D 25-hydroxylase (CYP2R1)] occurs to form 
25-hydroxyvitamin D (25OHD3).  25OHD3 is the major circulating form of vitamin D, and due to 
its half-life of one month, makes it the main form clinically measured to determine vitamin D 
status (DeLuca, 2004; Elder & Bishop, 2014; M. F. Holick, 2007, 2009; Vieth, 1999).  The second 
hydroxylation step predominantly occurs in the kidney (but also in some tissues including 
macrophages and the placenta) and is under the control of the 1α-hydroxlase enzyme 
(CYP27B1).  The end product of these sequential reactions is 1,25(OH)2D, the active form of 
vitamin D, which exerts its biological effect by subsequent binding to the vitamin D receptor 
(VDR).  See Figure 1 as an overview of the above process.     
The final part of this metabolic process is inactivation of 1,25(OH)2D.  This occurs via the process 
of 24-hydroxylation (DeLuca, 2004; M. F. Holick, 2007) carried out by 24-hydroxylase (CYP24).  
24-hydroxylase converts 1,25(OH)2D firstly to calcitoic acid which is excreted in bile(Elder & 
Bishop, 2014; M. F. Holick, 2007) (See Figure 2).  Of interest clinically, autosomal inherited loss 
of function mutations in CYP24A1 have recently been discovered as a cause of infantile 
hypercalcaemia (Schlingmann et al., 2011).  These mutations lead to a prolonged activity of 
1,25(OH)2D, due to failure of inactivation; and in consequence, in spite of a normally non-toxic 






Figure 1: The structure and metabolism of vitamin D (Hochberg, 2003). © Copyright S. Karger 









Figure 2: The metabolism and function of vitamin D.  Reproduced with permission from (M. 






The primary role of vitamin D is in maintenance of calcium and bone homeostasis (DeLuca, 
2004; M. F. Holick, 2007).  This is complex process is illustrated in Figure 2.  Extracellular calcium 
is of critical importance for normal muscle and nerve cell function, and is maintained within a 
constant and tight range (Cooper & Gittoes, 2008; DeLuca, 2004).  Both hypo- and 
hypercalcaemia rapidly lead to symptoms and can be life threatening.  Classic symptoms of 
these are shown in Table 1.   
 
Table 1: Clinical manifestations of hypo- and hypercalcaemia 
Hypocalcaemia 
















Flushing, fatigue, weight loss, anorexia 
Cardiovascular: 
Various ECG abnormalities including - Prolonged PR interval, widened 
QRS complex, shortened QT interval, bundle branch block, 
bradycardia 
Arrhythmias and cardiac arrest  





Polyuria and dehydration 
Polydipsia and thirst  
Renal stones / nephrocalcinosis 
 Neurological: 


















As shown in Figure 2 and Table 2, both vitamin D and parathyroid hormone (PTH) are at play to 
regulate calcium.  PTH is released from the four parathyroid glands in response to decreasing 
ionised calcium, detected by the calcium sensing receptor (CaSR) located on the surface of 
parathyroid cells(Hochberg, 2003).  Firstly, PTH works on the kidney to activate 1α-
hydroxylation to stimulate 1,25(OH)2D synthesis.  Secondly, also at the kidney, PTH acts at the 
proximal tubule to increase calcium absorption, and decrease phosphate resorption.  PTH in 
concert with 1,25(OH)2D also has direct bone effects (described below).    
Vitamin D acts to increase calcium via three main mechanisms, all mediated via the VDR: 1) 
increasing intestinal calcium and phosphate absorption.  This is done via 1,25(OH)2D interaction 
with the intestinal VDR (DeLuca, 2004; M. F. Holick, 2007); 2) Mobilisation of calcium stores 
from bone.  Acting in conjunction with parathyroid hormone (both must be present) 1,25(OH)2D 
stimulates osteoblasts to produce Receptor Activator Nuclear Factor-κB ligand (RANKL).  RANKL 
acts on Receptor Activator Nuclear Factor-κB (RANK) and these are essential regulators of 
osteoclast function (DeLuca, 2004; Wada, Nakashima, Hiroshi, & Penninger, 2006).  This process 
stimulates osteoclastogenesis as well as activating inactive osteoclasts, both processes leading 
to bone resorption and thus liberation of stored calcium and phosphate.  Of interest, sex 
steroids such as oestrogen and androgens inhibit RANKL induced osteoclast stimulation and 
their loss is one mechanism for increased post-menopausal osteoporosis (Wada et al., 2006); 
lastly 3) again in conjunction with PTH (highlighted above), 1,25(OH)2D acts on the kidney to 
directly increase calcium absorption.  Finally, Fibroblast growth Factor 23 (FGF23) briefly 
mentioned in Figure 2 (M. F. Holick, 2007), is important to mention as part of this complex 
system.  FGF23 is produced in bone (by osteocysts and osteoblasts) and has a primary role to 
maintain serum phosphate levels within the normal range, which is achieved by its role as an 









Table 2: Sites and actions for PTH and calcitriol (1,25(OH)2D) 
Site: Action: PTH Action: Calcitriol 
Bone (osteoblast) In synergy with 1,25(OH)2D 
stimulates osteoblasts to produce 
RANKL, which stimulates 
osteoclasts.  Leads to bone 
resorption and liberation of 
stored calcium and phosphate 
In synergy with PTH stimulates 
osteoblasts to produce RANKL, 
which stimulates osteoclasts.  
Leads to bone resorption and 
liberation of stored calcium and 
phosphate 
 
Kidney Activates renal 1α-hydroxylation 
to stimulate 1,25(OH)2D synthesis  
Direct action at proximal renal 
tubule.  Stimulates calcium 
reabsorption and inhibits 
phosphate reabsorption 
 
Stimulation of calcium 
reabsorption at renal tubule.   
Gastrointestinal Stimulates production of 
1,25(OH)2D – which leads to 
subsequent increasing intestinal 
calcium and phosphate 
absorption 
Increasing intestinal calcium and 
phosphate absorption 
PTH - parathyroid hormone; 1,25(OH)2D – calcitriol/1,25 dihydroxyvitamin D3  
 
1.2.1.1 Non-osseous functions  
The widespread presence of the VDR at sites other than the kidney, bone, and gut has given rise 
to considerable speculation as to possible non-osseous effects of vitamin D.  Of particular 
interest is the existence of the VDR on cells of the immune and vascular system, giving rise to 
considerable exploration of the role vitamin D may play in infection, malignancy, autoimmune 
disease, and cardiovascular health (among others).  These discussions have been detailed in a 
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number of systematic reviews, including but not limited to an excellent and very detailed 
assessment by the Institute of Medicine (IOM, now known as the National Academy of 
Medicine) on behalf of the United States and Canadian governments (Autier, Boniol, Pizot, & 
Mullie, 2014; Martineau et al., 2017; A. Catharine Ross & Institute of Medicine (U. S.). 
Committee to Review Dietary Reference Intakes for Vitamin D and Calcium., 2011; 
Theodoratou, Tzoulaki, Zgaga, & Ioannidis, 2014). 
The key limitation from these findings, including the IOM report, is the observational-nature of 
the studies, presenting associations as opposed to demonstrating true causality.  These include 
studies showing associations between low vitamin D status and cancer (Garland & Garland, 
1980; Wu et al., 2007), cardiovascular health (Giovannucci, Liu, Hollis, & Rimm, 2008; Wang et 
al., 2008), diabetes (Pittas, Lau, Hu, & Dawson-Hughes, 2007), multiple sclerosis (Munger et al., 
2004), and psychological health (Anglin, Samaan, Walter, & McDonald, 2013).   However, this 
evidence has been deemed to be inconclusive, and notably often provides inconsistent 
(Freedman, Looker, Abnet, Linet, & Graubard, 2010) and conflicting results, e.g. convincing 
negative data from the 36,000 post-menopausal participants of the Women's Health Initiative 
study published in the New England Journal of Medicine, which showed no difference in 
incidence for colon cancer after 7 years of calcium and vitamin D supplementation (p=0.51) 
(Wactawski-Wende et al., 2006).  In addition, various important confounders have also not been 
adequately controlled for in these studies.  Importantly, in those studies with positive findings, 
the non-osseous outcomes described were often not the primary outcomes of the available trial 
data, usually being secondary analyses of data collected in studies looking at vitamin D status 
or bone outcomes.   
However, considerable debate exists, and dissent is illustrated nicely by the title of this paper 
in response to the IOM “The vitamin D requirement during human lactation: the facts and IOM's 
'utter' failure” (Hollis & Wagner, 2011).  In addition, in children some interesting data are 
emerging in the area of respiratory health and infection.  An example of this is the finding of a 
recent systematic review and meta-analysis, which found after analysis of 25 eligible 
randomised controlled trials and individual patient data for 10,933 participants (aged 0-95) that 
Vitamin D supplementation reduced the risk of acute respiratory tract infection (adjusted odds 
ratio 0.88 (95% CI 0.81 - 0.96) (P <0.001) (Martineau et al., 2017).  This included data from New 
Zealand children showing reduced primary care visits for acute respiratory infection after high 
dose vitamin D supplementation in pregnancy and infancy (Grant et al., 2015).  Again of note, 
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as with much of the trial data on non-osseous vitamin D outcomes, this was a not the primary 
outcome of this NZ study.    
Clearly more information from trials specifically addressing these questions are needed, but in 
the meantime, as per the above section (1.1.2), and the conclusions of the IOM report (A. 
Catharine Ross & Institute of Medicine (U. S.). Committee to Review Dietary Reference Intakes 
for Vitamin D and Calcium., 2011), calcium homeostasis and bone health remain the key role of 
vitamin D; and notwithstanding the interest of other factors, and given the practicalities of the 
present studies, bone remains the focus of this thesis.   
 
1.2.2 Summary 
Vitamin D is a complex fat-soluble vitamin with an essential role in calcium and bone 
homeostasis.  In addition, based on growing data and the widespread presence of the VDR 
throughout the body vitamin D is likely to have many other secondary roles.  It is present in two 
main forms: cholecalciferol and ergocalciferol.  These then undergo two hydroxylation steps, 
first in the liver and then the kidney, to become the active hormone 1,25-dihydroxyvitamin D.  
1,25OHD in conjunction with PTH and FGF23 are then responsible for the maintenance of 
calcium and phosphate homeostasis, and associated bone health.         
 
1.3 Vitamin D status  
The following section aims to summarise and address the literature on vitamin D status.  This 
includes the epidemiology of deficiency, including a summary of the literature for the general 
population, children and infants, as well as that pertaining to pregnancy.  However, before this 
can be addressed, an understanding of how and what is measured when referring to vitamin D 
status is required, as well as a summary of the current debate around definitions of vitamin D 
deficiency/sufficiency. 
    
1.3.1 Measurement of vitamin D 
As discussed in section 1.1.1, serum or plasma 25OHD is widely accepted as being the primary 
marker of vitamin D status (DeLuca, 2004; Elder & Bishop, 2014; M. F. Holick, 2007, 2009; A. 
Catharine Ross & Institute of Medicine (U. S.). Committee to Review Dietary Reference Intakes 
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for Vitamin D and Calcium., 2011; Vieth, 1999).  When measured, 25-hydroxyvitamin D3 makes 
up most of this total measured 25OHD in the New Zealand context, with 25-hydroxyvitamin D2 
making up a much smaller component, which varies based on D2 dietary intake and supplement 
use.   
25OHD is the preferred marker of status for a number of reasons:  
1) It is the best indicator of incoming vitamin D from the diet and UVB photosynthesis (A. 
Catharine Ross & Institute of Medicine (U. S.). Committee to Review Dietary Reference Intakes 
for Vitamin D and Calcium., 2011). 
2) It is also the major circulating form of vitamin D, measured in nmol/L, whereas, for example, 
1,25(OH)2D is measured in pmol/L. 
3) It has a stable and long half-life –approximately one month (Vieth, 1999), vs. 1,25(OH)2D (the 
active hormone) which is tightly regulated with a half-life of only 4-6 hours (Datta et al., 2017). 
4) Finally, serum 25OHD levels are inversely correlated with a range of clinically relevant 
measures including PTH levels (Houghton et al., 2010; M. K. Thomas et al., 1998) and rickets 
(Markestad, Halvorsen, Halvorsen, Aksnes, & Aarskog, 1984).  In comparison, 1,25(OH)2D levels 
are directly and closely regulated by factors such as PTH and calcium status, and in the presence 
of even severe deficiency/rickets levels may be low, normal, or elevated.   
There are a number of assays available to measure 25OHD.  Liquid chromatography mass 
spectrometry (LC-MS/MS) is currently the technique of choice (Elder & Bishop, 2014);  
particularly due to increased sensitivity, improved differentiation and detection of both 25-
hydroxyvitamin D2 and D3, and the potential (not available with all systems) to simultaneously 
measure other important metabolites such as the C3-epi isomer.  Another common assay used 
to measure 25OHD is via radioimmunoassay techniques (RIA), which until recently was the 
method most frequently used (Zerwekh, 2004).  RIA techniques remain acceptable, but have a 
number of potential drawbacks, including underestimation of 25-hydroxyvitamin D2 and cross-
reactivity with 24,25 dihydroxyvitamin D (Maunsell, Wright, & Rainbow, 2005), as well as the 
use of radioactive tracers (Maunsell et al., 2005).  
Finally, of critical importance to both clinical and research analysis, 25OHD is very stable in 
serum/plasma, with evidence confirming this stability for periods of two years or more when 
stored at -20 to -80 degrees, despite undergoing multiple freeze/thaw cycles (Zerwekh, 2004).   
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1.3.2 Defining deficiency / sufficiency   
Once 25OHD has been measured, there remains a lack of consensus with regards to defining 
optimal vitamin D status.  The following is an attempt to briefly summarise the reasons for this 
debate: 
The ideal would be a 25OHD threshold that unequivocally correlates with optimum general 
health; however, this remains to be determined.  The key factor here is that determining a 
25OHD threshold regarded as “normal” or “sufficient” varies depending on what clinical or 
biochemical endpoint one chooses.  The non-osseous endpoints are lacking clarity currently (as 
discussed in 1.2.1.1 above), and as such clearly give rise to much of this debate.  Therefore, for 
the sake of this thesis, and as previously stated, bone health will be the primary focus of the 
review.  Rickets is arguably the most important bone consequence of vitamin D deficiency, and 
this rarely occurs at levels >30nmol/L (Munns et al., 2016; Munns et al., 2012; Ward, Gaboury, 
Ladhani, & Zlotkin, 2007), although higher levels than this (<50nmol/L) have been implicated in 
some studies, making an absolute threshold hard to establish (A. Catharine Ross & Institute of 
Medicine (U. S.). Committee to Review Dietary Reference Intakes for Vitamin D and Calcium., 
2011).  PTH, a marker of bone turnover, is inversely related to 25OHD status, achieves a plateau 
at levels of 25OHD of 60-90 nmol/L (M. F. Holick et al., 2011; Houghton et al., 2010; A. Catharine 
Ross & Institute of Medicine (U. S.). Committee to Review Dietary Reference Intakes for Vitamin 
D and Calcium., 2011).  This is useful in establishing 25OHD status, but limitations include the 
fact that PTH values increase during some life stages e.g. puberty (Abrams et al., 2005).  Lastly, 
the efficiency of intestinal calcium absorption may continue to improve until a threshold of 
≥75nmol/L is reached (Heaney, Dowell, Hale, & Bendich, 2003).   
In conclusion, given the above data, both national and international guidelines, as well as most 
experts agree that a 25OHD level of ≤50nmol/L is considered deficient (M. F. Holick, 2007; M. 
F. Holick et al., 2011; Paxton et al., 2013; A. Catharine Ross & Institute of Medicine (U. S.). 
Committee to Review Dietary Reference Intakes for Vitamin D and Calcium., 2011).  However, 
defining sufficiency or what is a “normal” level remains a challenge, with definitions varying 
between 50nmol/L (Munns et al., 2016; Paxton et al., 2013) and ≥75nmol/L (M. F. Holick, 2009; 
M. F. Holick et al., 2011).  The reasons for this variation in guideline and expert opinion regarding 
sufficiency are attested by the various PTH and calcium absorption data presented above.  
Specific aspects of this issue are also discussed in subsequent chapters on rickets (1.3), 
pregnancy and lactation (1.4).      
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1.3.3 Main determinants of Vitamin D status 
Multiple factors influence an individual’s vitamin D status, and therefore potentially have a 
bearing on their risk for vitamin D deficiency and rickets.  For individuals who have multiple 
concurrent risk factors, this is particularly important (as is often the case clinically).   Factors 
influencing status are generally well recognised and can be summarised as:   
1) Factors limiting skin exposure to UVB radiation e.g. Latitude, obstruction by clothing / 
religious or cultural clothing such as veiling, modern lifestyle factors, disability, chronic 
illness and/or prolonged hospitalisation.  
2) Skin pigment – dark skin increases the risk of deficiency/rickets, and in the rickets 
literature is most commonly associated with those of African or South Asian (e.g. Indian) 
ethnicity. 
3) Dietary factors – e.g.  Degree of exposure to food fortification, supplementation, and 
for infants, exclusive breast-feeding.  
4) Medical conditions that affect vitamin D metabolism or storage e.g. obesity, 
gastrointestinal malabsorption (celiac disease or inflammatory bowel disease), severe 
liver and/or renal disease. 
5) Medications that interfere with vitamin D metabolism e.g. anticonvulsants or 
antibiotics (rifampicin).   
 Literature highlighting these factors is addressed below. 
 
1.3.3.1 Factors limiting skin exposure to UVB radiation 
Latitude is an important factor for UVB exposure, particularly for a country like New Zealand, 
spanning latitudes 35 – 47 degrees south.  Much of this is related to the interplay of latitude 
and season.  Higher latitudes (more southern or northern) experience greater variations in UVB 
exposure with season (Webb, Kline, & Holick, 1988) – and thus potentially greater fluctuations 
in measured 25OHD (Rockell et al., 2005) and PTH (Rockell, Skeaff, Venn, Williams, & Green, 
2008).  This is potentially very important in Otago at 45-47 degrees latitude (Houghton et al., 
2010).  Due to earths elliptical orbital of the sun, New Zealand also experiences greater UVB 
intensity (~7% greater) in Southern latitude (Hemisphere) summers vs the Northern hemisphere 
(Diffey, 2002).     
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In addition, UVB exposure clearly changes with time of day (earth rotating on its own axis) as 
well as with season (the tilted axis earth orbiting the sun).  These factors influence the angle of 
the sun, e.g. the more oblique the sun’s rays are to the earth (as seen at the start or end of a 
day, or in winter/spring), the further UVB radiation has to travel, and the more atmospheric 
attenuation of solar UVB radiation occurs (Diffey, 2002).  The National Institute for Water and 
Atmospheric Research (NIWA) in New Zealand have produced some detailed reviews on this 
topic.  These demonstrate the markedly differing sun exposure times in New Zealand for vitamin 
D production between summer and winter e.g. 1-10 minutes summer (depending on extent of 
skin exposure – whole body vs face and hands) vs 20 – 200 minutes in winter(McKenzie, Liley, 
& Bjorn, 2009).  Clinically, season is clearly identified as a risk factor in the rickets literature 
(Munns et al., 2012; Ward et al., 2007).   
Public health policy also limits UVB exposure, as ultraviolet radiation (UVR) is a cause of skin 
cancer, including melanoma (AAP, 1999).  This is particularly the case for younger children and 
infants, with the American Academy of Pediatrics (AAP) and New Zealand Ministry of Health 
(MOH) recommending no direct sun exposure to infants less than six months of age, in order to 
reduce skin cancer risk in later years (AAP, 1999; Ministry of Health, 2013).  A recent study from 
Germany highlights this low UVB exposure in infants, with very low UVB exposure seen in the 
40 study infants irrespective of season (Siafarikas et al., 2011).  Sunscreen use also blocks UVR 
including UVB (Matsuoka, Ide, Wortsman, MacLaughlin, & Holick, 1987), although some 
promising efforts are being made to optimise sunscreens to allow for improved vitamin D 
synthesis(Kockott, Herzog, Reichrath, Keane, & Holick, 2016). 
7-Dehydrocholesterol in the skin also decreases substantially with age, therefore reducing the 
body’s ability to make cutaneous vitamin D even with appropriate UVB exposure(Malik, 2007).  
When combined with the fact that UVB can only act on exposed skin and is unable to penetrate 
clothing or glass, those who spend the majority of their time indoors due to lifestyle or health 
reasons are at risk, particularly the institutionalised elderly(Malik, 2007).  Clothing has the same 
effect e.g. the cultural practice of veiling substantially decreases vitamin D status (Beck-Nielsen, 
Jensen, Gram, Brixen, & Brock-Jacobsen, 2009).   
In contrast, the negative relationships mentioned above is that vitamin D status when living 
under sun-rich conditions is generally sufficient (Vieth, 1999), with the highest level ever 




1.3.3.2 Skin pigment 
Skin colour has a considerable influence on vitamin status.  Melanin competes with 7-
dehydrocholesterol for UVB photons, and therefore more UVB exposure is required in dark 
skinned individuals to generate the same vitamin D as light skinned (Clemens, Adams, 
Henderson, & Holick, 1982). Thus dark skin pigment, particularly when combined with the 
impacts of season and latitude (above), is one of the greatest risk factor for vitamin D deficiency 
and rickets, predominating in those of African and South Asian (Indian) descent (seen in Table 
3 – page 34). 
1.3.3.3 Dietary factors 
Dietary intake in the absence of fortification is not normally an important source of vitamin D 
(small quantities are naturally found in fatty fish, liver, eggs, shitake mushrooms – in decreasing 
order of quantity) (Ministry of Health, 2013).  This is particularly the case in New Zealand where 
comparatively little vitamin D food fortification occurs, as opposed for North America where 
there is universal supplementation of milk products (Moore, Murphy, & Holick, 2005; 
Vatanparast, Calvo, Green, & Whiting, 2010).  However, even with near universal 
supplementation of dairy products (usually the biggest source of fortification) individuals often 
still do not achieve a recommended daily intake (RDI) of vitamin D in the diet (Moore et al., 
2005; Vatanparast et al., 2010).  This lack of fortification in NZ provides strong grounds for 
conducting vitamin D trials, and observational studies such as those described in Chapters 3 and 
4.   
Breastmilk, the ideal food source for infants, is naturally a poor source of vitamin D, a topic 
which will also be discussed in the subsequent section on vitamin D and lactation (section 1.4.2).  
For this reason, breastfeeding, particularly when prolonged is an insignificant contributor to 
vitamin D status compared to UVB (Specker, Tsang, & Hollis, 1985).  It is also an independent 
risk factor for deficiency and rickets (Munns et al., 2012; A. Catharine Ross & Institute of 
Medicine (U. S.). Committee to Review Dietary Reference Intakes for Vitamin D and Calcium., 
2011; Ward et al., 2007).  However, in contrast, due to fortification, commercial infant formula 
when consumed at a volume of 1000ml daily, does reach the RDI (A. Catharine Ross & Institute 
of Medicine (U. S.). Committee to Review Dietary Reference Intakes for Vitamin D and Calcium., 
2011). 
In response to the low vitamin D state of breastmilk, many countries and guidelines recommend 
universal daily supplementation of exclusively breastfed infants (Wagner, Greer, American 
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Academy of Pediatrics Section on, & American Academy of Pediatrics Committee on, 2008).  
While trials have demonstrated appropriate vitamin D status when used in doses of between 
250-500IU/day (as per various RDI guidelines) (Siafarikas et al., 2011), rickets continues to be 
seen in countries recommending universal supplementation (Ward et al., 2007; Weisberg, 
Scanlon, Li, & Cogswell, 2004).  This is in part due to the degree of adherence to guidelines, 
which has been found to be very variable (Crocker et al., 2011; Gallo, Jean-Philippe, Rodd, & 
Weiler, 2010; Lehtonen et al., 2014; Perrine, Sharma, Jefferds, Serdula, & Scanlon, 2010; Taylor, 
Geyer, & Feldman, 2010).  For example, a recent study from the United States suggests that 
80% of breastfed infants failed to achieve the recommended intake of 400IU/day (Ahrens, 
Rossen, & Simon, 2016).  Closer to home, data from Australia suggests very few breastfed 
infants receive vitamin D supplementation (Lehtonen et al., 2014), which is likely to be very 
similar to the NZ situation.     
Clearly, supplementation at all ages positively contributes to vitamin D status.  For this thesis, 
more detail will be provided in the sections related to pregnancy and lactation.  Of importance, 
there is often, as discussed in the previous paragraph, a poor uptake of supplement 
recommendations, even for instance in high risk Middle Eastern populations (Saadi et al., 2006).  
Interestingly, the relationship between 25OHD and intake does not appear to linear e.g. 
increasing status above 50nmol/L requires more intake than for levels <50nmol/L (A. Catharine 
Ross & Institute of Medicine (U. S.). Committee to Review Dietary Reference Intakes for Vitamin 
D and Calcium., 2011).  This clearly has important clinical implications when considering 
supplementation and dosing regimens.   
Of interest, but only rarely implicated in rickets, some dietary factors may also be detrimental 
to both calcium and vitamin D status e.g. the high phytic acid content in some south Asian foods 
(Ladhani, Srinivasan, Buchanan, & Allgrove, 2004), and some unfortified health food milk 
alternatives (Carvalho, Kenney, Carrington, & Hall, 2001).  
 
1.3.3.4 Medical conditions that affect vitamin D metabolism or storage 
Obesity, one of the commonest medical conditions, has a direct effect on vitamin D status,  
being associated with lower levels of serum 25OHD (A. Catharine Ross & Institute of Medicine 
(U. S.). Committee to Review Dietary Reference Intakes for Vitamin D and Calcium., 2011).  As 
vitamin D is a fat-soluble vitamin, this is likely mostly due to sequestration of 25OHD into 
adipose tissue.  Additional evidence for this is seen in the fact that 25OHD levels may actually 
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increase when weight loss is achieved (Reinehr, de Sousa, Alexy, Kersting, & Andler, 2007; 
Tzotzas et al., 2010).     
Any disease process which chronically reduces liver or renal function is likely to have an adverse 
impact on 25OHD status (M. K. Thomas et al., 1998).  This is due to the importance of the liver 
and kidney for hydroxylation of vitamin D to 1,25(OH)2D.  Again, as a fat-soluble vitamin, disease 
states associated with malabsorption are also implicated in low vitamin D status.  Classically 
these include coeliac disease and inflammatory bowel disease.  However, a recent study has 
suggested that when BMI (as a marker of adiposity) was controlled for, vitamin D status in fact 
did not differ between those with and without celiac disease (Villanueva, Maranda, & Nwosu, 
2012).   
       
1.3.3.5 Medications 
A number of medications are well documented to interfere with vitamin D metabolism, and 
thus negatively influence vitamin D status.  These include anticonvulsants (particularly 
phenytoin and carbamazepine); antibiotics (rifampicin); and potentially some anti-retroviral 
drugs and anti-hypertensives.  The drugs all share a common mechanism for this interference, 
which is in the activation of the Pregnane X receptor.  This is an intracellular receptor that plays 
a role in de-toxifying drugs.  Activation of the Pregnane X receptor upregulates 24-hydroxylase 
and therefore increases catabolism of 1,25(OH)2D and 25OHD, thus potentially decreasing 
vitamin D status (Grober & Kisters, 2012; Michael F. Holick, 2005). 
 
1.3.3.6 Other factors 
Finally, specific to newborn infants, not surprisingly, infant vitamin D status is strongly 
influenced by maternal status in pregnancy (Ladhani et al., 2004), with the two closely 
correlated (Bowyer et al., 2009; Grant et al., 2014; S. D. Thomas, Fudge, Whiting, & Coates, 
2011), infant levels being approximately 75-80% of maternal levels.  This will be discussed 




1.3.4 Epidemiology of Vitamin D deficiency 
The epidemiology of vitamin D deficiency has varied over the past century.  Previously heralded 
as a disappearing diagnosis (Harrison, 1966), by the 1990s numerous articles were appearing 
discussing deficiency in adults and rickets in children.  Given that determinants of status have 
been discussed previously, this section will provide an overview of the prevalence of vitamin D 
deficiency in children, adults and pregnancy.  The epidemiology of vitamin D deficiency rickets 
will be discussed in 1.3.3.   
 
1.3.4.1 Prevalence of vitamin D deficiency in childhood 
Vitamin D status in newborns has been examined both within New Zealand and abroad.  Overall 
deficiency is relatively common at all ages.  New Zealand provides an ideal place to investigate 
vitamin D deficiency due to our southern latitude, variable UVB levels with season, and minimal 
public health policy for supplementation and food fortification.   
Camargo et al. have published data from Christchurch and Wellington on cord blood levels of 
newborns (Camargo et al., 2010).  The median cord blood 25OHD from this population of 929 
newborns was deficient at 44nmol/L, with 57% demonstrating levels <50nmol/L and only 27% 
reaching sufficiency defined as ≥75nmol/L.  In this sample, the main determinants of deficiency 
were season and non-European ethnicity.  Emphasising breastfeeding as an additional risk 
factor, a study in 2-3 month old exclusively breastfed infants in Auckland found a median 25OHD 
of 53nmol/L, with 24% <27.5 nmol/L.  Season was again important.  In slightly older children 
from Auckland (aged 6-23 months), deficiency was associated with season (winter), ethnicity 
(Pacific), age (younger), and no exposure to “follow-on” formula (Grant, Wall, Crengle, & Scragg, 
2009).  Local Dunedin data in children aged 12-22months are very similar with the mean winter 
25OHD value of 38.7nmol/L compared with summer values of 74.1nmol/L (a 35nmol/L 
difference between summer and winter at the Dunedin latitude of 45°S).  In these data, in 
addition to season, breastfeeding and higher primary caregiver education attainment were 
negatively associated with status, and smoking and male gender positively associated 
(Houghton et al., 2010).  In older children (aged 5-14 years), a snapshot of national data are 
provided by 1585 children in the 2002 NZ National Children's Nutrition Survey (Rockell et al., 
2005).  Overall, the mean 25OHD level was 50nmol/L, season and ethnicity again were major 
determinants, with risk of deficiency more commonly reported in Maori and Pacifika children 
(mean 25OHD levels of 43 and 36nmol/L, respectively).   
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International data support these findings.  With regards to the southern hemisphere, data from 
Sydney (latitude 34°S), using cord blood from 901 neonates found a median 25OHD of 60nmol/L 
(range 17-245) (Bowyer et al., 2009).  Maternal levels were slightly lower, median 52nmol/L (17-
174), however these were taken between 8 and 17 weeks prior to delivery (median 2.7 months).  
In this study, a higher risk of low vitamin D status were associated with winter/early spring, 
veiling, dark skin colour, and younger maternal age.  After adjusting for potential confounders, 
in this sample mean birth weight was 151grams (95% CI 50-250) lower in vitamin D deficient 
mothers (Bowyer et al., 2009).  Other Australian data provides similar rates of vitamin D 
deficiency in neonates and children (S. D. Thomas et al., 2011).  Publications from around the 
world are similar, with variable rates of deficiency (depending on definitions) and similar 
determinants of status, including from large population based samples in the Northern 
Hemisphere (Lawson & Thomas, 1999; Prentice, 2008), and also sunny areas like the Middle 
East (Molla et al., 2005).           
Finally, children of recent immigrants and refugees appear at particular risk.  This is a worldwide 
phenomenon (Madar, Stene, & Meyer, 2009), but also seen in our region with deficiency found 
in 61% of children in a Sydney based study by Sheikh et al (Sheikh et al., 2009).   
 
1.3.4.2 Prevalence of vitamin D deficiency in pregnancy 
As with children and infants, vitamin D deficiency is common during pregnancy, and largely 
follows the same patterns with the same determinants.  Specific longitudinal data and 
intervention trials (focusing on infant outcomes) in pregnancy will be discussed in 1.4.1, and as 
stated in 1.2.3.6 above, pregnancy is of great importance to subsequent infant status, as infant 
status is determined by maternal status in pregnancy with 25OHD levels being closely 
correlated.   
Rates of antenatal deficiency vary from 10% in Queensland, Australia (latitude 12-28°S) 
(McLeod, Scott, Lust, & McIntyre, 2011) to 80-87% respectively in multi-ethnic high-risk samples 
from Melbourne (Grover & Morley, 2001) (38°S) and Wellington (41°S), New Zealand (Judkins 
& Eagleton, 2006).  Latitude and ethnicity are clearly important as reflected in status from these 
studies.  Median 25OHD in the mainly light-skinned Queensland sample was 92nmol/L (McLeod 
et al., 2011).  This compares to the high risk(multi-ethnic, mostly dark skinned or covered) 
pregnancy sample from Wellington, where 100% of the Indian and Middle Eastern women had 
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levels below 50nmol/L, including 10 women who were discovered to have secondary 
hyperparathyroidism with elevated PTH levels (Judkins & Eagleton, 2006). 
Veiled mothers are particularly at risk, with one study finding 71% of veiled mothers in a 
population based Sydney sample with levels <25nmol/L, and a risk of deficiency 21 times that 
of unveiled (Bowyer et al., 2009).  This is confirmed in Middle Eastern data from Israel (Mukamel 
et al., 2001) and Saudi Arabia (Serenius, Elidrissy, & Dandona, 1984).  However, as seen in the 
Wellington study above (where veiling was uncommon), deficiency and severe deficiency are 
not confined to those who are covered/veiled (Judkins & Eagleton, 2006).   
Of great relevance to New Zealand, in a recent Auckland study, 43% of “low” risk light-skinned 
European women also had vitamin D deficiency (25OHD < 50 nmol/L) during winter and spring 
(Ekeroma et al., 2015).  In addition, data from the New Zealand Adult Nutrition Survey highlights 
that one-third of New Zealand women of childbearing age (15 - 44 years) had vitamin D 
deficiency (Ministry of Health, 2012).  This raises considerable concerns regarding New 
Zealand’s current targeted supplementation strategy for vitamin D in pregnancy (Ministry of 
Health, 2013), as many of the aforementioned women would not be offered supplementation 
under this strategy.   
No data reporting vitamin D status in pregnancy for those living in the South Island latitudes are 
available, however given the latitude, and traditionally largely “low” risk European majority of 
the South, these data would also be of great importance to gaining a better understanding of 
whether a targeted vitamin D supplementation strategy to only those at “high” risk is suitable 
for southern New Zealand.   
     
1.3.4.3 Prevalence of vitamin D deficiency in adults 
Adult studies of prevalence also differ by definition of status and by the determinants of status, 
as highlighted above.  Overall, as with children and pregnancy, deficiency is common.  The 
National Health and Nutrition Examination Survey (NHANES) 2005/2006 examined 4495 US 
adults.  Vitamin D deficiency as defined by 25OHD status <50nmol/L was found in 42% of this 
sample, and the major determinants of deficiency were non-white ethnicity, poor health, 
reduced diary intake (an important source of vitamin D in the US due to fortification).  The effect 
of season was not examined.  Similar population based NZ data from the New Zealand Adult 
Nutrition Survey 2008/09 found 32% of NZ adults have vitamin D deficiency (25OHD < 25 
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nmol/L) (all seasons combined).  Season, that is, late winter and early spring, was the major 
negative determinant of status, particularly for those living in the South Island (Ministry of 
Health, 2012).  Those of Pacific ethnicity were also 2.3 times more likely to be deficient, as were 
those who were obese.        
Additional risk factors (as seen in children and pregnancy), include recent immigration and 
refugee status, and include NZ experience (Wishart, Reeve, & Grant, 2007).  In the Wishart NZ 
refugee data collected over 12 months in 2014/15, reproductive age women aged 17-45 years 
and men >46years were at greatest risk.  This risk with increasing age as discussed in 1.2.3.1, 
and is related to decreasing 7-dehydrocholesterol in the skin (Malik, 2007), and compounded 
by illness in the elderly, particularly those who are institutionalised (Malik, 2007). 
   
1.3.5 Summary 
Serum 25OHD is the primary biochemical marker of vitamin D status.  While subject to some 
debate, vitamin D deficiency on the basis of bone health is defined as a 25OHD level <50nmol/L.  
Vitamin D deficiency remains common across the life cycle, including in childhood and in women 
of childbearing age and during pregnancy.  There are multiple determinants of vitamin D status, 
the most important being season, and factors reducing skin UVB exposure such as dark pigment 
and clothing.  Latitude (as a surrogate for solar radiation exposure) is also very important, and 
particularly relevant in countries like New Zealand that span multiple latitudes with associated 
large swings in 25OHD status with season.  To date, there are minimal published studies from 
more southern NZ latitudes, and none focusing on vitamin D status during pregnancy.   
 
1.4 Vitamin D Deficiency Rickets (VDDR) 
Adequate supply of calcium and phosphate is required for successful mineralisation of bone 
osteoid tissue.  Failure of this mineral supply (for any reason) results in a mineralisation defect.    
In adults this leads to osteomalacia (impaired mineralisation of bone matrix) and osteoporosis 
(overall low bone mass).  In children, this failure leads to rickets.  There are multiple causes of 
rickets, but as discussed above, vitamin D is vital for calcium and phosphate balance, and 
vitamin D deficiency is the leading cause of rickets in children.  Rickets is a mineralisation defect, 
and as in adults, it causes generalised osteomalacia, but specific to children, due to their open 
growth plate and rapid growth rate, leads to a failure of mineralisation at the growth plate.  
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These two defects lead to the classic bony features of rickets, including: weakening of long 
bones, particularly those involved in weight bearing, hence the classic lower limb bowing seen 
in Figure 4; poor growth, delayed dentition, slowed motor development, and rarely, 
pathological fracture.  The growth plate defect leads to the other stigmata of rickets, including 
swelling at the ends of long bones, particularly wrists and knees, costo-chondral abnormalities 
known as “rachitic rosary”, and frontal bossing of the skull.  The most significant and dangerous 
feature of rickets is hypocalcaemia, particularly common during periods of rapid growth e.g. 
infancy and early childhood (Ladhani et al., 2004).  As highlighted in Table 1 from section 1.1.2 
hypocalcaemia is a leading cause of morbidity leading to neuromuscular irritability, tetany, 
paraesthesia, and eventually seizures (Munns et al., 2016). 
 
1.4.1 Growth plate physiology and pathophysiology (rickets)       
To understand rickets, one must first have a basic understanding of the growth plate.  Rickets 
is an illness exclusive to childhood, due to the mineralisation defect that is present at the open 
growth plate or physis (Tiosano & Hochberg, 2009).  The growth plate in the context of a long 
bone is illustrated in Figure 3.  In children, longitudinal growth relies on proliferation and 
hypertrophy of growth plate chondrocytes (cells which produce cartilage, the flexible scaffold 
upon which bone is made) (Muir, 1995).  This resultant cartilage then undergoes apoptosis 
(programmed cell death), vascular and bony invasion, and remodelling to form new bone tissue 
(Nilsson, Marino, De Luca, Phillip, & Baron, 2005).  This whole process is referred to as 
endochondral ossification (Nilsson et al., 2005).  The hardness and rigidity of final bone is due 
to the presence of hydroxyapatite (a crystalline complex of calcium and phosphate) in the 
osteoid matrix.   
Longitudinal growth starts at the top of the histological image in Figure 3 and pushes down, 
with chondrocytes progressing through the stages from the relatively inactive initial germinal 
zone (often referred to as the resting zone), through the proliferating and hypertrophic zones.  
Once in the hypertrophic zone, cell division ceases, and at the bottom of the histological aspects 
of Figure 3, terminal chondrocyte maturation occurs with apoptosis, and vascular invasion.  
Mineralisation also occurs longitudinally between the columns of hypertrophic chondrocytes.  
This mixed tissue is subsequently remodelled in the metaphysis (zone incorporating the growth 
plate adjacent to the diaphysis) to become “bone” (Ballock & O'Keefe, 2003; Muir, 1995; Nilsson 







                                                                                            Metaphysis 
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Figure 3: (A) Long bone and the cartilaginous growth plate – [reproduced from open access 
source PLOS Biology distributed under the terms of the Creative Commons Attribution 
License, which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original author and source are credited (Wolpert, 2010)]; (B) A histological 
depiction of the growth plate, illustrating chondrocyte development (Ballock & O'Keefe, 
2003) Copyright Wolters Kluwer Health, Inc., used with permission. 
 
For this normal process of growth plate mineralisation to occur, a sufficient supply of calcium, 
phosphate, and vitamin D must be available.  While most attention is focused on calcium, 
phosphate also plays a vital role in rickets aetiology (Munns et al., 2016; Tiosano & Hochberg, 
2009), and once serum phosphate concentrations decrease, defects in bone mineralisation 
occur, including rickets and osteomalacia.  How hypophosphatemia leads to this is explained 
below. 
Once serum calcium levels become insufficient [due to vitamin D deficiency in most cases 
worldwide, but in some very UVB rich (sunny) countries such as Bangladesh and Africa, may also 
occur in severe calcium intake deficiency (Fischer et al., 1999)], PTH levels rise in response.  As 
discussed previously, PTH stimulates osteoclastic resorption of bone (via RANKL), liberating 
stored calcium and phosphate into the circulation.  However, the effects of PTH on the kidney 
are key in rickets.  PTH acts at the proximal tubule in order to maximise calcium resorption, but 
at the expense of phosphate loss.  This causes lowered serum phosphate levels.  Phosphate is a 
key promoter of chondrocyte apoptosis.  This was initially shown in a series of experiments in 
embryonic chick tibial chondrocytes in which injection of phosphate caused dose and time 
dependant apoptosis (Mansfield, Rajpurohit, & Shapiro, 1999; Mansfield, Teixeira, Adams, & 
Shapiro, 2001).  In states of lowered circulating phosphate, apoptosis of chondrocytes in the 
hyperplastic zone of the growth plate is therefore impaired, and further expansion and 
hyperplasia occurs in this zone (Munns et al., 2016; Tiosano & Hochberg, 2009).  In addition, 
impaired cartilage mineralisation (including relative hypophosphataemia in the osteoblast) 
impairs vascular invasion at the level of the junction with the hypertrophic zone and metaphysis 
and hence new bone formation is impacted, with reduced removal and remodelling of cartilage 
in the hypertrophic zone.  The resulting pathology at the tissue level is reflected in the classic 
radiological signs of rickets (Figure 4) including growth plate widening, cupping, and fraying (all 




Figure 4: Xray image of rachitic bone, and demonstration of classic changes including growth 
plate widening, cupping, and fraying (Tiosano & Hochberg, 2009).  Copyright Japanese Society 
for Bone and Mineral Research. 
The pathogenic mechanism as outlined above is common to all forms of rickets, both acquired 
and genetic, and is one method used to classify rickets: as PTH dependant (e.g. VDDR/nutritional 
rickets, VDR and post-receptor mutations); FGF23 dependant (e.g. X-linked or autosomally 
inherited forms of hypophosphatemic rickets); or renal (Fanconi syndrome) (Tiosano & 






Figure 5:  Child suffering from vitamin D deficiency rickets - image obtained from the Center 
for Disease Control via the Public Health Image Library (PHIL) at 






1.4.2 A brief history of rickets 
 
Figure 6: Glissonius de Rachitide – “Glisson examines child with rickets as the mother looks on. 
Two more children with rickets play in the background and bones deformed by rickets hang on 
the wall.” The US National Library of Medicine digital collection 
http://resource.nlm.nih.gov/101434430 (open access) 
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The origins of the word “rickets” are somewhat unclear, but may originate from the German 
word “wricken” meaning “twisted” (Elder & Bishop, 2014).  The first clear descriptions of rickets 
occurred in the 17th century, by English physicians Daniel Whistler in 1645, and Francis Glisson 
in 1650(Glisson, Bate, Regemorter, & Pre-1801 Imprint Collection (Library of Congress), 1660).  
However, clearly the importance and impacts of vitamin D on human health were recognized 
well before this time.  Not only was rickets described in early Greek and Roman medical writings 
of the 1st and 2nd century AD (Rajakumar, 2003), but the body’s thirst for vitamin D is considered 
to be the leading theory for the evolution of human skin colour (Yuen & Jablonski, 2010).  This 
is supported by archeological evidence from the far north of Greenland, in which a colony of 
settlers appears to have become extinct secondary to “gross pelvic deformities of osteomalacia” 
(Murray, 1934).     
In the 17th century, due to severe overcrowding and pollution in industrial cities, rickets was 
very common (the “first wave of rickets”), and  despite excellent scientific descriptions of the 
disease, the aetiology remained poorly understood and the rationale of potential treatments 
poorly validated (Glisson apparently suggested splinting, cautery, and pendulous suspension of 
the infant to help straighten out crooked bones) (Rajakumar, 2003).  It was not until the early 
20th century, when Mellanby discovered the 4th vitamin (Mellanby, 1989), subsequently named 
“vitamin D” by McCollum (McCollum, Simmonds, Becker, & Shipley, 1922), that a proper 
scientific understanding of the basis of rickets could begin.   Alfred Hess (and others), a 
paediatrician and nutrition researcher, pioneered the use of cod liver oil, rich in vitamin D, in an 
at-risk black community in 1917 (Hess & Unger, 1917).  Interestingly, Hess also made 
observations of the increased risk of rickets with unsupplemented breastfeeding and seasonal 
variation (Hess & Unger, 1917; Hess & Weinstock, 1924a, 1924b).  Also at this time, animal 
experiments by Shipley and Park (Shipley & Park, 1921) highlighted the healing of rickets with 
cod liver oil and UVB light exposure.   
Despite these advances in knowledge and treatment, rickets continued to be common during 
the early 20th century.  A local illustration of how common rickets was at this time comes from 
the Renwick hospital for sick infants in Sydney, Australia (Maddox, 1932).  In this study, rickets 
was identified in 52% of 218 consecutive infants reviewed in the outpatient department.  
Maddox also offered some excellent advice on preventing rickets, much of which remains 
applicable today: “1) public education in the dangers to the child of an ill-balanced diet in the 
mothers as regards vitamin content during pregnancy and lactation….; 2) a stronger insistence 
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on daily exposure to the half-naked child to the direct rays of the morning sun; 3) The routine 
provision to all outpatients of a stronger preparation of cod-liver oil…”. 
Use of cod liver oil and food fortification strategies (including increased use of infant formula) 
led to a decrease in rickets over the next few decades(Harrison, 1966).  This was until increasing 
immigration to Europe and England of dark-skinned individuals from equatorial regions (e.g. 
India/South Asia, and the West Indies) led to the identification of a “second wave” of rickets 
(Allgrove, 2004).  Again, successful public health campaigns targeting these new immigrants 
reduced rickets presentations (Dunnigan et al., 1985).  Unfortunately, as will be discussed in the 
following epidemiology section, we are now in a “third wave” of rickets.  In part, this is caused 
by lack of sun exposure due to modern lifestyles and sun avoidance measures, as well as lapses 
in awareness of existing public health policies for supplementation or targeted supplementation 
to at risk groups.  
 
1.4.3 Epidemiology of vitamin D deficiency rickets 
Clearly, as described in 1.3.2 a brief history of rickets (above), VDDR has always been with us, 
but worldwide concerns have more recently been raised that VDDR is again increasing in 
frequency (Allgrove, 2004; Elder & Bishop, 2014; Ladhani et al., 2004).  Considerable data has 
been collected over the past 20 years and are collated in Table 3.  When incidence has been 
calculated, this ranges from 2.9/100,000 – 60/100,000 depending on the population studied.  
Most of this data consists of retrospective case series, and are not national, but usually focused 
to specific areas or hospitals.  In contrast, two recent prospective national paediatric 
surveillance unit studies have been conducted in Canada (Ward et al., 2007) and 
Australia(Munns et al., 2012), and these are likely able to give a more accurate idea of incidence 
for these countries.  The first of these, conducted in Canada between 2002 and 2004, found 104 
cases, giving an overall annual incidence of 2.9 cases/100,000 children aged < 18 years.  The 
more recent Australian study was conducted between 2006 and 2007, and found a slightly 
higher overall incidence of 4.9 /100,000 children aged ≤ 15 years.  To give these figures some 
clinical context, this is about the same as for childhood leukaemia at 4.4/100,000 (Kaatsch & 
Mergenthaler, 2008), and considerably less than for type 1 diabetes, one of the commonest 
chronic diseases in childhood, which has an estimated New Zealand incidence of 17.9 cases / 
100,000(Campbell-Stokes, Taylor, & New Zealand Children's Diabetes Working, 2005).  
Regarding incidence estimates from the retrospectively collected studies, the estimated 
incidence from Denmark was 2.9/100,000 (children aged 0-15 years), and 5.8/100,000 (aged 0-
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3 years).  In addition, for immigrant children in Denmark the incidence was 10-fold higher at 
60/100,000 (Beck-Nielsen, Brock-Jacobsen, Gram, Brixen, & Jensen, 2009).  It is also important 
to note that the above studies likely underestimate the total community burden of VDDR.  This 
is because the data summarised in Table 3 are generally produced by hospital specialists and 
/or retrospective audit of hospital case records.  As milder VDDR may be managed and/or 
incidentally diagnosed in the community by family doctors/general practitioners, these cases 
are missing from all published data.     
Younger age appears to be an important risk factor, with incidence in the Canadian data 
9/100,000 and 12/100,000 in those aged <1 and between 1 and 2 years, respectively (Ward et 
al., 2007).  This is supported by retrospective regional incidence data from Japan in those <4 
years, identical to Canada at 9/100,000 (Matsuo, Mukai, Suzuki, & Fujieda, 2009).  In most of 
the retrospective case studies, we find mean/median (which ever was presented) ages usually 
less than 2 years (Blok, Grant, McNeil, & Reid, 2000; Kreiter et al., 2000; Nozza & Rodda, 2001).  
The prospective Australian study however is an outlier, with a median age at diagnosis of 6.24 
years (Munns et al., 2012), although this is likely explained by the fact that most (75%) cases in 
this study were detected as part of screening of new refugee intakes into Australia.  
Concerning gender, the risk is usually evenly distributed, particularly in the available prospective 
national data (Munns et al., 2012; Ward et al., 2007).  There are discrepancies in this, with some 
retrospective data in younger children suggesting more males affected (Al-Atawi, Al-Alwan, Al-
Mutair, Tamim, & Al-Jurayyan, 2009; Matsuo et al., 2009; Robinson et al., 2006), and one paper 
from the Denmark noting in children older than 4 years, veiled girls comprised 78% of the 
sample (Beck-Nielsen, Brock-Jacobsen, et al., 2009).     
Supplementation with vitamin D is clearly also another vital factor.  For example in the Canadian 
PSU study, there were no cases reported in children who had received vitamin D 
supplementation as recommended (400IU/day) (Ward et al., 2007).  In fact, to the best of my 
knowledge, no cases of rickets have been reported in infants who have had the opportunity to 
receive adequate daily supplementation; this is also mentioned in the recent global consensus 
statement on nutritional rickets (Munns et al., 2016).  Subsequently, un-supplemented breast-
feeding is seen as a risk factor in most available studies (DeLucia, Mitnick, & Carpenter, 2003; 
Kreiter et al., 2000; Ladhani et al., 2004; Ward et al., 2007; Weisberg et al., 2004).  This includes 
the prospective Canadian study, where 94% were breast-fed at the time of diagnosis, with only 
three exclusively fed formula (in these three cases, presentation with hypocalcaemia was seen 
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shortly after birth, and maternal 25OHD levels were found to be “critically low” (Ward et al., 
2007).  The Australian PSU data also showed that duration of exclusive breastfeeding was 
inversely related to serum 25OHD levels in those aged < 3 years (Munns et al., 2012). 
Other risk factors seen for VDDR are identical to vitamin D deficiency in general (discussed 
above in section 1.2.3), and these include: season (increased risk in winter/spring (Blok et al., 
2000; Munns et al., 2012; Nozza & Rodda, 2001)); darker skin pigmentation (maternal and/or 
infant); non-European ethnicity (in the southern hemisphere usually African or south Asian 
(Blok et al., 2000; Munns et al., 2012)); and more northern/southern latitude.   
VDDR is also more likely to occur in the presence of any chronic disease that may contribute to 
vitamin D deficiency, such as an underlying disorder of the liver, kidney, or fat malabsorption. 
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1.4.4 Clinical presentation/features of rickets 
The classic clinical presentations of children presenting with rickets are demonstrated in Figure 
5 and Table 4.  Presentation is often dependant on the age of the child.  Hypocalcaemia is almost 
exclusively seen in those < 3 years of age (Ladhani et al., 2004; Nozza & Rodda, 2001; Ward et 
al., 2007).  Fracture as a presentation remains quite controversial, particularly after a range of 
publications from Paterson (a controversial advocate for “temporary brittle bone disease” and 
vitamin D deficiency as an alternative explanation for fracture and trauma attributed to non-
accidental injury (Paterson, 2009a, 2009b)).  In the latest global consensus statement, fracture 
is acknowledged to occur with rickets, but only when clear radiological evidence of rickets is 
present (as opposed to simple vitamin D deficiency, or solely biochemical evidence of rickets) 
(Munns et al., 2016).  
Table 4: Clinical presentation of rickets 
Skeletal abnormality/deformity‡ 
Poor growth / Failure to thrive 
Delayed motor milestones / weakness 
Symptomatic hypocalcaemia – Seizure /Tetany (generally confined to those <3 years) 




Incidental finding / Found on screening e.g. sibling with rickets / refugee screening 
Fracture  
Cardiomyopathy 
‡ lower limb deformity (bowed legs); swollen wrists or ankles; large anterior fontanelle/splayed 
sutures; frontal bossing; delayed tooth eruption; rachitic rosary (enlarged costochodral joints 
of the ribs); craniotabes (a softening of the skull found in infants)   
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1.4.5 The diagnosis of vitamin D deficiency rickets 
The diagnosis of VDDR is made by clinical (as discussed above 1.3.4) and biochemical evaluation 
and confirmed by xray (Munns et al., 2016).  Figure 4 demonstrates a photograph of a child with 
classic vitamin D deficiency rickets.   
The classic radiographic signs were discussed in section 1.3.1 above, and demonstrated in Figure 
4.  However, it should be noted that while the recent global consensus statement requires x-ray 
confirmation, a subset of young infants have been described who present with symptomatic 
hypocalcaemia and biochemical evidence of severe vitamin D deficiency / VDDR, but who do 
not have xray changes (Ladhani et al., 2004).  In these infants it has been proposed due to their 
very young age, rapid growth, high calcium need, and inability to adequately mobilise calcium 
from the skeleton, symptomatic hypocalcaemia can occur before radiological changes have had 
time to develop (Ladhani et al., 2004).   
The key biochemical markers of VDDR are: 
1) Low vitamin D status as measured by serum 25OHD.  This is essential to define VDDR 
and in most cases this should reveal deficiency (<50nmol/L) and in most cases severe 
deficiency, usually less than 30-34 nmol/L (Munns et al., 2016).     
2) Elevated total Alkaline phosphatase (ALP).  In addition to the liver, ALP is found in the 
cell membrane of osteoblasts, and therefore increased levels of total serum ALP may 
indicate increased bone formation and/or turnover (Corathers, 2006; Munns et al., 
2016).  Rickets represents a situation of markedly increased bone turnover.  When 
measured, ALP is elevated in 94-100% of VDDR cases reported in the literature (even if 
ALP was not used in the initial definition of rickets) (Blok et al., 2000; DeLucia et al., 
2003; Kreiter et al., 2000; Munns et al., 2012; Ward et al., 2007).  This has led to ALP 
being used as part of the diagnostic criteria in the only two published prospective 
reviews of rickets incidence and characteristics (Munns et al., 2012; Ward et al., 2007). 
3) Serum PTH, released in response to decreased ionised calcium, is raised in most cases 
of VDDR (Elder & Bishop, 2014; Munns et al., 2016)   
4) Classically in severe VDDR, serum calcium and phosphate are both low (particularly in 
younger children).  However, in early or milder cases of VDDR, as both serum calcium 
and phosphate are tightly regulated and essential for life, bone can be mobilised (hence 
the rickets) to maintain normal serum status.   
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5) Serum measures of 1,25(OH)2D are not helpful in the acute situation for VDDR, as levels 
may be elevated, normal of low (Robinson et al., 2006).   
Therefore, review of the above factors, as with the two prospective rickets trials to date, 
indicates that the best definition of simple VDDR consists of evidence of vitamin D deficiency 
(<50nmol/L), an elevated ALP and ideally accompanied by confirmatory x-ray findings at the 
wrist or knee (large and rapidly growing bones).  Other findings such as an elevated PTH, or 
hypophosphataemia and hypocalcaemia, are supportive but not essential. 
Finally, for a diagnosis of simple vitamin D deficiency rickets to be made, rickets secondary to 
any heritable disorder of vitamin D deficiency, including but not limited to: 1-alpha hydroxylase 
deficiency, vitamin D receptor defects, hypophosphataemic rickets, and secondary 
hyperparathyroidism of any other cause other than vitamin D deficiency, must also be excluded.  
 
1.4.6 NZ vitamin D deficiency rickets data 
Prior to the work presented in this thesis there has been relatively little NZ specific study of 
rickets, and nothing before 2000 (Blok et al., 2000).  Blok et al (Blok et al., 2000) were the first 
to explore VDDR in New Zealand children, identifying 18 children, all <5 years of age, presenting 
with rickets to Auckland Starship Children’s Hospital in 1998. The key characteristics were: a 
median age of 12 months; 12/18 Indian origin, with no European children described; 12/18 
presented in Winter-Spring (July-December) with a peak in August; and 10/18 had a history of 
breastfeeding, with a mean duration of 16 months.  The most common presentation was with 
bony deformity/delayed walking in 7/18, while 3/18 presented with hypocalcaemic seizures all 
aged 12 months or younger.  Biochemically, 11/18 had hypocalcaemia at presentation, 15/18 
had 25OHD levels <12.5nmol/L, and all had raised ALPs.  However, it is possible cases were 
overlooked, particularly milder cases, or infants with hypocalcaemia, as xray confirmation was 
essential for inclusion.   
Only two other New Zealand papers mention VDDR.   One, published in 2006 and focused on 
maternal status during pregnancy (Judkins & Eagleton, 2006), has a passing reference to rickets 
anecdotally found in a single Wellington GP practice database review which identified 10 cases 
in children < 5 years of age, over a three year period prior to publication.  It was beyond the 
scope of this paper to describe the characteristics or features of rickets seen or even mention 
what diagnostic criteria were used.  Finally, a single case report from 2008 (Wallis, 2008) 
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describes a classic case of rickets presenting as hypocalcaemia in a black African 5 month old 
male in Dunedin.   
 
1.4.7 Summary 
Vitamin D is essential for calcium and bone metabolism.  Vitamin D deficiency is relatively 
common, and the most severe consequence of deficiency is rickets.  VDDR is a disease unique 
to growing children, as it is a mineralisation defect affecting the open growth plate.  
Manifestations include bony deformity, poor growth, delayed dentition, slowed motor 
development, and symptomatic hypocalcaemia (seizures and tetany).  The risk factors for 
rickets are relatively well defined, but most current epidemiological data relies on retrospective 
hospital case series.  Prior to the present work (Chapter two), only two international prospective 
studies on rickets have been conducted, and few studies exist in the New Zealand context.         
 
1.5 A focus on vitamin D during pregnancy and lactation 
1.5.1 Vitamin D and Pregnancy 
Vitamin D status and pregnancy epidemiology have been covered in previous aspects of this 
thesis, and highlight the point that deficiency during pregnancy is common in New Zealand and 
worldwide.  As seen in the previous section, rickets is the most severe consequence of childhood 
vitamin D deficiency.  Pregnancy plays an important role in the aetiology of rickets in the child, 
and this section will therefore focus on the impacts of maternal deficiency on the foetus and 
neonate, intervention trials in pregnancy to improve neonatal vitamin D status, as well as a 
spotlight on previous longitudinal studies looking at vitamin D status spanning pregnancy (and 
beyond).   
 
1.5.1.1 Impacts of maternal deficiency on the foetus and neonate 
Pregnancy is clearly one of the most important stages of the human lifecycle, and therefore 
nutrition during pregnancy is of critical importance.  Regarding vitamin D nutrition, pregnancy 
is a vital period for not only maternal health, but also infant status, particularly with regard to 
skeletal development and mineralisation.  The third trimester is the most important aspect and 
is where the majority of foetal skeletal mineralisation occurs (Givens & Macy, 1933; Trotter & 
Hixon, 1974).  This is particularly important in the modern world, as once born, many infants 
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will have minimal sun exposure for the first 6 months of life (AAP, 1999; Ministry of Health, 
2013), and a favourable milieu during in utero life may stand the child in better stead. 
As early as 1924, Hess (one of the early vitamin D pioneers) stated “It would be interesting to 
ascertain how often women suffering from osteomalacia give birth to infants with congenital 
rickets” (Hess & Weinstock, 1924b).  It has been subsequently confirmed that 25OHD readily 
crosses the placenta, and infant status at birth is closely correlated to maternal vitamin D status 
(Bowyer et al., 2009; Grant et al., 2014; Rodda et al., 2015; S. D. Thomas et al., 2011).  Thus, 
Hess’s speculation was very precisely on the mark, and indeed it is from his inspired insight that 
much of the work in the present document flows.  Multiple subsequent studies including those 
identifying a relationship between poor maternal D status and neonatal hypocalcaemic 
convulsions (Roberts, Cohen, & Forfar, 1973), and newer local data by Nozza et al. who showed 
that in young Australian children with rickets, 90% had mothers with severe deficiency 
themselves (81% <25nmol/L) (Nozza & Rodda, 2001) have since been conducted.   
In addition, maternal status in pregnancy may impact on foetal growth (Bowyer et al., 2009), 
foetal bone accrual and subsequent bone size (Viljakainen et al., 2011; Viljakainen et al., 2010).  
Impacts on foetal bone have been seen as early as 19 weeks gestation using high resolution 3D 
ultrasound (Mahon et al., 2010), and out to 20 years post-partum (Zhu et al., 2014).  RCT studies 
from regions with high rates of infant growth problems, have also suggested improvements in 
early postnatal linear growth (Roth et al., 2013).    
Dental health also appears important.  This was first seen in an early study from 1973, showing 
the presence of enamel hypoplasia in those with early neonatal tetany associated with maternal 
vitamin-D deficiency (Purvis et al., 1973).  More recently, increased prevalence of early onset 
dental caries has been associated with poorer prenatal maternal vitamin D status (Schroth et 
al., 2014). 
 
1.5.1.2 Supplementation trials in pregnancy and neonatal vitamin D status  
Given the above, it was clearly apparent that pregnancy is an ideal time to ensure adequate 
vitamin D status.  There are many reasons for this, including the high rates of deficiency 
described in previous sections, and noting the attractive potential of treating two patients in 
one go.  The ideal situation would be safely increasing both maternal and foetal status enough 
during pregnancy, so that no infant supplementation would be required during lactation.   
42 
 
While there is limited data with follow up out to 4-6 months of exclusive breast-feeding, some 
evidence exists (Grant et al., 2014; Hollis, Johnson, Hulsey, Ebeling, & Wagner, 2011; March et 
al., 2015; Roth et al., 2013), with the most recent study by March et al (March et al., 2015).  
These studies have demonstrated that supplemental vitamin D doses ranging between 400 to 
2000 IU/d during pregnancy result in substantially higher cord blood 25(OH)D (ranging from 73 
to 95 nmol/L).  March et al, supplemented mothers with 2000 IU/d from mid-pregnancy, and 
this appeared to protect 98% of unsupplemented breastfed infants against vitamin D deficiency 
(serum 25(OH)D < 30 nmol/L) out to at least until 8 weeks postpartum, the end point of the 
study (March et al., 2015).   
In the only New Zealand study examining this to date, maternal pregnancy doses of 1000-2000 
IU daily were given from 27 weeks gestation until delivery (Grant et al., 2014).  This treatment 
considerably increased maternal status at 36 weeks compared to placebo, by 35nmol/L (95% CI 
27.5-42.5), as well as infant cord blood status (by 27.5nmol/L).  When combined with 
subsequent infant supplementation at 400IU or 800IU / day from birth to 6 months of age, 82-
92% of infants had 25OHD status >50nmol/L at aged 6 months.  In addition, no safety concerns 
were raised (at the above vitamin D supplementation doses) by this or any of the above 
pregnancy intervention studies.  It must be noted that in order to achieve these rates of 
sufficiency at 6 months of age, postnatal infant supplementation was also required.      
These studies highlight some important issues.  Firstly, cord blood 25OHD levels reflect maternal 
status at delivery (but are overall lower, on average 35nmol/L lower than maternal 36 week 
gestation levels in the grant et al study) (Grant et al., 2014).  This means that maternal 
pregnancy 25OHD status must be clearly > 50nmol/L in order to avoid deficiency in all infants 
at birth, highlighting the importance of maternal supplementation during pregnancy.  Secondly, 
it is likely some form of infant supplementation is required regardless of maternal 
supplementation in pregnancy, to ensure sufficiency in exclusively breastfed infants to 4-6 
months postnatally.  At this stage, the currently available data only supports infant protection 
from 2000IU daily maternal pregnancy supplementation out to 8 weeks post-partum (March et 
al., 2015), at which point, in order to maintain sufficiency, additional infant supplementation is 
likely required.   
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1.5.1.3 Longitudinal studies in pregnancy  
There are a number of published longitudinal studies investigating pregnancy vitamin D status 
and beyond to varying degrees, of which only three had been published when the longitudinal 
study detailed in Chapter 4 was commenced.  In addition, to date all available studies are from 
the northern hemisphere, latitudes ranging from 39°N - 63.8°N (Cross, Hillman, Allen, Krause, & 
Vieira, 1995; Haliloglu et al., 2011; Holmes, Barnes, Alexander, McFaul, & Wallace, 2009; 
Lundqvist, Sandstrom, Stenlund, Johansson, & Hultdin, 2016; Milman, Hvas, & Bergholt, 2011; 
Ritchie et al., 1998; Zhang, Lucey, Horgan, Kenny, & Kiely, 2014).   
The first, published in 1995, followed 10 women (39°N Kansas, US) who were part of a larger 
calcium supplementation trial, and therefore 6 out of 10 participants were in a calcium 
intervention arm during the study (Cross et al., 1995).  Key findings were an increase in 25OHD 
over pregnancy, while on a pregnancy supplement containing vitamin D, and PTH 
concentrations that were higher post-weaning than during pregnancy (p<0.01).  1,25(OH)2D 
levels also increased across pregnancy and then declined during lactation and post-weaning.  
An important factor in these participants was the sufficient 25OHD in all subjects throughout 
the study (likely due to dietary fortification and pregnancy supplement use).  This makes the 
findings less translatable to the NZ setting where deficiency is common, and season is a major 
determinant of status.  
The second, published in 1998 (Latitude 40°N Berkley, US) is similar, again largely focusing on 
calcium, and with only 14 participants.  Like Cross et al. above, as the focus was on calcium, 
season is not mentioned nor taken into account which is an important confounder of 25OHD 
status, and again all participants were taking vitamin D and calcium supplements (Cross et al., 
1995; Ritchie et al., 1998).  Similarly, PTH also appeared lower in pregnancy, but this did not 
achieve statistical significance.  If this were a valid observation, a potential contributory 
mechanism could be secondary to 1,25(OH)2D increases in pregnancy (Ritchie et al., 1998).   
The third study, published in 2009, was confined to pregnancy, with no postnatal assessment, 
and was in 99 women, at latitude 54-55°N Belfast, Ireland.  Similar to the study by Cross et al., 
assessments were taken around 12, 20, and 35 weeks (Holmes et al., 2009).  Compared to Cross 
and Ritchie, only 22% were on a vitamin D containing multivitamin preparation.  Spanning 
pregnancy, between 76-96% of all participants had a 25OHD level <50nmol/L.  Season and low 
supplementation were risk factors.  Non-pregnant controls were included, and 25OHD status in 
pregnancy was significantly lower than non-pregnancy, with 25OHD levels increasing at the end 
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of pregnancy and postpartum (although season clearly played a role in this increase as 1st 
trimester was winter for all, with all deliveries in summer).    
A trend of decreasing maternal 25OHD as pregnancy progressed was also seen in a recent study 
from Zhang et al, who reported this pattern irrespective of season (Zhang et al., 2014).  This has 
also been seen compared to non-pregnancy controls in one study(Holmes et al., 2009).  
However, Milman et al (Milman et al., 2011) found an increase in 25OHD until 32 weeks 
followed by a decrease to delivery.  From Scandinavia, Lundqqvist et al (Lundqvist et al., 2016) 
similarly found a steady increase over pregnancy, as has Park et al. based on a single 
measurement at 26-29weeks (Park et al., 2016).  The reason for these contrasting results 
remains uncertain, but differing season, dietary intake/supplement use/other life style factors, 
and ethnicity potentially all may play a role.  Physiological explanations may also be possible, 
including variations in the VDR, or vitamin D binding protein (VDBP).  Analysis issues may also 
contribute, for instance the detection or not of the C3-epimer of vitamin D (Yazdanpanah, 
Bailey, Walsh, Wan, & Adeli, 2013), which has also been shown to increase in pregnancy (Park 
et al., 2016).   
Fluctuation in other aspects of vitamin D metabolism have been revealed in pregnancy by these 
longitudinal studies, and may have a role in these 25OHD changes.  This includes increasing 
VDBP levels during pregnancy (Park et al., 2016; Zhang et al., 2014), and the possible PTH 
suppression mentioned above and in Haliloglu et al. (Haliloglu et al., 2011)).  Certainly, 
compared to non-pregnancy, the relationship between PTH and 25OHD appears weaker.  
1,25OHD levels have also been reported to increase as pregnancy progresses (Hollis et al., 
2011), and this is likely interconnected to these possible VDBP and PTH changes (Cross et al., 
1995; Ritchie et al., 1998; Wilson, Retallack, Kent, Worth, & Gutteridge, 1990).  Increases in 
1,25(OH)2D are likely due to increased maternal renal and placental 1αhydroxylase activity 
(Turner, Barre, Benjamin, Goltzman, & Gascon-Barre, 1988).     
There are limitations in this available northern hemispheric longitudinal data.  These include: 1) 
variable and often high rates of maternal supplement use, varying from 22-100% of participants; 
2) high rates of dietary fortification (when documented), estimated to equate to approximately 
200IU/day; 2) infant data is not included; 3) variable reporting of PTH; and 4) variable reporting 
and distribution of participants by season (Cross et al., 1995; Haliloglu et al., 2011; Holmes et 
al., 2009; Lundqvist et al., 2016; Milman et al., 2011; Ritchie et al., 1998; Zhang et al., 2014).  
The mixed findings of these studies, and their potential limitations, leave many questions 
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unanswered regarding vitamin D status and metabolism longitudinally during pregnancy and 
lactation.   
Finally, an important message coming from these studies is that overall, vitamin D deficiency 
(25OHD <50nmol/L) is not uncommon, being seen in 19-96% of participants at one or more time 
points (Holmes et al., 2009; Milman et al., 2011).  Based on this, all these studies conclude with 
a statement on the importance of supplementation with vitamin D during pregnancy in the 
Northern hemisphere context.  Public health policy in New Zealand currently uses a targeted, 
albeit vague strategy, stating that women at “higher risk” may benefit from supplementation 
(Ministry of Health, 2013). Further, other than in large doses (50,000IU capsules), there is 
currently no funded daily vitamin D supplement in New Zealand.  However, the policy also 
specifically states these guidelines will be updated when new research comes to light, and 
acknowledges that New Zealand studies are ongoing.   
Chapter 4 of this thesis focuses on a longitudinal descriptive study in pregnancy and contributes 
new knowledge, including describing status in largely unsupplemented infants and mothers out 
to month five of lactation.  An aim of the project is to provide further information to inform 
public policy on vitamin D during pregnancy and lactation, and in particular, to add detailed 
longitudinal data from southern NZ.      
 
1.5.2 Vitamin D and Lactation  
Breast milk is the ideal food for infants, with current global recommendations aiming for 6 
months of exclusive breastfeeding (Kramer & Kakuma, 2002; Ministry of Health, 2013).  
However, breast milk is not normally a significant source of vitamin D for the neonate unless 
maternal supplement intakes are >2000IU/day (A. Catharine Ross & Institute of Medicine (U. 
S.). Committee to Review Dietary Reference Intakes for Vitamin D and Calcium., 2011).  This is 
compounded by the fact that vitamin D deficiency is common in pregnancy and in women of 
childbearing age (Saadi et al., 2007).  In addition, as mentioned previously, unsupplemented 
breastfeeding (particularly when prolonged) is an independent risk factor for VDDR.   
Given this, a number of countries and guidelines recommend universal supplementation of 
breastfed infants with daily vitamin D (usually 400 IU/day) (Finberg, 1981; Munns et al., 2016; 
Wagner et al., 2008).  However, uptake of infant supplementation can be variable (Crocker et 
al., 2011; Gallo et al., 2010; Perrine et al., 2010; Taylor et al., 2010), with up to 80% of breastfed 
46 
 
infants failing to reach RDIs of vitamin D (Ahrens et al., 2016).  This has led to a number of 
studies investigating strategies of increasing breast milk vitamin D content via maternal 
supplementation.  This section will therefore address the literature on breastmilk vitamin D, 
and supplementation trials to increase breastmilk vitamin D concentrations.   
 
1.5.2.1 How much vitamin D is there in breast milk? 
It is well established that breast milk is not naturally a significant source of vitamin D.  While 
Hess and early researchers in the 1920s noticed that there were high rates of rickets even in 
breastfed babies (Hess & Weinstock, 1924b), it was not until the 1980s that Hollis et al. in a 
number of studies using high-performance liquid chromatography (HPLC), confirmed the 
naturally low vitamin D concentrations in milk (Hollis, 1983; Hollis, Roos, Draper, & Lambert, 
1981).  These and other more recent studies have confirmed in natural, non-fortified (e.g. 
exposed to high dose maternal supplements/UVB) human milk the vitamin D mean activity 
appears to range from 35-52nmol/L(Hollis & Wagner, 2004; Wall et al., 2016).   
This vitamin D activity of human milk is predominantly composed of dietary cholecalciferol or 
ergocalciferol, with only a small proportion coming from 25OHD (Greer, Hollis, & Napoli, 1984; 
Oberhelman et al., 2013).  As a result, milk vitamin D activity is largely dependent on how much 
D2 or D3 is consumed, or generated by UVB exposure (D3 only), and this D3 is only detectable in 
milk for a very short period (out to 3-7 days) post-ingestion (Oberhelman et al., 2013).  
It should also be noted that measuring vitamin D activity in milk is a complex and expensive 
process, particularly relating to obtaining an appropriate milk sample (as most vitamin D activity 
is in the fat of hind milk (Hollis, 1983; Hollis & Wagner, 2004)); and extraction of lipid and other 
sample preparation prior to analysis(Hollis, 1983).  These factors have limited the analysis (and 
for those analysing - the accurate analysis) of breastmilk vitamin D activity, with only a handful 
studies actually achieving this (Hollis & Wagner, 2004; Saadi et al., 2009; Wagner, Hulsey, 
Fanning, Ebeling, & Hollis, 2006; Wall et al., 2016).  Once specimen preparation has occurred 
the final analysis includes the measurement and addition of relevant compounds including 
vitamin D2, D3, 25OHD2 and 25OHD3(Wall et al., 2016).      
These findings have led to major guidelines, including the global consensus recommendations 
on the prevention and management of nutritional rickets recommending traditional RDIs of 
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vitamin D for lactating mothers to support their own needs, but not as a means of 
supplementing their infants (Munns et al., 2016).       
 
1.5.2.2 Can we increase the vitamin D content of breast milk?  
The naturally low human milk levels leads to an important question of whether maternal 
supplementation could provide adequate vitamin D intake for both mothers and their babies 
during lactation.   
Hess was the first to ask this question, and he conducted a number of experiments using cod 
liver oil in rats.  Unfortunately, all failed to show a benefit (Hess & Weinstock, 1924b).  This led 
to little interest in breastmilk as a vehicle for preventing or treating rickets until the late 20th 
century.  In the 1980s, the first studies by Greer and Hollis confirmed that breastmilk vitamin D 
activity could be substantially increased, and in one publication up to a staggering equivalent of 
7660 IU/L (compared to the 400 IU/L of most infant formula milks) (Greer et al., 1984).  In 
another of these early works, they showed that using UVB exposure to the mother, milk 
concentrations of up to 148IU/L were achievable.  An important conclusion of this work was 
that, even with this UVB intervention, the human milk concentration was still well below half of 
the RDI for infants (400 IU/L).  
The first randomised study to investigate the impact of maternal supplementation on both 
maternal and infant status was conducted by Hollis and Wagner (Hollis & Wagner, 2004).  They 
supplemented 18 lactating women beginning at 1 month postpartum with either 1600 or 3600 
IU/day of ergocalciferol (vitamin D2) for 3 months, together with a supplement of 400 IU/D 
vitamin D3.  At 4 months of age, infants had attained a mean of 25OHD concentration of 69 and 
77 nmol/L, for the two doses respectively.  The authors concluded that maternal vitamin D 
intakes ≥ 4000 IU/d appear to ensure adequate infant vitamin D status.  There are some 
important limitations with this study, in particular the lack of a control group, lack of blinding, 
and accounting for the concurrent daily supplementation with daily vitamin D (400IU/day) that 
all infants received.  Moreover, a number of observational studies examining vitamin D status 
over time in unsupplemented infants have observed similar increases in infant 25OHD (Challa 
et al., 2005; Grant et al., 2014; Kim et al., 2010; Narchi, Kochiyil, Zayed, Abdulrazzak, & Agarwal, 
2011; Perumal, Al Mahmud, Baqui, & Roth, 2017; Ziegler, Hollis, Nelson, & Jeter, 2006).  Similar 
issues regarding lack of controls and often inadequate blinding have plagued all available 
maternal supplementation trials to date (Hollis & Wagner, 2004; Hollis et al., 2015; March et 
48 
 
al., 2015; Oberhelman et al., 2013; Saadi et al., 2009).  Only the well-designed New Zealand 
study by Wall et al. avoids all of these limitations (Wall et al., 2016).  However, the maternal 
intervention was limited to pregnancy, with no postnatal supplementation.  In addition, at 2 
weeks postpartum the mean milk vitamin D activity was only 74IU/L in the women taking the 
largest pregnancy supplementation dose (2000IU/day), compared to 51IU/L in the placebo 
group.  These levels are, again, well below RDIs for breastfed infants, and consistent with what 
is known about the duration of D3 in human milk (Oberhelman et al., 2013).       
The results from the available maternal breastmilk supplementation studies are highlighted in 
Figure 7. 
  
Figure 7: Maternal supplementation trials and milk outcomes (Munns et al., 2016).  Used with 
permission Oxford University Press and The Endocrine Society.  
At the time the present study detailed in Chapter 3 was commenced, little data was available 
on intermittent moderate-to-high dose maternal supplementation.  Intermittent dosing is an 
attractive option for maternal adherence, as even in the trial setting 10-20% of participants in 
the original Hollis/Wagner study reported poor compliance e.g., missed doses (Hollis & Wagner, 
2004).  Subsequently, the Oberhelman study, detailed above in Figure 7 was published 
(Oberhelman et al., 2013).  This was a two-arm study comparing a single maternal vitamin D3 
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dose of 150,000 IU to 5000 IU/day over 28 days.  Maternal and infant outcomes with either 
regimen were similar, with significant increases in both maternal and infant serum 25OHD 
concentrations from baseline (40.8 nmol/L) to Day 28 (96.8 nmol/L) (Oberhelman et al., 2013).  
However, this study only administered a single 150,000 IU dose.  The safety of this dosage with 
regular use (e.g. every 4 weeks spanning 4-6 months of lactation) is unknown, and currently 
exceeds the tolerable upper intake level of daily intake suggested by the U.S. IOM by over 30% 
(A. Catharine Ross & Institute of Medicine (U. S.). Committee to Review Dietary Reference 
Intakes for Vitamin D and Calcium., 2011).   
 
1.5.2.3 Summary 
Pregnancy and lactation are of great importance for both maternal and infant vitamin D status.  
Studies spanning this vital period of the human life cycle highlight that maternal vitamin D status 
in pregnancy determines infant status at birth, with the two closely correlated.  There are few 
studies longitudinally assessing pregnancy and lactation, especially providing dual maternal and 
infant data.  The available studies confirm that vitamin D deficiency during pregnancy and 
lactation is common, and that a number of aspects of vitamin D and calcium metabolism appear 
altered during these stages.   
While breastmilk is the ideal food source for infants, it is not naturally a rich source of vitamin 
D.  However, there is growing evidence that breast milk concentrations can be increased, and 
at times quite impressively, with moderate-to-high dose daily, and intermittent maternal 
supplementation.  The results of the studies investigating this to date must also be interpreted 
with some caution, due to a number of methodological limitations.  In addition, to date, only 
high maternal doses, exceeding those recommended by the IOM, have been shown to achieve 
milk vitamin D activities similar to or exceeding infant RDIs.  For this reason, pending new 
information, global recommendations for preventing rickets continue to recommend daily 
infant supplementation only (Munns et al., 2016; A. Catharine Ross & Institute of Medicine (U. 






1.6 Thesis Objectives 
This thesis aims to investigate aspects of the role of vitamin D during pregnancy, lactation, and 
childhood.  This encompasses the broad goal of increasing understanding and awareness of 
vitamin D deficiency rickets in children, and vitamin D status in pregnancy, as well as a better 
understanding of maternal supplementation to prevent vitamin D deficiency in exclusively 
breast-fed infants and their mothers.     
Specific Aims 
Chapter 2: 
1) To determine the annual incidence of vitamin D deficiency rickets in New Zealand 
children 
2) To describe the associated clinical and demographic characteristics of New Zealand 
children with rickets. 
Chapter 3: 
3) To evaluate, by way of a randomised placebo controlled trial, the effect of two 
different intermittent monthly doses of maternal Cholecalciferol supplementation, 
over 5 months of exclusive breastfeeding, on serum 25OHD status of both the infant 
and mother.    
Chapter 4: 
4) To describe longitudinal vitamin D and PTH status throughout pregnancy, and for the 









2 Paper 1 - Incidence and characteristics of vitamin D deficiency 
rickets in New Zealand children 
2.1 Preface 
The following chapter contains a published original manuscript titled “Incidence and 
characteristics of vitamin D deficiency rickets in New Zealand children: A New Zealand Paediatric 
Surveillance Unit study”.  This manuscript was published in the Australian and New Zealand 
Journal of Public Health in 2015. Aust NZ J Public Health 2015 Aug;39(4):380-3. doi: 
10.1111/1753-6405.12390. Epub 2015 Jun 29 (B. J. Wheeler, Dickson, Houghton, Ward, & 
Taylor, 2015). 
As established in chapter one, worldwide vitamin D deficiency is common during pregnancy, 
and childhood.  However, for rickets, most data in children comes from retrospective case series 
studies, often taken from hospital records.  To date, and at the time this study was conducted 
and published, only two prospective national data sets were available, from Canada (Ward et 
al., 2007) and Australia (Munns et al., 2012).  In addition, the only New Zealand data available 
was published in 1998, a retrospective audit of rickets presentations to the Starship Children’s 
Hospital.           
Therefore, the aims of this chapter/project were to prospectively determine the annual 
incidence of vitamin D deficiency rickets in New Zealand children as recognised by 
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To investigate the incidence and characteristics of vitamin D deficiency rickets in New Zealand. 
Methods 
Prospective surveillance of Vitamin D Deficiency Rickets among specialist paediatricians was 
conducted by the New Zealand Paediatric Surveillance Unit (NZPSU), for 36 months, from July 
2010 – June 2013 inclusive.  Inclusion criteria were: children and adolescents <15 years of age 
with vitamin D deficiency rickets (defined by low serum 25-hydroxyvitamin D and elevated 
alkaline phosphatase levels, and/or radiological rickets). 
Results 
Fifty-eight children with confirmed vitamin D deficiency rickets were identified.  Median age 
was 1.4 (range 0.3 – 11) years, 47% were male, and 95% of children were born in New Zealand, 
however the majority of the mothers (68%) were born outside New Zealand.  Overall annual 
incidence of rickets in children aged <15 years was 2.2/100,000 (95% CI 1.4-3.5); with incidence 
in those < 3 years, 10.5/100,000 (95% CI 6.7-16.6).  Skeletal abnormalities, poor growth, and 
developmental motor delay were the most common presenting features, with hypocalcaemic 
convulsion in 16% of children.  Key risk factors identified were: darker skin pigment, Indian and 
African ethnicity, age <3 years, exclusive breast feeding, and southern latitude, particularly 
when combined with season (winter/spring).  Of the patients reported, none had received 
appropriate vitamin D supplementation.   
Conclusions 
Vitamin D deficiency rickets remains a health problem for New Zealand children.  Key risk factors 
remain similar to those identified in the international literature. Preventative targeted vitamin 
D supplementation, as per existing national guidelines, was lacking in all cases reported.   
Implications 
Vitamin D deficiency rickets is the most significant manifestation of vitamin D deficiency in 
growing children.  To reduce the incidence of this disease among those at high risk, increasing 
awareness and implementation of current public health policies for targeted maternal, infant, 




Vitamin D is critical for calcium homeostasis and mineralization of the skeleton, especially 
during periods of growth.  A severe deficiency in vitamin D can result in rickets (a mineralization 
defect at the epiphyseal growth plates, specific to growing children), and osteomalacia (a 
mineralization defect of bone tissue).  Clinically, rickets may be associated with pain, fractures, 
skeletal deformity, growth retardation, defects in dental enamel, delayed developmental 
milestones, and hypocalcaemic tetany and seizure (Ladhani et al., 2004; Ward et al., 2007; 
Weisberg et al., 2004). 
The main determinants of vitamin D status in humans are: any factor which limits the exposure 
of the epidermal layers of the skin to ultraviolet B radiation (UVB) from sunlight including darker 
skin, clothing/veiling, sunscreen, indoor lifestyle, and seasonal changes in countries at higher 
latitudes, such as New Zealand (35 to 47 degrees south) (Elder & Bishop, 2014; M. F. Holick, 
2007); and dietary intake (including human milk), which in the absence of fortification is not 
normally an important source.  Worldwide, there has been increasing concern that the number 
of children suffering from vitamin D deficiency and vitamin D deficiency rickets may be 
increasing (Allgrove, 2004; Elder & Bishop, 2014). 
Currently, there are no national statistics on vitamin D deficiency rickets in New Zealand.  
However, there is increasing evidence that vitamin D deficiency in pregnant women, infants and 
young children is relatively common (Blok et al., 2000; Camargo et al., 2010; Grant et al., 2009; 
Houghton et al.; Judkins & Eagleton, 2006).  The aim of this study was to determine the current, 
annual incidence of vitamin D deficiency rickets in New Zealand children as recognised by 
paediatricians, and to describe the associated clinical and demographic characteristics. 
 
2.2.2 Methods 
The New Zealand Paediatric Surveillance Unit (NZPSU) (Dow et al., 1999) was used to 
prospectively collect cases of vitamin D deficiency rickets for 36 months, between July 2010 and  
June 2013 inclusive.  The NZPSU undertakes surveillance of a number of uncommon childhood 
conditions through a reporting card or email sent to New Zealand paediatricians (approximately 
n=220, representing approximately 92% of New Zealand paediatricians registered with the 
Medical Council) on a monthly basis, asking if they have seen any cases of conditions under 
surveillance.  We included vitamin D deficiency rickets in children and adolescents under 15 
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years of age on the monthly card/email over this period.  During the study period, the mean 
NZPSU response rate was 92%. 
In response to a notification of vitamin D deficiency rickets, a questionnaire was then sent to 
obtain relevant de-identified clinical, biochemical, management, and demographic data.  
Demographics collected included date of birth, gender, parental/child ethnicity and place of 
birth, pregnancy/ birth details, feeding and breastfeeding history, previous use of supplements 
and/or formula, clinician observed child/parental skin colour, and history of veiling. 
Vitamin D deficiency rickets was defined as:  25-hydroxyvitamin D (25OHD) <50 nmol/L, and 
elevated alkaline phosphatase (ALP) levels (as per local pathology service reference values), 
and/or radiological rickets.  Exclusion criteria were any case of vitamin D deficiency rickets 
associated with an underlying chronic disease such as fat malabsorption, liver disease and renal 
insufficiency, all genetic forms of rickets, and being on total parenteral nutrition.  Forms were 
returned directly to the investigators and reviewed, to determine inclusion. 
Descriptive results are expressed as median (range).  Incidence rates were annualised based on 
the number of cases over the 36-month study period.  Estimates of population by age group 
were provided by Statistics NZ 2013 national census data (Statistics New Zealand, 2014) and 
95% confidence intervals were calculated using the Poisson distribution.  Ethical approval for 




Over the 36-month study period, 73 cases of vitamin D deficiency rickets were notified from 38 
different specialists.  Of these, 15 cases were excluded due to either not meeting case definition 
e.g. having isolated vitamin D deficiency, and/or not having a raised ALP and/or radiological 
evidence of rickets (n=13), or being duplicate cases (n=2), hence 58 cases were confirmed. 
Incidence of reported vitamin D-deficiency rickets 
The overall annual incidence of reported rickets was 2.2/100,000 (95% CI 1.4-3.5) for children 
and adolescents under 15 years of age.  For children less than 3 years, the incidence was higher 
at 10.5/100,000 (95% CI 6.7-16.6).  The incidence rates for all confirmed cases of vitamin D 
deficiency rickets by region are presented in Table 5, with highest rates among case children 
residing at the highest latitude in the South Island. 
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Table 5: Incidence of vitamin D deficiency rickets in New Zealand by province (ranked north to south) and age group 
  Age group, years 
  <3 3 - <15 
Combined Provincial Regions Total no. (%) of 
confirmed cases 





rate per 100 000 





rate per 100 000 
Auckland/Northland 19 (33) 19 68241 9.3 (4.3-20.2) - - - 
Waikato/Bay of 
Plenty/Taranaki/ Gisborne 
9 (15) 8 35286 7.6 (2.3-25.1) 1 145161 0.2 (0.01-6.9) 
Wellington/ Hawke’s Bay/ 
Wanganui  
14 (24) 13 34041 
 





5 (9) 5 25920 6.4 (1.4-29.3) - - - 
Otago/Southland 11 (19) 10 10881 30.6  (10.5-89.6) 1 44112 0.8 (0.03-22) 
Total 58 (100) 55 174369 10.5 (6.7-16.6) 3 696009 0.1 (0.02-1.0) 
‡Population estimates provided by statistics New Zealand, from 2013 census data.   
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Description of the children with rickets  
Median age of children presenting with vitamin D deficiency rickets was 1.4 (range 0.3 – 11) 
years and 17 (47.0%) were male.  Median birth weight was 3185 (1970-4300) grams.  Of those 
with known birth gestation (52), most (45 [86.5%]) were born full term (gestation ≥37 weeks), 
with 7 (13.5%) born between 32-36 weeks, and none under 32 weeks gestation.   
The vast majority of the children (55 [95%]) were born in New Zealand, as opposed to only 13 
(22.4%) of their mothers. Table 6 shows the country of birth of the child and of the mother; 
most of the latter were born in Africa (14 [24.1%]) and India (13 [22%]).  Similarly, maternal 
ethnicity, which differs in some cases from place of birth, in descending order of frequency was 
as follows: 24 (41.4%) Asian (Indian 21, Pakistani 1, Nepalese 1, Malaysian 1); 16 (27.6%) Middle 
Eastern/Latin American/African (African 14, Middle Eastern 2); 10 (17.2%) European; 5 (8.6%) 
Pacific; and 3 (5.2%) Maori. Paternal ethnicity as reported was very similar:  Asian 23 (40.0%); 
Middle Eastern/Latin American/African 16 (27.6%); European 10 (17.2%); Maori 5 (8.6%); Pacific 
3 (5.2%).  Most of the children had dark (29 [50%]), or intermediate (18 [31%]) skin colour, with 
the remaining cases identified as being fair-skinned. 
Table 6: Region of birth of children with vitamin D deficiency rickets and their mothers 
Child country of 
birth 
n (%) Mother n (%) 
New Zealand 55 (94.8%) Africa  14 (24.1%) 
Pacific 1 (1.7%) India 13 (22.4%) 
Middle East 1 (1.7%) New Zealand 13 (22.4%) 
Africa 1 (1.7%) Pacific 8 (13.8%) 
  Other Asian  4 (6.9%) 
  Middle East 2 (3.4%) 
  North America 1 (1.7%) 




A history of exclusive breastfeeding (past and/or current) was reported in most cases (54/58 
[93.1%]), with a median duration of 11 (range 2 – 26) months. Any exposure to commercial 
infant formula was present in 18 (31.0%) children.  Only 5 [(8.6%) had received any vitamin D 
supplementation prior to diagnosis.  Of these, four had been prescribed 400 IU vitamin D per 
day as infants (< 1 year of age), however, no data were available on compliance during this 
supplementation period, and all four children were subsequently diagnosed after 2 years of age.  
The remaining case had received 50,000 IU as a single dose just prior to formal diagnosis.  
Likewise, only 2 (3.4%) of all case mothers had received vitamin D supplementation during their 
pregnancy. 
Skeletal abnormality, poor growth, and motor delay were the most common presenting 
features (Table 7).  Median age of those presenting with symptomatic hypocalcaemia was 0.9 
(0.5-2.5) years.  Of the five children presenting with fracture, four were ambulant, and one aged 
3 months experienced multiple fractures (with the possibly of additional non-accidental injury 
subsequently raised), and had biochemical evidence of rickets (25-hydroxyvitamin D 5 nmol/L 
[RR >50]); ALP 746 IU/L [RR 80-360]; PTH 12.5 pmol/L [RR 1-7]; phosphate 1.0 mmol/L [RR 1.15-
2.15]) without x-ray changes at ulna/femur.  All biochemistry returned to within normal ranges 
with vitamin D treatment, and no further fractures occurred during/after treatment with 
alternative care in place.   
Biochemical and x-ray data are outlined in Table 8.  Median age of those without x-ray 
confirmation was 0.8 (0.3 – 2.8) years. Maternal 25-hydroxyvitamin D was available in nearly 
one-third of the mothers (18 of 58) with median concentration of 30 (5 – 68) nmol/L.  Veiling 
was reported in 6 (10%) of case mothers, but none of the children.  Figure 8 depicts the cases 
of vitamin D deficiency rickets by month of diagnosis, with the highest number of cases 









Table 7: Reason for presentation of vitamin D deficiency rickets 
Reason for presentation No. of cases (%), Total n=58† 
Skeletal abnormality/deformity‡ 17 (29.3%) 
Poor growth 15 (25.9%) 
Motor Delay 12 (20.7%) 
Symptomatic hypocalcaemia – Seizure (8) /Tetany 
(1)  
9 (15.5%) 
Bone pain 7 (12.1%) 
Respiratory disease 5 (8.6%) 
Fracture 5 (8.6%) 
Incidental finding 4 (7%) 
Eczema 3 (5.2%) 
Screening (as sibling with rickets) 2 (3.4%) 
Cardiomyopathy 1 (1.7%) 
†Percentages add up to >100% as more than one presenting feature was present in some 
instances 
‡14 with limb deformity; 1 with “swollen wrists”; 2 with large anterior fontanelle/splayed 









Table 8: Biochemical analysis and x-ray status for cases of vitamin D deficiency rickets, 
reported between July 2010, and June 2013  








58 <50 12 5 - 48 58/58 (100%) 
Alkaline 
phosphatase (IU/L) 
58 80 - 360† 768 361 - 3100 58/58 (100%) 
Parathyroid 
hormone (pmol/L) 
43 1.0 – 7.0 24.7 1.1 – 96.5 34/43 (79%) 
Calcium  
(mmol/L) 
55 2.1 – 2.65* 2.3 1.1 – 2.7 20/55 (36%) 
Phosphate  
(mmol/L) 
55 0.9 – 2.2* 1.3 0.5 – 2.2‡ 19/55 (35%) 
Ferritin#  
(mcg/L) 
28 15 - 150 25.5 2.9 - 288 6/28 (21%) 
Mean cell volume 
(f/L) 




41 - - - 41/53 (77.4%) 
†Quoted reference range for Canterbury Health Laboratories. Laboratory ranges varied by age 
and location, leading to 100% incidence of elevated levels 
*Reference ranges vary based on age.  Cut-point determined by age appropriate ranges. 
‡No phosphate was elevated based on age appropriate cut points 
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Figure 8: Cases of vitamin D deficiency rickets by month of diagnosis
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In this prospective analysis of vitamin D deficient rickets, we found an incidence rate for children 
under three years of 10.6/100,000.  This is the first national New Zealand study, and one of the 
few studies worldwide, to prospectively assess the incidence of vitamin D deficiency rickets.  
Our findings raise concerns about the implementation and awareness of current targeted 
guidelines for prevention of vitamin D deficiency and rickets.  For the majority of cases, given 
they had defined risk factors and were born in New Zealand, prevention guidelines were not 
followed, as seen by the lack of vitamin D supplementation, in both the cases and their mothers. 
Rickets is the most profound manifestation of vitamin D deficiency.  In the New Zealand context, 
a number of prevention guidelines are available (Ministry of Health, 2006, 2013; Paxton et al., 
2013).  Over the time period of the study, the New Zealand Ministry of Health recommended 
that health practitioners identify breastfeeding women and infants at risk of vitamin D 
deficiency, and encourage the consumption of oily fish, eggs, and vitamin D fortified margarine.  
In addition, it has been recommended that targeted supplementation of 400 IU to the mother 
and infant should be considered (Ministry of Health, 2006).  In April 2013 (two months before 
the study completed), a formal targeted supplementation strategy for breastfed infants at risk 
was adopted (Ministry of Health, 2013).  It remains important to emphasise that while breast 
milk remains the ideal fluid source for infants, it is well known that it is not a rich source of 
vitamin D.  Because of this, and the potential difficulties in implementation of a targeted 
strategy, many higher latitude countries have recommended universal supplementation of 
predominantly breastfed infants (Gartner, Greer, Section on, & Committee on Nutrition. 
American Academy of, 2003; Wagner et al., 2008).  Additionally, as maternal vitamin D 
deficiency in pregnancy is a significant risk factor for rickets (Nozza & Rodda, 2001; Thomson, 
Morley, Grover, & Zacharin, 2004; Wharton & Bishop, 2003), targeted pregnancy screening and 
supplementation has also been recommended in a recent Australian and New Zealand 
consensus statement (Paxton et al., 2013).  With minimal supplementation seen for reported 
cases in high-risk mothers during pregnancy and their offspring, our data highlight the 
importance of implementing current maternal and child vitamin D guidelines for targeted 
supplementation. 
The overall incidence rate in all children < 15 years of 2.2/100,000, is similar to Canada 
(2.9/100,000) (Ward et al., 2007), but less than recently published Australian data (4.9/100,000) 
(Munns et al., 2012).  However, when excluding those screened in Australia as refugees, the 
rate would be considerably higher than the Australian data, where refugee screening 
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contributed 75% of cases.  It is no surprise that the non-refugee New Zealand incidence, 
excluding those screened at immigration is higher given the latitude of New Zealand.  This is 
most markedly shown in the data from the southern (44-46 degrees south) Otago/Southland 
region, where the incidence is >30/100,000.  Additionally, 10.6/100,000 incidence in the under 
3 age group appears higher than Australian data (<4 years, 5.9/100000).  Our data supports past 
reports (Ladhani et al., 2004; Ward et al., 2007), highlighting age < 3 years as a peak time for 
development and diagnosis of rickets, as well as the serious associated complications of seizures 
and symptomatic hypocalcaemia.   
Our data support existing literature, highlighting risk factors such as breastfeeding, darker skin, 
and migrant status of the mother (Munns et al., 2012; Nozza & Rodda, 2001; Ward et al., 2007; 
Weisberg et al., 2004).  In addition, the observed influence of season and latitude were 
contributing factors, as seen in similar prospective Australian data (Munns et al., 2012).  Indian, 
and African ethnicities account for the majority of vitamin D deficiency rickets cases reported.  
This finding builds on a previous case series from New Zealand (Blok et al., 2000), as well as data 
from around the world, emphasising skin colour and specific ethnicities, that are frequently 
associated, as key risk factors (Kreiter et al., 2000; Ladhani et al., 2004; Robinson et al., 2006; 
Weisberg et al., 2004).   
Skeletal deformity, poor growth, and motor delay were the most common presenting features.  
Symptomatic hypocalcaemia was also present in 16% of children, exclusively in those ≤ 2 years, 
as seen in Ward et al (Ward et al., 2007), but less than in retrospective hospital case series 
(Ladhani et al., 2004; Nozza & Rodda, 2001; Robinson et al., 2006).  Skeletal deformity (excluding 
older screened refugees, which made up >80% of Australian data) was also the most common 
presenting feature in the only other prospective data for comparison (Munns et al., 2012; Ward 
et al., 2007).  Again, similar to all previous prospective studies, x-ray changes were present in 
approximately 80% (Munns et al., 2012; Ward et al., 2007). 
A particular strength of this study is the prospective data collection, using an established 
surveillance network that encompasses New Zealand’s currently practising paediatricians.  The 
detailed data collection provides robust information on characteristics of those diagnosed with 
vitamin D deficiency rickets.  Study weaknesses include the issue of under-reporting/under 
diagnosis.  The study was limited to paediatricians and will therefore underestimate the overall 
incidence.  Under reporting of cases is a possibility; in particular, the Canterbury region of the 
South Island experienced two catastrophic earthquakes in the first year of reporting, perhaps 
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accounting for the lower number of cases reported from this region.  In addition there is 
possible under diagnosis, which is likely as few cases were reported as incidental findings as 
part of screening programs.  These factors would mean that overall observed incidence rate 
calculated is at least 2.2/100,000 for children and adolescents under 15 years of age and 
10.5/100,000 for children less than 3 years.   
In conclusion, vitamin D deficiency rickets is a health concern for New Zealand children, with a 
higher incidence seen, in those with mothers from India and Africa, children under three years 
of age who are currently or were previously breastfed, and those living further south at a higher 
latitude.  The question remains as to whether rickets has re-emerged in recent years, or whether 
it has simply remained a persistent problem.  To reduce the incidence of this disease among 
those at risk, efforts should be focused on increasing awareness, and implementation, of 















3 Paper 2 – The Vitamin D and Breastfeeding study 
3.1 Preface 
The following chapter contains a published original manuscript titled “High-Dose Monthly 
Maternal Cholecalciferol Supplementation during Breastfeeding Affects Maternal and Infant 
Vitamin D Status at 5 Months Postpartum: A Randomized Controlled Trial”.  This manuscript 
was published in The Journal of Nutrition in 2016. J Nutr. 2016 Oct;146(10):1999-2006. Epub 
2016 Aug 24. (B. J. Wheeler et al., 2016) 
In chapter one it was highlighted that vitamin D is unique among vitamins as its main source is 
not dietary, but direct synthesis in the skin following exposure to UVB radiation, from sunlight.  
However, UVB radiation exposure varies based on latitude, skin colour, sunscreen use and 
clothing (McKenzie et al., 2009).  Unfortunately, changes in human lifestyle including sun 
avoidance practices, indoor occupations and recreation, added to NZ’s geographical location at 
35ºS to 47ºS, mean that children and adults cannot depend on adequate skin exposure to 
sunlight for vitamin D synthesis, especially during winter months (McKenzie et al., 2009; Rockell 
et al., 2008).  At latitude 45 ºS the Otago region is particularly at risk. 
Dietary intake is a secondary source, but without additional supplementation there is little in 
foods most humans normally ingest.  As opposed to many countries NZ currently has no 
mandatory, and little voluntary food supplementation (Ministry of Health, 2013).  Compounding 
this, human milk, which is advocated as the ideal fluid source for infants, is generally low in 
vitamin D and this has led to recommendations for universal supplementation of breast feeding 
infants in some countries (Wagner et al., 2008).   
One of the main reasons breast milk may not be a rich source of vitamin D is that many breast 
feeding mothers are themselves vitamin D deficient (Judkins & Eagleton, 2006; Nozza & Rodda, 
2001).  In addition, some studies suggest that daily or intermittent supplementation of the 
breast feeding mother with high dose vitamin D can safely lead to not only improved vitamin D 
levels for her, but also in her milk and subsequently her nursing infant (Hollis & Wagner, 2004; 
Oberhelman et al., 2013).  However, the results of these studies must be interpreted with 
caution due to the lack of control group, unblinded treatment, and/or concurrent infant vitamin 
D supplementation. 
If effective, supplementation of mothers (and hence their breast milk) would be an attractive 
alternative to universal supplementation of breast-fed infants.  This would support current 
66 
 
WHO recommendations on the importance of breast-feeding and also avoid the issue of direct 
supplementation of exclusively breast-fed infants which in New Zealand can be controversial 
and poorly complied with by families (Taylor et al., 2010).   
The primary aim of this chapter/project was to determine the effect of 2 different intermittent 
monthly doses of maternal cholecalciferol supplementation (weeks 4–20 postpartum) on serum 
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Background:  Many countries recommend daily infant vitamin D supplementation during 
breast feeding, but compliance is often poor.  A monthly, high dose maternal regimen may 
offer an alternative strategy for dual maternal and infant supplementation, but its efficacy is 
unknown.   
Objectives:  The objective of this study was to determine the effect of two different monthly 
maternal doses of cholecalciferol (D3) on both maternal and infant 25-hydroxyvitamin D 
(25[OH]D) status during the first 5 months of breastfeeding.  
Methods:  Using a randomized, double blind, placebo-controlled design, breastfeeding 
women (n=90, mean age 32.1 years) were assigned to receive either placebo/mo, 50,000 
IU/mo, or 100,000 IU/mo of D3 from Week 4 to Week 20 postpartum.  Comparison between 
intervention and placebo groups for change in maternal and infant mean serum 25OHD from 
baseline to week 20 was made using linear regression.   
Results:  Compared to the control group, the effect size for mean change in maternal serum 
25OHD from baseline to Week 20 was 12.8 nmol/L (95%CI 0.4 to 25.2; P=0.043) higher for the 
50,000 IU/mo and 21.5 nmol/L (95%CI 9.2 to 33.8; P=0.001) higher for 100,000 IU/mo groups.  
For infants, the mean changes in serum 25OHD were higher in the intervention groups 
compared to the control, but not statistically significant: 50,000 IU /mo (4.5 nmol/L 95%CI -
16.2 to 25.0; P=0.67) and 100,000 IU /mo (15.8nmol/L 95%CI -4.7 to 36.4; P=0.13) groups.  
However, after adjustment for season of birth, vitamin D-fortified formula intake, and infant 
skin color, the effect size for the 100,000 IU group was 19.1 nmol/L (95% CI 2.5 to 35.6; 
P=0.025) higher compared to placebo.   
Conclusions:  For infants, maternal D3 supplementation at a dose of 100,000 IU /mo during 
the first 5 months of breastfeeding potentially benefits vitamin D status.  While attractive 
from a compliance perspective, further studies are required to determine optimum dose and 
dosing frequency.   
 





Vitamin D is essential for calcium and bone metabolism.  It is unique among vitamins, in that 
its main source is derived from synthesis in the skin following exposure to ultraviolet-B 
radiation.  In the absence of fortification, few foods are rich in vitamin D, including low levels 
present in human milk (Hollis et al., 1981).  This suboptimal intake leads to an increased risk of 
deficiency in higher latitude countries like New Zealand, particularly during winter months 
(Grant et al., 2014; Houghton et al., 2010; McKenzie et al., 2009; Rockell et al., 2005; Wall, 
Grant, & Jones, 2013).  For infants, this risk is compounded as direct sunlight exposure is not 
recommended in the first 6 months of life (AAP, 1999). 
The most profound manifestation of vitamin D deficiency in growing children is rickets, a 
mineralization defect of the growth plate, characterized by bone deformities, impaired 
growth, biochemical abnormalities, and, depending on the stage of deficiency, seizures 
(Munns et al., 2012; Pettifor & Prentice, 2011; Ward et al., 2007; B. J. Wheeler et al., 2015).  
Recent prospective surveillance studies in New Zealand, Canada, and Australia have drawn 
attention to this continuing problem, especially among young children (Munns et al., 2012; 
Ward et al., 2007; B. J. Wheeler et al., 2015).  Common risk factors identified include darker 
pigmented skin, maternal vitamin D deficiency during pregnancy, season of birth, age <3 
years, and exclusive breastfeeding (Munns et al., 2012; Ward et al., 2007; B. J. Wheeler et al., 
2015).  
In light of this, several countries have recommended universal vitamin D supplementation for 
all breastfed infants (Wagner et al., 2008) for the prevention of rickets.  However, compliance 
is variable (Crocker et al., 2011; Gallo et al., 2010; Perrine et al., 2010; Taylor et al., 2010), with 
recent data published from US National Health and Nutrition Examination Survey (NHANES) 
suggesting that 80% of US breast-fed infants failed to achieve the recommended daily intake 
of 400 IU (Ahrens et al., 2016).  In addition, cases of rickets continue to be reported in 
countries using this preventive approach (Ward et al., 2007; Weisberg et al., 2004).  
A potential alternative strategy to improve the vitamin D status in breastfed infants is high 
dose cholecalciferol (D3) supplementation to pregnant and lactating women.  This has been 
shown to increase both maternal and infant serum 25-hydroxyvitamin D (25OHD) 
concentrations (Basile, Taylor, Wagner, Horst, & Hollis, 2006; Hollis & Wagner, 2004; March et 
al., 2015; Oberhelman et al., 2013; Saadi et al., 2009); however, interpretation of these studies 
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is often complicated by lack of a control group, un-blinded treatment, and concurrent vitamin 
D supplementation to infant study participants. 
New Zealand is a unique environment in that it has both negligible food fortification, and at 
the time of this study, a public health policy to only “consider” supplementation to infants “at 
risk”.  Thus, the primary aim of this randomized placebo-controlled study was to determine 
the effect of two different intermittent monthly doses of maternal D3 supplementation 
(Weeks 4 to 20 postpartum) on vitamin D status of non-supplemented, breastfed infants.  A 
monthly dose was chosen to improve compliance. 
 
3.2.2 Subjects and Methods  
Study population and design 
Healthy pregnant women planning to exclusively breastfeed for at least five months following 
delivery were recruited from July 2012 to June 2013 through the Queen Mary Maternity 
Centre (QMMC), Dunedin Hospital, Dunedin, New Zealand (45ºS latitude).  QMMC provides 
publically funded, tertiary level maternity and newborn care to the Otago/Southland region of 
New Zealand (population ~310,000), and is the only birthing unit in Dunedin, with 
approximately 97% of all city births (the remaining 3% being home births).  Exclusion criteria 
included: 1) preterm delivery prior to 37 weeks gestation; 2) intent to use vitamin D 
supplements (either mother or infant) in the postnatal period; 3) a history of disorders known 
to affect calcium and/or vitamin D metabolism, including abnormal calcium levels/urine Ca/Cr 
ratio at study baseline; and 4) planned travel outside of New Zealand over the study period; 5) 
living outside of Dunedin.  The study was approved by the New Zealand Lower South Regional 
Ethics Committee (LRS/11/02/007), and written informed consent was obtained from each 
mother.  The study was registered prior to study commencement with the Australian New 
Zealand Clinical Trials Registry at www.anzctr.org.au as ACTRN12611000108910. 
The study was a 16 week randomized, double-blind, placebo-controlled trial of 90 mother and 
infant pairs, beginning at 4 weeks postpartum.  Women were enrolled from 20 weeks 
gestation until delivery.  Following delivery, lactation support was provided, along with breast 
pumps as needed.  At 4 weeks postpartum, mothers were randomized in blocks of 15 to one 
of three treatment arms: placebo, 50,000 IU, or 100,000 IU to be administered every month 
until 16 weeks postpartum.  Randomization was not stratified by season.  These intervention 
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doses were selected as they conformed with commonly available D3 preparations, and 
administration of 50,000 IU D3 /mo is a commonly prescribed and funded regimen for the 
treatment of vitamin D insufficiency in New Zealand adults (with no daily dosing options 
publically funded); and as previously discussed, daily maternal and infant dosing have been 
subject to issues of noncompliance.  All tablets were supplied to the participants, and self-
administered with written and verbal prompting (e.g. reminder phone calls) to take one tablet 
at baseline (4 weeks postpartum) and every month thereafter with the last dose administered 
at 16 weeks postpartum.   
Socio-demographic data were obtained from interviews at enrolment (maternal only), and at 
4 and 20 weeks postpartum (both mother and baby). Information was obtained on maternal 
age, education, ethnicity, smoking status, vitamin and mineral supplement use, breastfeeding 
and use of infant formula (frequency and duration), sun exposure, and sunscreen use.  
Maternal height and weight measurements were taken at enrolment and at 4 weeks post-
partum using standardized techniques.  Infant length and weight measurements were taken at 
birth, 4, and 20 weeks of age.  Body Mass Index (BMI; in kg/m2) was calculated, and infant z-
scores utilized the WHO Child Growth Standards (Group, 2006).  Blood was drawn at birth 
(cord), 4 weeks (maternal), and 20 weeks postpartum (infant and maternal).  Lastly, maternal 
and infant skin reflectance was measured at each visit by spectrophotometer (CM2006d, 
Minolta Co. Ltd, Osaka, Japan) and converted to a final skin color assessment of “very light”, 
“light”, “intermediate”, “dark” and “very dark”.  Measurement sites included the medial 
aspect of the upper arm (natural skin color) and dorsal aspect of the forearm (sun exposed 
surface).  
Supplements 
The study supplements were manufactured by OPTIMUS Healthcare Limited (Auckland, New 
Zealand) as identical hard tablets each containing lactose powder (placebo), and a target of 
either 50,000 IU D3, or 100,000 IU D3.  Vitamin D content was measured at an independent 
laboratory, Eurofins NZ Laboratory Services Ltd.  The placebo tablet contained no detectable 
D3, and the mean D3 content of tablets used for the 50,000 IU D3 and 100,000 IU D3 were 
51,139 and 93,630 IU D3/tablet, respectively.  Supplements were coded by a third party 
(Dunedin Public Hospital Pharmacy) and participants, investigators and biostatisticians were 
blinded to treatment.  The randomization list was kept strictly confidential in a sealed 
envelope until all aspects of the study had been performed.  Participants were instructed to 
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take one tablet every month and to return all unused pills.  They were also advised to avoid 
any additional supplemental vitamin D ingestion and overseas travel, and to use sunscreen for 
the duration of the study.  Mothers were contacted every month during the study to remind 
them to take their monthly dose, and compliance was assessed by counting returned pills at 
the end of the study, 
Dietary vitamin D intake 
From birth to week 20, mothers recorded in a diary the brand of infant formula used and daily 
volume consumed (if any).  The quantity of vitamin D consumed was estimated from the 
vitamin D content of infant formula (IU/100 g) by mean daily intake over this 20 week study 
period.   
Blood/urine sampling and laboratory analysis 
Fasting, second void urine of the morning for maternal calcium/creatinine (Ca/Cr) ratio was 
also measured at 4 weeks and 20 weeks postpartum.  Non-fasting venous maternal, cord, and 
infant blood samples were collected. Serum calcium, phosphate, albumin, alkaline 
phosphatase (ALP) were measured immediately, and remaining serum was aliquoted and 
stored at –80°C until study completion.  Creatinine was measured using photometric analysis 
via fully automated cobas® 8000 c502 (Roche Diagnostics, Mannheim, Germany), with the 
remaining assays analyzed by cobas® 8000 c702 analyzer (Roche Diagnostics, Mannheim, 
Germany).  The clinical cut-offs used to define maternal serum hypercalcemia and elevated 
urine Ca/Cr ratios at any time point were > 2.6 mmol/L (Chan et al., 2009) and > 0.6 mole ratio 
(Metz, 2006), respectively.  For infants at 20 weeks, serum hypercalcaemia was defined as 
>2.8 mmol/L (Chan et al., 2009).   
Serum samples for 25OHD and parathyroid hormone (PTH) from each participant pair were 
analyzed in the same run to avoid inter-assay variation.  Serum levels of 25OHD were 
measured by isotope-dilution liquid chromatography tandem mass spectrometry (Maunsell et 
al., 2005), using an API 3200 instrument (Applied Biosystems) connected to a Dionex Ultimate 
3000 HPLC system.  The limit of quantification for the assay was < 5 nmol/L for both 
metabolites.  To assess accuracy and inter-assay variability, external quality control serum 
material (UTAK Laboratories) containing low and medium levels of both metabolites were 
analyzed with every run.  Measurements fell within the expected range with mean ± SD values 
of 29.0 ± 1.2 nmol/L and 67.3 ± 2.1 nmol/L for 25OHD3 (UTAK verified values 25.0, 69.9 
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nmol/L), and 26.2 ± 1.4 nmol/L and 67.0 ± 2.9 nmol/L for 25OH D2 (UTAK verified values 29.1, 
67.9 nmol/L). Internal quality control pooled serum samples were also analyzed, the inter-
assay CV for 25OHD3 being 3.7% at 56.9 nmol/L, 25OH D2 was below the limit of 
quantification.  
PTH was measured using an automated electrochemiluminescence immunoassay 
(Elecsys®2010, Roche Diagnostics, Mannheim, Germany).  The PTH assay showed a detection 
sensitivity of 1.2 pg/mL.  The control samples provided by the manufacturer were within the 
recommended target value and the inter-assay CV based on a pooled serum was 4.4% (n=22).  
Statistical analyses 
Sample size was calculated on the basis of detecting a minimum 15 nmol/L difference in infant 
serum 25OHD between placebo and intervention at study end.  To have 80% power to detect 
such an effect with a standard deviation of 20 nmol/L, it was estimated that 28 infants would 
be required in each treatment arm.  Allowing for an estimated 10% loss to follow-up, we 
planned to recruit a total of 90 mother-infant pairs.  
Baseline characteristics were summarized as means ± SD for continuous variables and as the 
percentage distribution for categorical variables.  The primary study outcomes were 1) change 
in infant 25OHD from baseline to week 20, and 2) proportion defined with deficiency at week 
20 (as per Australian and New Zealand guidelines (Paxton et al., 2013)).  For the change in 
infant 25OHD, the data were analyzed using linear regression with 20 week 25OHD as the 
outcome, randomized group as a fixed effect with the control group as reference, and baseline 
25OHD as a covariate.  As season of birth, infant underarm skin color, and infant formula 
intake are likely prognostic variables for breast-fed infant 25OHD levels, a secondary analysis 
for infants was carried out adjusting for these variables.  A Fisher’s exact test was used to 
determine if the proportion of infants that were classified as deficient (serum 25OHD <50 
nmol/L) or moderately/severely deficient (serum 25OHD <30 nmol/L) at 20 weeks was 
different between intervention groups (28). These proportions were plotted on a bar graph as 
percentages. 
Secondary outcome measures included change in maternal 25OHD from baseline to Week 20 
and proportion of maternal deficiency at 20 weeks, which were assessed using the same 
methods as for infants, with the exception of the secondary adjusted analysis that included 
season of birth and maternal underarm skin color as covariates.  
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To examine whether supplementation affected other biochemical/safety indices such as PTH, 
calcium, phosphate, and urine calcium creatinine ratio, change in these variables for both 
mother and infant (as appropriate) was assessed using linear regression, with randomized 
group as a fixed effect with control group as reference, and baseline level as a covariate. 
Clinically meaningful elevations were defined as above, and proportions compared between 
groups. 
To illustrate how 25OHD changed in each group over the time of the trial, mean serum 25OHD 
and standard error bars were plotted with a line graph for both mothers and infants. 
Pearson’s correlation coefficient and p-value were calculated between baseline maternal 
25OHD and infant cord 25OHD. Change in forearm skin color over the trial period was also 
investigated, as a proxy to sun exposure. Forearm skin color was categorized into “very light”, 
“light”, “intermediate”, “dark” and “very dark” (as per spectrophotometry described above) at 
baseline and at Week 20. Mothers and infants were then further categorized into three 
categories: “became lighter” (if their skin color changed to a lighter category); “unchanged”; 
or “became darker” (if their skin color changed to a darker category).  A chi-squared test was 
used to determine if skin color change categories were different between treatment groups.   
All statistical analyses were performed using Stata (version 13.1; StataCorp, College Station, 
TX). Residuals were calculated and plotted to visually assess whether the assumptions of the 
statistical models had been met (no transformations were made). A two-sided P value <0.05 
was considered statistically significant.  
 
3.2.3 Results 
Of the 90 women and infant pairs randomized, 87 completed the trial (Figure 9), giving a 97% 
retention rate.  Across the treatment groups the loss to follow-up was similar: 3% (n=1) for the 
placebo, 6% (n=2) in the 50,000 IU D3 group, and 0% (n=0) in the 100,000 IU D3 group.  
Participant characteristics of mothers and infants are shown in Table 9.  Median weight, 
length and BMI at 1 month were 3.5 kg (weight-for-age z score -1.2), 51 cm (length-for-age z 
score -1.2), and 13.0 kg/m2 (BMI-for-age z score -1.0) respectively for girls and 3.7 kg (weight-
for-age z score -1.3), 53 cm (length-for-age z score -0.8), and 13.5 kg/m2 (BMI-for-age z score -





Figure 9: CONSORT diagram depicting participant flow and follow up.  
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Table 9: Baseline participant demographics for maternal vitamin D3 treated and control 
groups1  
 Control  50,000 IU /mo  100,000 IU /mo  
Maternal:    









































Primiparous 14 (47%) 13 (43%) 13 (43%) 
Tertiary education2 23 (77%) 18 (60%) 21 (70%) 
BMI, kg/m2  27.5 ± 4.4 29.7 ± 4.2 29.6 ± 6.3 
Smoker 4 (13%) 3 (10%) 1 (3%) 
25OHD, nmol/L 51.7 ± 23.4  51.6 ± 24.9  50.6 ± 23.1  
PTH, pg/mL 34 ± 14  30 ± 12 38 ± 21 
Corrected calcium ,mmol/L 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 
Phosphate, mmol/L 1.3 ± 0.2 1.3 ± 0.2 1.3 ± 0.2 




Infant: Control  50,000 IU /mo  100,000 IU /mo  
Gestation, wk 39.6 ± 1.0 39.7 ± 1.0 39.7 ± 1.1 
Gender, male 16 (53%) 12 (40%) 15 (50%) 









































Exclusive breast feeding3 22 (73%) 22 (73%) 20 (67%) 
Infant vitamin D exposure4, 
IU/d  
14 ± 47 16 ± 42 23 ± 70 
25OHD total, nmol/L  37 ± 21 36 ± 18 40 ± 20 
PTH, pg/mL 6.1 ± 7.9 4.6 ± 1.7 4.8 ± 3.7 
Corrected calcium, mmol/L 2.6 ± 0.2 2.6 ± 0.1 2.6 ± 0.2 
Phosphate, mmol/L 2.0 ± 0.4 1.9 ± 0.4 2.0 ± 0.4 
1 Values are means ± SDs or n (%), and all laboratory analyses in serum, unless otherwise 
indicated, n = 30 for each intervention group, no statistical tests for between group differences 
at baseline were undertaken as per the CONSORT statement (Moher et al., 2010);  
2Completed university or other higher education qualification 
3No exposure to infant formula over 20 weeks 
4Birth – week 20  
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Overall, compliance with respect to supplement intake was high (96%) and similar for the 3 
groups: 94% for placebo, 94% for 50,000 IU D3 group, and 100% for 100,000 IU D3 group.  As a 
surrogate for sun exposure, 70% of infants, and 8% of mothers had a lighter forearm skin color 
at Week 20 compared to baseline, 27% of infants and 55% of mothers were unchanged, and 
3% of infants and 30% of mothers were darker.  There were no statistically significant 
differences in skin color change between groups of infants and mothers from baseline to 
Week 20.    
In terms of baseline vitamin D status, overall mean maternal serum 25OHD concentration at 4 
weeks postpartum was 51.3 ± 23.6 nmol/L, with 55% (48 of 87) and 14% (12 of 87) of women 
having a serum 25OHD concentration <50 and <30 nmol/L, respectively (Table 9 depicts data 
by treatment group).  Mean infant cord 25OHD concentrations of 37.3 ± 19.5 nmol/L were 
substantially lower than maternal concentrations, and over three quarters  (77%; 66 of 86) of 
the infant participants had a cord 25OHD below 50 nmol/L.  A statistically significant 
correlation was observed between cord 25OHD and maternal 25OHD (r = 0.81, P < 0.001).  
Over the 20 week study period, mean maternal serum 25OHD increased in all 3 groups (Figure 
10), although the changes in mean serum 25OHD among mothers randomly assigned to 
monthly vitamin D supplementation after 16 weeks were significantly greater than those of 
the placebo group (Table 10).  Adjustment for season of delivery, and maternal skin color 
improved the precision of the estimates for the difference in changes in maternal serum 
25OHD levels.  Effect size (95%CI) =10.8 (0.5, 21.1) nmol/L, P=0.041 for the 50,000 IU group 
compared to placebo, and 20.7 (10.6, 30.9) nmol/L, P<0.001) for the 100,000 IU group 









Table 10: Mean change in maternal and infant serum 25OHD and other serum biochemical indices, from baseline to week 20, for control and vitamin D3 
treated groups1 
 Control (n=28) 50,000 IU/mo (n=28) 100,000 IU/mo (n=29) 
Maternal (week 4 to week 20)  P2  P2 
25OHD, nmol/L 17.3 ± 32.7 30.2 ± 25.9  40.0 ± 29.3  
Change in 25OHD compared to 
control, nmol/L/16wk 
Reference 12.8 (0.4, 25.2)  0.043 21.5 (9.2, 33.8)  0.001 
PTH, pg/mL -1.1 ± 12.8 -0.8 ± 14.2  -5.5 ± 19.6  
Change in PTH compared to 
control, pg/mL/16wk 
Reference -1.6 (-8.7, 5.4) 0.65 -1.9 (-8.8, 5.1) 0.59 
Corrected calcium, mmol/L 0.07 ± 0.11 0.07 ± 0.13  0.11 ± 0.12  
Change in corrected calcium 
compared to control, 
mmol/L/16wk 
Reference -0.01 (-0.07, 0.04) 0.63 0.02 (-0.03, 0.07) 0.46 
Phosphate, mmol/L 0.01 ± 0.20 -0.01 ± 0.18  0.05 ± 0.28  
Change in phosphate compared to 
control, mmol/L/16wk 
Reference -0.05 (-0.14, 0.04) 0.27 0.01 (-0.07, 0.10) 0.75 
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Infant (birth to 20 weeks)   P2  P2 
25OHD, nmol/L 37.4 ± 51.9 44.7 ± 44.7  52.8 ± 46.4  
Change in 25OHD compared to 
control, nmol/L/20wk 
Reference 4.5 (-16.1, 25.0)  0.67 15.8 (-4.7, 36.4)  0.13 
PTH, pg/mL 31.9 ± 61.4 17.6 ± 10.9  13.6 ± 7.8)  
Change in PTH compared to 
control, pg/mL/20wk 
Reference -17.0 (-38.2, 4.2) 0.11 -20.7 (-42.8, 1.4) 0.066 
Corrected calcium, mmol/L 0.06 ± 0.22 0.04 ± 0.19  0.04 ± 0.21  
Change in corrected calcium 
compared to control, 
mmol/L/20wk 
Reference 0.02 (-0.02, 0.07) 0.35 0.01 (-0.03, 0.06) 0.56 
Phosphate, mmol/L -0.22 ± 0.43 -0.06 ± 0.43  -0.13 ± 0.48  
Change in phosphate compared to 
control, mmol/L/20wk 
Reference 0.06 (-0.02, 0.15) 0.15 0.06 (-0.02, 0.15) 0.14 
1 Values are ± SDs or (95% CI), unless otherwise indicated. 25OHD, 25-hydroxyvitamin D; PTH, parathyroid hormone  







Figure 10: Mean ± SE maternal (A) and infant (B) serum 25-hydroxyvitamin D at baseline and week 20, for vitamin D3 treated and control groups. 




Among infants, the mean change in serum 25OHD concentrations among the treatment and placebo 
groups from cord blood to 20 weeks postnatally are shown in Table 10.  In contrast to change in 
maternal serum 25OHD concentrations, the magnitude of the change in infant serum 25OHD over 
time did not significantly differ among the 3 groups.  Adjustment for the confounding effects of 
infant skin color, season of birth, and infant formula intake was undertaken as these were important 
prognostic variables identified in the literature.  As a result the effect estimates for the difference in 
changes in infant 25OHD levels were strengthened and more precise.  The effect size (95% CI) was 
5.0 (-11.3, 21.3) nmol/L, P=0.54, for the 50,000 IU group compared to control, and 19.1 (2.5, 35.6) 
nmol/L, P=0.025, for the 100,000 IU group compared to control. 
The prevalence of having a maternal serum of 25OHD < 50 nmol/L was 26% (7 of 27) in the placebo 
group at the end of the 20 weeks postpartum, which was significantly higher than the 50,000 IU 
group (4%; 1 of 27) and the 100,000 IU group (0%) (P=0.002) (Figure 11).  At study conclusion, none 
of the maternal participants taking vitamin D supplements had a serum 25OHD <30 nmol/L whereas 
7% (2 of 27) on placebo remained below 30 nmol/L.  Among the infant participants, there was no 
difference in the prevalence of having a serum 25OHD level <50 nmol/L between groups at study 
completion (prevalence = 27%, 29%, and 19% for the placebo, 50,000IU, and 100,000IU groups 
respectively, P=0.65) (Figure 11).  While the number of infants with a 25OHD levels < 30 nmol/L was 
greater in the placebo group (23%, 6 of 26) compared to the 50,000 IU group (11%; 3 of 28) and 














Figure 11: Percentage of maternal and infant vitamin D3 treated and control groups that were 
deficient, serum 25OHD <50nmol/L (A), or moderately/severely deficient, serum 25OHD 
<30nmol/L (B), at 20 weeks postnatal age.  Vitamin D3 supplement intake (IU/mo) is represented in 
3 categories, for maternal groups: placebo (n=27), 50,000 IU/mo (n=27), and 100,000 IU/mo (n=28); 
for infant groups: placebo (n=26), 50,000 IU/mo (n=28), and 100,000 IU/mo (n=27).  Fisher’s exact 
test was used to test for difference between: maternal groups <30nmol/L, not testable; maternal 
groups <50 nmol/L, P=0.002; infant groups <30 nmol/L, P=0.09; infant groups <50nmol/L, P=0.65. 





Additional biochemistry and safety data  
In both mothers and infants, there were no statistically significant differences in the mean changes 
of serum PTH, corrected calcium, and phosphate among groups over the trial period (Table 2).  
However, two infants in the placebo group did have clinically meaningful elevations in PTH (above 
the upper normal limit of 65) of 120 and 281 pg/mL at the end of the intervention.  Although normal 
values for PTH concentration in infants and young children have not been clearly defined, in these 
two infants, PTH values were also both associated with severe vitamin D deficiency, (25OHD levels of 
6.4 and 8.6 nmol/L) and elevated ALP values (352 and 507 U/L) – all biochemically suggestive of 
vitamin D deficiency rickets.   
No cases of hyper- or hypocalcaemia were found in any maternal or infant participant.  Mean change 
in maternal urinary Ca/Cr ratios over the study intervention were comparable between control and 
intervention groups (50,000 IU D3/mo P=0.96; 100,000 IU D3/mo P=0.22).  Nevertheless, six mothers 
had a higher than normal Ca/Cr ratio at 20 weeks postpartum (normal range <0.6; n=2 placebo, n=1 
50,000 IU and n=3 100,000 IU groups).  All of these were considered non-fasting specimens and a 
repeat fasting specimen as per study protocol was not undertaken.    
 
3.2.4 Discussion 
The results of the present study reveal new insights into the potential relevance of a maternal 
vitamin D dosing strategy for breastfed infants, that have been lacking from previous studies due to 
lack of controls, blinding and/or concomitant daily infant vitamin D administration (Hollis & Wagner, 
2004; Hollis et al., 2015; March et al., 2015; Oberhelman et al., 2013; Saadi et al., 2009).  As 
expected, once monthly moderate (50,000 IU) or high (100,000 IU) dose maternal D3 elevated serum 
25OHD concentrations in mothers by Week 20, and were well tolerated.  However, the results in 
infants are more complex.  For the primary analysis, no significant differential effect of maternal 
supplementation on infant vitamin D status, or prevalence of having a serum 25OHD below 50 
nmol/L was seen at the end of the study period.  However, once adjusted for potentially important 
confounders including season of birth, infant formula exposure, and infant skin color, high dose 
maternal monthly vitamin D3 (100,000 IU) supplementation resulted in a statistically significant and 
clinically meaningful increase in infant serum 25OHD of 19 nmol/L compared to the placebo group.  
Moreover, this dose (100,000 IU) may also offer some protection against moderate to severe infant 
deficiency with only one infant in this group (as compared to six infants in the placebo) presenting 




To our knowledge, this is the first randomized, double-blinded placebo-controlled trial to document 
the effect of maternal vitamin D supplementation on the vitamin D status of breastfed infants.  
Importantly, in the present study, infants did not consume any other oral vitamin D supplements.  
Thus, the observed changes can therefore be attributed to the supplementation of the mothers.  
Our secondary findings of effect for infants in the 100,000 IU intervention, align with previous 
maternal supplementation studies in lactating women (Hollis & Wagner, 2004; Hollis et al., 2015; 
March et al., 2015; Oberhelman et al., 2013; Saadi et al., 2009).  These studies have trialed both daily 
and monthly supplementation, however all lack controls, in addition to often inadequate blinding.  
One of the first maternal vitamin D supplementation trials conducted (Hollis & Wagner, 2004), 
supplemented 18 lactating women beginning at 1 month postpartum with either 1600 IU/d or 3600 
IU/d ergocalciferol (vitamin D2) for a period of 3 months together with a supplement of 400 IU/D 
vitamin D3.  At 4 months of age, infants had attained a mean of 25OHD concentration of 69 and 77 
nmol/L, respectively.  The authors concluded that maternal vitamin D intakes ≥ 4000 IU/d appear to 
ensure adequate infant vitamin D status.  Of importance, we report a similar mean serum infant 
25OHD concentration of 76 nmol/L at Week 20 in study infants whose mothers were receiving 
placebo.  This highlights one of the most notable findings of our study, which was the observed 
increase in 25OHD concentrations of placebo assigned infants over the 20 week postnatal period.  
Similar increases in 25OHD have been shown in a number of longitudinal studies among 
unsupplemented breastfed infants (Challa et al., 2005; Grant et al., 2014; Kim et al., 2010; Narchi et 
al., 2011; Perumal et al., 2017; Ziegler et al., 2006).  The reasons for this rise in 25OHD are complex 
but may be the result of a seasonal imbalance in recruitment and/or a physiological increase in 
vitamin D binding proteins (DBP) with age – a key determinant of 25OHD levels (Carpenter et al., 
2013).  Information on DBP in early infancy is limited, but it is known that adult levels of albumin 
concentration and binding affinity are not reached until 10 to 12 months of age.  Regardless, these 
results emphasize the importance of a control group.  In light of our findings, the reported effect size 
of previous uncontrolled studies may have been potentially confounded by a natural temporal trend 
towards increased vitamin D status in the first year of life.   
It is unknown whether a higher monthly maternal dose would have achieved greater improvements 
in infant vitamin D status, but the lower 50,000 IU vitamin D3 dose every 4 weeks appeared 
ineffective.  A recent uncontrolled, blinded study administering a single maternal vitamin D3 dose of 
150,000 IU demonstrated a significant increase in infant serum 25OHD concentrations from baseline 
(40.8 nmol/L) to Day 28 (96.8 nmol/L) (Oberhelman et al., 2013).  However, safety of this dosage 




of daily intake suggested by the Institute of Medicine by over 30% (A. C. Ross et al., 2011).  In our 
current investigation, we found that doses of up to 100,000 IU every 4 weeks were well tolerated, 
and the incidence of maternal hypercalcemia and hypercalciuria did not differ between groups, nor 
was vitamin D treatment associated with any laboratory, clinical, or serious adverse effect.  In 
addition, we did not observe hypervitaminosis D (defined as 25OHD concentration > 225 nmol/L) in 
any of our participants (peak maternal and infant 136 nmol/L and 140 nmol/L, respectively). 
An alternative strategy for improving the vitamin D status of breastfed infants is to increase fetal 
vitamin D status via maternal supplementation during pregnancy, as cord blood levels of 25OHD in 
the present study highly correlated with maternal levels. A number of studies have supported this 
finding (Grant et al., 2014; Hollis et al., 2011; March et al., 2015; Roth et al., 2013), with the most 
recent study by March et al (March et al., 2015), demonstrating that doses between 400 to 2000 
IU/d during pregnancy resulted in substantially higher cord blood 25OHD, ranging from 73 to 95 
nmol/L. In the present study, the mean cord 25OHD of unsupplemented mothers was 37.3 nmol/L.  
Supplementation with 2000 IU/d antenatally also appeared to protect 98% of unsupplemented 
breastfed infants against vitamin D deficiency (serum 25OHD < 30 nmol/L) at least until 8 weeks 
postpartum (March et al., 2015).  
A particular strength of this study is that this is the first known randomized, double blind, placebo 
controlled design conducted in a setting with little interference from food fortification.  In addition, 
there was no policy for universal vitamin D supplementation for breastfed infants at the time the 
study was conducted.  The longer duration of our study over the recommended period of exclusive 
breastfeeding with high rates reported in each group (67-73%), and close to 100% rate of current 
breastfeeding at study completion further strengthened the design in comparison to previous 
studies (Grant et al., 2014; Hollis & Wagner, 2004; Hollis et al., 2015; March et al., 2015; Oberhelman 
et al., 2013; Saadi et al., 2009).  Study limitations include the convenience sample of healthy women 
in the south island of New Zealand who were mainly of European descent (72%).  As a result, it is 
unknown whether these results can be generalized to other ethnic groups or other regions of 
varying latitude in New Zealand.  Another limitation is breast milk analysis for vitamin D content was 
not available, which would have been ideal as a secondary outcome measure, albeit the half-life of 
vitamin D3 in milk is approximately 24-72 hours (Oberhelman et al., 2013). Lastly, the lack of effect in 
the primary analysis may be due to type 2 error, and is a limitation reflecting both a potentially small 




In conclusion, our study shows that maternal vitamin D supplementation of lactating women during 
the first 5 months of breastfeeding improved the vitamin D status of the mother, and suggests that 
doses of 100,000 IU D3 / mo are not only safe, but may improve the vitamin D status of the 
breastfeeding infant, and subsequently prevent deficiency.  In addition, these data demonstrate a 
general rise in serum 25OHD concentrations over the first 20 weeks of life, which questions the 
effect size and beneficial effects of previous uncontrolled maternal supplementation studies.  
Further work is warranted to support our findings, and to more fully investigate the efficacy of 
varying maternal dosage regimens (e.g. daily or weekly) on both maternal and infant vitamin D 

















4 Paper 3 – A longitudinal study of maternal and infant vitamin D 
and parathyroid hormone status throughout pregnancy and 
lactation in New Zealand mothers and their infants at 45⁰ South 
4.1 Preface 
The following chapter contains a published original manuscript titled “A longitudinal study of 25-
hydroxy vitamin D and parathyroid hormone status throughout pregnancy and exclusive lactation in 
New Zealand mothers and their infants at 45⁰ South”.  This manuscript was published in Nutrients 
2018.  Nutrients 2018, 10(1), 86; doi:10.3390/nu10010086 (B. Wheeler et al., 2018).   
The importance of pregnancy and the early postnatal period have been highlighted in Chapter 1.   
Pregnancy is a unique time in terms of vitamin D and calcium metabolism, with not only the mineral 
needs of the mother, but also the fetus needing to be maintained and developed.  This is particularly 
the case in the third trimester when peak fetal bone mineral accrual occurs (Givens & Macy, 1933; 
Trotter & Hixon, 1974).  In addition, as previously stated, maternal vitamin D status during pregnancy 
is also essential in establishing final infant status, with infant 25OHD levels at birth closely correlated 
to maternal pregnancy vitamin D status (Bowyer et al., 2009; Grant et al., 2014; S. D. Thomas et al., 
2011).   
Given how important pregnancy is, there are but a few studies assessing pregnancy and lactation 
longitudinally.  The data available confirms that vitamin D deficiency during pregnancy and lactation 
appears common, and that a number of aspects of vitamin D and calcium metabolism appear altered 
during these stages.   Limitations in these papers include a lack of infant data, and questions around 
generalisability to the southern hemisphere, with all available studies originating from the northern 
hemisphere.  This suggests a need to better understand vitamin D status and metabolism during 
pregnancy and lactation.  This is particularly so for regions of the world where mothers are at risk of 
suboptimal vitamin D status.  New Zealand is one such country due to its southern latitude (spanning 
35 - 47⁰ South), negligible vitamin D food fortification, and public health policy to only consider vitamin 
D supplementation to women during pregnancy and to breastfed infants who are considered ‘‘at risk” 
(Ministry of Health, 2013).   
Therefore, the primary aim of this chapter/project was to describe longitudinal 25OHD and 
parathyroid hormone (PTH) status during pregnancy, and postnatally to 5 months, in a sample of New 
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Vitamin D status and associated metabolism during pregnancy and lactation have been assessed in 
only a limited number of longitudinal studies, all from the northern hemisphere, with no infant data 
concurrently reported.  Therefore, we aimed to describe longitudinal maternal and infant 25-hydroxy 
vitamin D (25OHD) and parathyroid hormone (PTH) status during pregnancy and out to 5 months 
postnatal age, in New Zealand women and their infants living at 45ºS latitude.  Between September 
2011 and June 2013, 126 pregnant women intending to exclusively breastfeed for at least 20 weeks 
were recruited.  Longitudinal data were collected at three time points spanning pregnancy, and 
following birth and at 20 weeks postpartum.  Vitamin D deficiency (25OHD <50nmol/L) was common, 
found at one or more time points in 65% and 76% of mothers and their infants, respectively.  Mean 
cord 25OHD was 41nmol/L, and three infants exhibited secondary hyperparathyroidism by postnatal 
week 20.  Maternal late pregnancy 25OHD (gestation 32-38 weeks) was closely correlated with infant 
cord 25OHD, r2 = 0.87 (95%CI 0.8-0.91), while no correlation was seen between early pregnancy (<20 
weeks gestation) maternal and cord 25OHD, r2=0.06 (95%CI -0.16-0.28).  Among other variables, 
pregnancy 25OHD status and therefore infant status at birth, were influenced by season of 
conception.  In conclusion, vitamin D deficiency in women and their infants is very common during 
pregnancy and lactation in New Zealand at 45°S.  These data raise questions regarding the applicability 
of current pregnancy and lactation policy at this latitude, particularly recommendations relating to 














Pregnancy is a unique and demanding life stage in terms of vitamin D and calcium metabolism due to 
increased need for fetal development of mineralised structures while maintaining optimal maternal 
status.  This is particularly the case in the third trimester of pregnancy when peak fetal bone mineral 
accrual occurs (Givens & Macy, 1933; Trotter & Hixon, 1974).  25-Hydroxyvitamin D (25OHD) readily 
crosses the placenta. As a result, 25OHD levels of mother-infant cord blood are positively correlated. 
Maternal vitamin D status during  pregnancy plays a key role in establishing the size of their neonate 
reserves at birth (Bowyer et al., 2009; Grant et al., 2014; S. D. Thomas et al., 2011), with 
supplementation studies during pregnancy demonstrating significantly improved infant status at birth 
and beyond (Grant et al., 2014; March et al., 2015; Roth et al., 2013).  
The potential adverse consequences to the neonate of maternal vitamin D deficiency have been 
demonstrated with both maternal vitamin D deficiency and lack of prenatal supplementation 
associated with an increased risk of infancy and childhood rickets (Moncrieff & Fadahunsi, 1974; Nozza 
& Rodda, 2001; Roberts et al., 1973; Ward et al., 2007).  In addition, other aspects of foetal and child 
bone health may also be impacted by maternal vitamin D status, including foetal growth (Bowyer et 
al., 2009), foetal bone accrual and subsequent bone size (Viljakainen et al., 2011; Viljakainen et al., 
2010), and dental health including enamel hypoplasia (Purvis et al., 1973) and dental caries (Schroth 
et al., 2014).  These impacts of low maternal vitamin D status on foetal bone have been reported as 
early as 19 weeks gestation using high resolution 3D ultrasound showing a poorer fetal femoral 
development (Mahon et al., 2010),  as well as longer-term follow up studies demonstrating lower peak 
offspring bone mass at 20 years of age (Zhu et al., 2014).  
Maternal vitamin D status during pregnancy is influenced by a range of factors, including season, skin 
colour, supplementation, latitude, and potential pregnancy specific variations in metabolism (Bowyer 
et al., 2009; Ekeroma et al., 2015; Lundqvist et al., 2016).  To better understand the magnitude of 
these factors, maternal vitamin D status and associated metabolism have been assessed in a number 
of longitudinal studies (Cross et al., 1995; Haliloglu et al., 2011; Holmes et al., 2009; Lundqvist et al., 
2016; Milman et al., 2011; Ritchie et al., 1998; Zhang et al., 2014).  Nonetheless, all of the studies to 
date have been conducted in the northern hemisphere (spanning 39°N - 63.8°N) where supplement 
use is common.  Many of these studies were also limited by unbalanced seasonal sampling or lack of 
seasonal data.  In addition, post-pregnancy maternal follow-up during lactation was variable and the 




A better understanding of vitamin D status and metabolism during pregnancy and lactation is needed, 
particularly in regions of the world where mothers are at risk of suboptimal vitamin D status.  New 
Zealand is one such country due to its southern latitude (spanning 35 - 47⁰ South), and negligible 
vitamin D food fortification. Pregnancy and infant vitamin D deficiency (25 OHD <50nmol/L) in New 
Zealand also appear common with high rates reported across diverse ethnicities and latitudes 
(Camargo et al., 2010; Ekeroma et al., 2015; Judkins & Eagleton, 2006; B. J. Wheeler et al., 2016). In 
addition, current public health policy is to only consider vitamin D supplementation to women during 
pregnancy and to breastfed infants who are ‘‘at risk” i.e. having 1 or more of the following: naturally 
dark skin; complete sun avoidance; a sibling with rickets; have liver or kidney disease, or on certain 
medications that affect vitamin D levels; and infants who are breastfed over winter (Ministry of Health, 
2013).    
Therefore, we aimed to describe longitudinal 25OHD and parathyroid hormone (PTH) status 
throughout pregnancy as well as 20 weeks postnatally in a sample of New Zealand women and their 
infants living at a latitude of 45⁰ south. 
  
4.2.2 Subjects and Methods 
Study population and design 
This longitudinal descriptive study includes 126 pregnant women intending to exclusively breastfeed 
for at least 20 weeks, and their infants.  Blood samples  obtained antenatally during routine care were 
collapsed into the following three categories: 1) < 20 weeks gestation “first trimester” screening 
bloods (with specific sample timing determined by when pregnancy was confirmed and antenatal care 
commenced); 2) 28 week maternal gestational diabetes screening (range 20 – 31 weeks); and 3) 36 
week routine maternal iron status determination (range 32-38 weeks).  There were two additional 
postnatal time points measured in both mothers and infants, at 4 and 20 weeks for mothers, and cord 
blood (at delivery) and 20 weeks for infants.  Overall, 40 women provided all five maternal 
observations, 40 provided four observations, 24 provided two observations, and 22 women only one 
observation – providing 431 maternal observations for analysis in total.   
This sample population of women and their infants was drawn from those recruited and screened as 
part of a previously published randomized controlled trial (RCT).  Detailed methods for this study have 
been published elsewhere (B. J. Wheeler et al., 2016).  In brief, healthy pregnant women planning to 




to June 2013 through the Queen Mary Maternity Centre (QMMC), Dunedin Hospital, Dunedin, New 
Zealand (45ºS latitude).  QMMC provides publically funded, tertiary level maternity and newborn care 
to the Otago/Southland region of New Zealand (population ~320,000), and is the only birthing unit in 
Dunedin, with approximately 97% of all city births (the remaining 3% being home births).  Exclusion 
criteria included: 1) delivery prior to 37 weeks gestation; 2) intent to use postnatal vitamin D 
supplements (mother or infant); 3) a history of disorders known to affect calcium and/or vitamin D 
metabolism, including abnormal calcium levels/urine Ca/Cr ratio at study baseline; and 4) planned 
travel outside of New Zealand over the study period.   
The study consisted of a 16 week randomized, double-blind, placebo-controlled trial of 90 mother and 
infant pairs, beginning at 4 weeks postpartum.  Following delivery, lactation support was provided, 
along with breast pumps as needed.  At 4 weeks postpartum, mothers were randomized in blocks of 
15 to one of three treatment arms: placebo, 50,000 IU, or 100,000 IU cholecalciferol to be 
administered every month until 16 weeks postpartum (inclusive).  Women were enrolled from 20 
weeks gestation until delivery, and antenatal data were regularly collected for subsequent analysis for 
this longitudinal study.  Postnatal week 20 data for both mothers and infants for those in the two 
intervention arms of this study have been excluded for the purposes of this longitudinal study due to 
the potential impact of this intervention on their “free-living” vitamin D status. 
In addition, in the present study, an additional 36 women who were recruited prior to RCT 
commencement (due to initial delays with the availability of independently verified placebo and 
intervention vitamin supplement) from September 2011 – June 2012, were also included.  These 











    




Socio-demographic data were obtained from interviews at antenatal study enrolment (maternal only), 
and at 4 and 20 weeks postpartum (both mother and baby).  Information was obtained on maternal 
age, education, ethnicity (in 7 instances dual ethnicities were given, in these cases for the purposes of 
description in this study, these were allocated to a single ethnic group based order of priority: Māori, 
Pacific, Asian and European/Other), smoking status (yes/no – pre-pregnancy and pregnancy), vitamin 
and mineral supplement use (recall of number of days/week taken during each month of pregnancy), 
breastfeeding and use of infant formula (frequency and duration), sun exposure (including degree of 
veiling/covering behaviour, and hours of exposure previous month), and sunscreen use (frequency).  
Maternal height and weight measurements were taken at enrolment and at 4 weeks post-partum 
using standardized techniques, and body mass index (BMI) was subsequently calculated.  Infant length 
and weight measurements were taken at birth, 4, and 20 weeks of age.  Lastly, maternal and infant 
skin reflectance was measured at each visit by spectrophotometer (CM2600d, Minolta Co. Ltd, Osaka, 
Japan) and converted to a final skin colour assessment by calculating individual typology angles (ITA) 
using the following formula: ITA = (ArcTangent ((L - 50)/b)) - 180/π.  Skin colour was then classified 
using the ITA into the following groups: very light > 55 > light > 41 intermediate > 28 > dark > -10 > 
very dark.  Measurement sites included the medial aspect of the upper arm (natural skin colour) and 
dorsal aspect of the forearm (sun exposed surface).  
Dietary vitamin D intake 
From antenatal enrolment to week 20 postpartum, mothers recorded use of dietary supplements (if 
any), as well as the brand of infant formula used and daily volume consumed (if any) for the infant.  
These data were reviewed by study personnel at each study visit.   Maternal supplemental vitamin D 
intake was then determined by estimating mean supplement intake (IU/d) over the duration of 
pregnancy (there was no postnatal use once the RCT commenced). No infant vitamin supplements 
were used.  However, the amount of dietary vitamin D intake consumed by the infants was estimated 
from the mean daily intake of infant formula (mL/d) multiplied by the vitamin D content (IU/100 g) 
over the 20 week study period.   
Blood sampling and laboratory analysis 
Non-fasting venous maternal, cord, and infant blood samples were collected, and stored at–80°C until 
study completion.  Serum samples for 25(OH)D and PTH from each participant were analysed in the 
same run to avoid inter-assay variation.  Serum levels of 25(OH)D were measured by isotope-dilution 
liquid chromatography tandem mass spectrometry (Maunsell et al., 2005), using an API 3200 




quantification for the assay was < 5 nmol/L for both metabolites.  To assess accuracy and inter-assay 
variability, external quality control serum material (UTAK Laboratories) containing low and medium 
levels of both metabolites were analyzed with every run.  Measurements fell within the expected 
range with mean ± SD values of 29.0 ± 1.2 nmol/L and 67.3 ± 2.1 nmol/L for 25(OH)D3 (UTAK verified 
values 25.0, 69.9 nmol/L), and 26.2 ± 1.4 nmol/L and 67.0 ± 2.9 nmol/L for 25(OH)D2 (UTAK verified 
values 29.1, 67.9 nmol/L). Internal quality control pooled serum samples were also analyzed, the inter-
assay CV for 25(OH)D3 being 3.7% at 56.9 nmol/L, 25(OH)D2 was below the limit of quantification.  
PTH was measured using an automated electrochemiluminescence immunoassay (Elecsys®2010, 
Roche Diagnostics, Mannheim, Germany).  The PTH assay showed a detection sensitivity of 0.1 pmol/L.  
The control samples provided by the manufacturer were within the recommended target value and 
the inter-assay CV based on a pooled serum was 4.4% (n=22).  
Statistical analyses 
Baseline descriptive characteristics have been presented as means ± SDs for continuous variables and 
as counts and percentages for categorical variables.  Student’s t-tests, Fisher’s Exact tests, and Chi-
squared tests were used to examine differences between groups.  Pearson’s correlation coefficients 
were used to assess associations between continuous variables.  For all regression analyses, 25OHD 
values were log transformed (natural logs), these were back transformed to geometric means for the 
purposes of Figure 2. Linear models were used to analyse the relationships between cord 25OHD and 
season; maternal 25OHD and PTH; and maternal 25OHD and BMI, maternal skin colour, parity, season 
of 25OHD measurement, pregnancy (or not), and vitamin D supplement intake. Next, for maternal 
25OHD, factors that were significantly associated or considered biologically plausible were then 
included in a multivariable mixed model analysis.  Mixed models included a random intercept for each 
mother, using BMI (>30kg/m2), vitamin D supplement intake, parity, season of 25OHD measurement, 
pregnancy, and maternal skin colour as predictors. To examine the predictive potential of very early 
maternal pregnancy 25OHD status on final maternal 25OHD status at delivery, further modelling was 
undertaken to graphically illustrate longitudinal variation in maternal 25OHD status based on season 
of conception. Modelled means of maternal 25OHD status grouped by season of conception, spanning 
pregnancy (earliest sampling points were at 6 weeks gestation) out to 20 weeks post-partum, centred 
by date of delivery (gestational ages adjusted relative to date of delivery) were plotted adjusting for 
all factors included in the mixed model analysis above, excluding only month of measurement, and 
pregnancy (both variables changing along the x-axis). For simplicity, whenever described, and for all 




February; autumn: March, April, May; winter: June, July, August; and spring: September, October, 
November.    
A 2-sided P value of <0.05 was considered significant.  All statistical analyses were performed using R 
version 3.4 (R Core Team, 2017), using the lme4, and lmerTest libraries (Bates, Machler, Bolker, & 
Walker, 2015). 
This study was approved by the New Zealand Lower South Regional Ethics Committee 
(LRS/11/02/007), and the study registered prior to commencement with the Australian New Zealand 
Clinical Trials Registry at www.anzctr.org.au as ACTRN12611000108910. 
 
4.2.3 Results 
Baseline characteristics of the 126 women and their infants are presented in Table 11.  There were no 
differences in basic demographics between those who provided samples at all time points vs. those 
with missing data points, other than there were fewer births in spring/summer in the “all time points” 
group 34% vs 53% respectively, p=0.02.  The majority of mothers and their infants had no vitamin D 


















Table 11: Baseline characteristics of participants (mother and infant)1  
Characteristics (total n=126) 
Maternal  





















Primiparous 37 (29%) 
Tertiary education3 90 (71%) 
Pre-pregnancy BMI, kg/m2  25.0 ± 6.2 
Smoker 9 (7%) 
Antenatal vitamin D supplement use4 35 (28%) 
Supplement intake IU/day4  
Consumers only 339 ± 269 
Infant  
Gestation, wk 39.3 ± 1.1 




Total (n=126); participants with data at all three antenatal time points (n=80); participants with data at postnatal month 5 
(n=66, due to exclusion of those in intervention arms). 
1 Values are means ± SDs or n (%)  
2Underarm “natural” skin colour as determined by skin reflectance using spectrophotometer  
3Completed university or other higher education qualification  
4Maternal supplement use during pregnancy 
5Infant received only breastmilk. No other liquid, solids, or supplements were given over 20 weeks 




The longitudinal serum 25OHD and PTH values spanning the three time points in pregnancy, and two 
time points postpartum (out to 20 weeks) in both mothers and infants are shown in Table 12.  Table 
12 also shows the proportion of mothers at each time point with vitamin D deficiency 
(25OHD<50nmol/L) by season.  Maternal vitamin D deficiency was common.  In those where both 
pregnancy and postnatal values were available, deficiency was found at one or more time points 





















Exclusive breast feeding5 90 (71%) 
Breastfeeding at week 20 110 (87%) 
Infant vitamin D intake,6 IU/d   




during the full longitudinal study (antenatal plus postnatal) in 65% (52/80), and during pregnancy in 
48% (38/80).  Infant vitamin D deficiency was also very common, seen in 76% at one or more time 
points, with 68% deficient at birth, and a mean cord blood of 41nmol/L.  Mean cord 25OHD was 25 
nmol/L greater when season of delivery was in summer (mean ± SD, 57 ± 23 nmol/l), compared to 
winter (32 nmol ± 16) (p < 0.001).  At 20 weeks postpartum, the majority remained exclusively 
breastfed (71% no dietary vitamin D exposure), but increased their 25OHD status to a mean of 57 ± 
42 nmol/L.  However, 51% remained deficient, and in three infants, there was potentially clinically 
important secondary hyperparathyroidism, serum PTH values between 12.6 and 29.5 pmol/L (upper 
limit normal 7 pmol/L).  Although normal values for serum PTH in infants have not been consistently 
defined, these PTH values were accompanied by severe vitamin D deficiency (25OHD concentrations 
of 4.7, 6.4, and 8.6nmol/L) and in two infants, elevated alkaline phosphatase levels (352 and 507U/L), 
all factors that suggest possible vitamin D deficiency rickets.  These three infants (only one with dark 
skin) were all born between late summer and mid-autumn, meaning this 20-week sample was taken 
in mid-winter/early spring – at the anticipated nadir of 25OHD status.                
Positive correlations were observed between infant cord blood 25OHD and two of three maternal 
25OHD antenatal sampling time points, as well as at 4 weeks postpartum.  The maternal AN3 antenatal 
time point (32-38 Weeks) was most closely correlated with infant cord blood status, r2 = 0.87 (95%CI 
0.8-0.91), followed by week 4 postpartum, r2 = 0.81 (95%CI 0.74-0.86), and AN2 (week 20-31), r2=0.4 
(95%CI 0.19-0.57).  There was no correlation seen between with the maternal AN1 (<20 week 
gestation) 25OHD and infant cord 25OHD, r2=0.06 (95%CI -0.16-0.28).  This is demonstrated in Figure 
13.  Additionally, there was a weak, negative correlation between maternal 25OHD and PTH (r2 
ranging between -0.12 - -0.31), with little difference in the correlations between the five available 
maternal time points (both throughout pregnancy and postpartum), with similar overlapping 
confidence intervals, (spanning -0.52 – 0.11).  The strongest negative correlation between 25OHD and 
PTH was seen in the infant at 5 months of age, r2=-0.35 (95%CI -0.50--0.16, p=0.0003).  No correlation 
was seen between cord 25OHD and cord PTH, r2=-0.11 (95%CI -0.29-0.08, p=0.2). 
Variables affecting maternal serum 25OHD fully adjusted for season, pregnancy, supplement intake, 
skin colour, parity, and BMI are shown in Table 13.  Due to the significant impact of time of year on 
25OHD status, maternal 25OHD status measured over time (gestation and postnatal) by season of 
conception is shown in Figure 14 demonstrating the variability in serum 25OHD at this latitude over 





Table 12: Serum total 25-hydroxyvitamin D and parathyroid hormone concentrations in mothers and their infants during pregnancy and lactation (first 
20 post-natal weeks)1  
1 Values are means ± SDs or % (n); AN, Antenatal; PN, Postnatal; AN1, <20 week gestation; AN2, week 20-31 gestation; AN3, week 32-38 gestation; 25(OH)D, 25-hydroxyvitamin D; PTH, 

















Gestation/postnatal week Week 6-19 Week 20-31 Week 32-38 Week 4 Week 20 Date of birth Week 20 
Serum 25OHD, nmol/L 70 ± 25 78 ± 32 76 ± 34 55 ± 24 59 ± 25 41 ± 21 57 ± 42 
Serum PTH,  pmol/L 1.7 ± 0.7 1.6 ± 0.88 1.5 ± 0.7 3.5 ± 1.7 3.8 ± 1.7 0.5 ± 0.5 2.8 ± 3.9 
Proportion with 25OHD deficiency (<50nmol/L) by season, % 
     Spring 26% (8/31) 56% (9/16)  50% (6/12) 59% (19/32) 50% (9/18) 93% (27/29) 39% (7/18) 
     Summer 5% (1/19) 6% (1/17) 6% (1/16) 20% (4/20) 9% (1/11) 37% (10/27) 0% (0/11) 
     Autumn 21% (3/14) 7% (2/30) 18% (5/28) 41% (12/29) 36% (5/14) 50% (14/28) 14% (2/14) 








Figure 13: (A) Correlation between infant cord 25-hydroxy vitamin D (25OHD) and maternal late 
pregnancy serum 25OHD (week 32-38), r2 = 0.87 (95%CI 0.8-0.91); (B) Correlation between infant 





Table 13: Predictors of maternal serum 25-hydroxyvitamin D status during pregnancy and lactation 
(first 20 post-natal weeks)1  
Predictor Estimate 95%CI P-value 
Season 
     Summer 
     Autumn 
     Winter 








0.67 - 0.78 
0.54 - 0.63 






Pregnancy2 1.25 1.17 – 1.33 <0.001 
Supplement Use 1.20 1.09 – 1.33 <0.001 
Skin Colour3 
     Very light 
     Light 
     Intermediate 








0.95 – 1.21 
0.74 – 1.36 






First Pregnancy 0.88 0.78 – 1.01 0.07 
BMI4 




0.85 – 1.05 
 
0.32 
1Multivariable mixed model analysis; 2Pregnancy life stage compared to postnatal (birth to 20 weeks); 3Skin colour as 






Figure 14: Variation in estimated mean maternal 25-hydroxyvitamin D, by season of conception 
Geometric Means ± 95% CI presented.  Time 0 on the x-axis represents time of birth, with negative values the antenatal months pre-delivery (no data was available earlier than 6 weeks 
gestation), and positive values postnatal months.  Season of conception deduced from gestational age.  Model adjusting for all variables in Table 13, excluding pregnancy status and season 





The results of the present study contribute to the growing literature on vitamin D and PTH status 
during pregnancy and lactation in both mother and offspring, and to the best of our knowledge, are 
the first longitudinal data from the southern hemisphere.  The main findings showed that during 
pregnancy and out to 5 months postnatally, at one or more time points, both infant and maternal 
vitamin D deficiency were very common, especially during winter and spring.  Infant cord 25OHD 
status was most strongly correlated with maternal status towards the end of the third trimester, and 
importantly had no correlation with maternal status prior to 20 weeks gestation.  In addition, 
pregnancy itself was an independent predictor of maternal vitamin D status with levels being higher 
at all measured time points throughout pregnancy compared with post-pregnancy values, a finding 
that remained after adjustment for all other measured variables.   
Maternal and infant vitamin D deficiency found in the present study was greater than other 
comparative longitudinal pregnancy cohorts (rates of 19-33% (25OHD<50nmol/L)), albeit these 
studies were conducted in Scandinavia where dietary fortification and supplementation is more 
prevalent (Lundqvist et al., 2016; Milman et al., 2011).  Our reported rates of deficiency are also 
greater than the 42% (maternal), and 57% (infant) deficiency rates (25OHD<50nmol/L) found in more 
northern New Zealand cohorts at 36-43°S (Camargo et al., 2010; Ekeroma et al., 2015).  In fact, 
deficiency rates in the present study (of generally “low” risk women) are more comparable to the rate 
reported in a “high risk” multi-ethnic population from Wellington, at 41°S (Judkins & Eagleton, 2006).  
The significance of the levels of deficiency seen is emphasised by the three otherwise healthy 
breastfed infants (only one dark skinned) at 5 months of age (sampled during mid-winter/spring) who 
had biochemical values consistent with vitamin D deficiency rickets, a clinical consequence not seen 
in any participants of the aforementioned studies. 
Our findings have important implications for those living in the south of the southern hemisphere.  
Firstly, the lack of correlation between cord 25OHD and early pregnancy maternal serum 25OHD 
(Figure 12), raises questions about the utility of screening for maternal vitamin D deficiency in early 
pregnancy as recommend by regional guidelines (Paxton et al., 2013).  This, combined with the high 
rates of deficiency found (irrespective of season) in largely “low risk” light skinned European women 
and infants, means that consideration should be given to strengthening current guidelines, including 
further thought given to recommending a universal supplementation strategy during pregnancy and 
exclusive lactation.  Currently, New Zealand’s supplementation policy recommends that 
supplementation be only considered for those who are: dark skinned; completely avoid sun exposure; 




data show that without supplementation, these individuals are clearly not achieving optimal vitamin 
D status throughout pregnancy (Ministry of Health, 2013; A. Catharine Ross & Institute of Medicine 
(U. S.). Committee to Review Dietary Reference Intakes for Vitamin D and Calcium.).  Furthermore, as 
pregnancy and lactation span multiple seasons, targeting only pregnant women in the “winter” is also 
not efficacious. Figure 14, which examines 25OHD status by season of conception, clearly 
demonstrates this, with first trimester summer participants having the lowest 25OHD status by the 
time of delivery (Figure 14).   
Our longitudinal data highlights that 25OHD status during pregnancy and lactation is influenced by 
many variables.  These include a dominant influence of season, which is well described in the literature 
in both pregnant and non-pregnant life stages (Ekeroma et al., 2015; Houghton et al., 2010; Rockell et 
al., 2005; A. Catharine Ross & Institute of Medicine (U. S.). Committee to Review Dietary Reference 
Intakes for Vitamin D and Calcium.).  In addition, maternal 25OHD status appears higher in pregnancy 
than after delivery, an association that appears to exist beyond that explained by the other variables 
in our model.  It is possible that this association is partially explained by other variables not in the 
model, such as sun exposure behaviour following pregnancy, but also suggest some of this longitudinal 
variability may be directly related to the physiological state of pregnancy itself.  This would be 
consistent with other longitudinal pregnancy studies, which have shown a decrease in 25OHD status 
by the time of delivery (Holmes et al., 2009; Zhang et al., 2014).  Milman et al found an increase in 
25OHD status up to 32 weeks followed by a decrease until delivery (Milman et al., 2011). Likewise, 
Lundqqvist et al. found 25OHD status increased until at least 35 weeks gestation, followed by a fall 
found at 12 weeks postnatal (Lundqvist et al., 2016).  Physiological changes in pregnancy may account 
for this including variation in the vitamin D binding protein (VDBP) which has been shown to increase 
in pregnancy (Park et al., 2016; Zhang et al., 2014).  The possible decline at the end of the third 
trimester could also reflect increasing 1,25-dihydroxyvitamin D production which is seen at this time 
(Hollis et al., 2011; Turner et al., 1988).  Analytical measurement issues may have also contributed to 
inconsistent results, for instance the detection or not of the C3-epimer of vitamin D (Yazdanpanah et 
al., 2013), which has also been shown to increase in pregnancy (Park et al., 2016).  Finally, PTH in 
pregnancy (and at birth and throughout lactation) in our data was shown to have a relatively weak 
inverse correlation with 25OHD status.  This has also been reported previously (Haddow et al., 2011), 
and therefore does not appear to be a reliable predictor of adequate 25OHD status during pregnancy.      
Sampling of both 25OHD and PTH in a setting of minimal dietary fortification and very little vitamin D 
supplementation to both mothers and infants throughout pregnancy and postpartum are particular 




multiple stages of pregnancy to 5 months of lactation is another strength, as is the traditionally “low 
risk” largely ethnically homogeneous population.  The latter point, however, is also a limitation, as it 
remains uncertain how generalizable the findings of this convenience population sample are to other 
latitudes (particularly those closer to the equator, where fluctuation in 25OHD status with season will 
be less) and to other ethnic groups.  A final limitation is the relatively small sample size, which may 
have influenced some of our findings. 
In conclusion, vitamin D deficiency in women and their infants is very common during pregnancy and 
lactation in New Zealand at 45°S.  The main predictors of maternal vitamin D status were season, 
supplement use, skin colour, and pregnancy itself.  However, the frequency, and at times severity of 
the vitamin D deficiency seen in this longitudinal cohort raise significant questions regarding the 
relevance and efficacy of current public health policies for those living in southern New Zealand, 
particularly the validity of first trimester screening and targeted supplementation for those currently 
















This thesis has aimed to investigate the incidence and characteristics of vitamin D deficiency rickets in 
New Zealand children; to longitudinally examine vitamin D and parathyroid hormone status in New 
Zealand women and infants throughout pregnancy and exclusive lactation; and to investigate a 
maternal vitamin D supplementation strategy during exclusive lactation to dual-supplement both 
mothers and their infants.   These research objectives were developed in order to complement and 
build on the existing literature in this field, and to utilise multiple research methodologies.  
Investigation or prevention of vitamin D deficiency and its consequences in childhood tie together the 
three investigation chapters of this thesis.   
First described in the 1600s (Glisson et al., 1660), understood in the 1900s (McCollum et al., 1922; 
Mellanby, 1989), and “conquered” in the 1960s(Harrison, 1966), vitamin D deficiency rickets is the 
most important and severe consequence of childhood vitamin D deficiency.  As previous recent studies 
on rickets incidence have confirmed, with a global incidence of between 2.9 - 60/100,000 children 
(Beck-Nielsen, Brock-Jacobsen, et al., 2009; Munns et al., 2012; Ward et al., 2007), rickets is occurring 
worldwide, and has definitely not been “conquered”.  The findings from the prospective Paediatric 
Surveillance Unit study presented in chapter 2 highlight this, with an overall NZ childhood VDDR 
incidence of 2.2/100,000, increasing to 10.5/100,000 in those under three years of age.  This work is 
the first national study from New Zealand, and only the third worldwide, which has prospectively 
collected national data on VDDR.   
Of direct relevance to the study detailed in chapter 3 of this thesis, exclusive breastfeeding was a risk 
factor in our national rickets data.  This was also found in the Canadian and Australian prospective 
studies (Munns et al., 2012; Ward et al., 2007).  The project detailed in chapter 3 specifically targets 
this period of exclusive lactation, and provides early evidence that high-dose monthly maternal 
cholecalciferol (100,000IU/month) may offer an alternative to daily infant supplementation in order 
to improve infant vitamin D status, thereby potentially preventing rickets in exclusively breastfeeding 
Dunedin infants.  The key results from this study were that, after adjustment for important variables 
(season, skin colour, and supplementation exposure), maternal cholecalciferol at 100,000IU/month 
resulted in a significant and clinically meaningful increase in infant 25OHD by 19.1 nmol/L, compared 
with that of the placebo group (p=0.025).   This, combined with promising results from other studies 
using high-dose daily or once only dosing of cholecalciferol (Basile et al., 2006; Hollis & Wagner, 2004; 
Hollis et al., 2015; Oberhelman et al., 2013), suggests further consideration of maternal 




Southern latitude was a further risk factor for childhood VDDR, as outlined in chapter 2.  This finding 
is fully supported by findings from chapter 4, which provide (to the best of my knowledge) the first 
longitudinal vitamin D data during pregnancy and lactation that includes both maternal and infant 
measures, as well as the first longitudinal southern hemisphere pregnancy data.  One of the key 
findings from this study was that at 45°S in largely unsupplemented women and their infants, rates of 
vitamin D deficiency are very high, found in 65% and 76% of all participants (women and their infants 
respectively) at one or more time points.  These high rates of deficiency in traditionally “low” risk 
healthy light-skinned southern women/infants is much higher than comparable northern NZ (Camargo 
et al., 2010; Ekeroma et al., 2015; Grant et al., 2014), and northern hemisphere datasets (Lundqvist et 
al., 2016; Milman et al., 2011).  The direct relevance of this finding to childhood rickets (chapter two) 
was further emphasised by the three cases of secondary hyperparathyroidism (and possible 
biochemical VDDR) found by week 20 of exclusive breastfeeding in this chapter four cohort.  To the 
best of my knowledge, deficiency of this magnitude has not been reported before in any 
prospective/longitudinal descriptive studies in otherwise healthy women and their infants. 
These findings from chapters 2 and 4 highlight the importance of infant supplementation during 
exclusive breastfeeding.  While breastfeeding is the ideal nutrition source for infants (Kramer & 
Kakuma, 2002; Ministry of Health, 2013), breastmilk does not normally contain sufficient vitamin D to 
meet recommended daily requirements.  This led to one of the conclusions from our rickets paper 
(published prior to completed analysis of chapters 3 and 4) that most of the cases we described would 
have been prevented, had the current NZ targeted vitamin D supplementation policy been adhered 
to (no cases with risk factors had received appropriate public health preventative measures).  Clearly 
raising awareness of the need for supplementation, at minimum in those with readily identifiable risk 
factors, is required.  However, based on the data from chapter 4 with very high rates of southern 
deficiency found in both mothers and their infants, considerably higher than comparable northern 
hemisphere, and northern NZ data, an argument could be made for universal supplementation, at 
least at southern NZ latitudes, in line with Northern hemisphere policy (Wagner et al., 2008).  This 
makes sense, as the risk factors seen in our rickets data are essentially identical to more northern 
datasets, and the rates of maternal and infant deficiency found in our longitudinal study are in fact 
greater than current northern data.  The important variation longitudinally during pregnancy, and 
therefore at birth, of vitamin D status when examined by season of conception, adds further weight 
to arguments for universal supplementation in pregnancy and lactation.    
The alternative option to universal infant supplementation is high dose maternal supplementation, as 




include: the benefit of dual supplementation of both mother and baby; no interference with exclusive 
breastfeeding; and potential improvements in adherence (as opposed to the poor rates of adherence 
reported using daily infant supplementation seen in some studies (Ahrens et al., 2016).  In addition, 
50,000IU capsules are the only maternal supplement option currently funded in NZ, with no funded 
daily maternal option available.  Funded infant options are also limited, the only infant option being 
vitadol C™, which also contains vitamin A and C (Ministry of Health, 2013).  Daily doses using vitadol 
C™ above 400 IU cholecalciferol (e.g. as required for management of more severe deficiency or rickets) 
are therefore not advisable, due to the risk of vitamin A toxicity with this preparation.  These New 
Zealand specific funding issues, for both infants and mothers, make a higher dose intermittent 
supplementation option attractive in the New Zealand setting.   
Finally, as seen in chapter 3 and 4, a number of natural physiological phenomena are likely occurring 
during pregnancy and infancy that impact on vitamin D status and metabolism.  These remain 
incompletely understood.  The first of these phenomena is highlighted in both chapters 3 and 4, with 
the observed increase in infant 25OHD concentrations from birth to week 20, in the placebo and 
unsupplemented observation study groups.  This potential natural temporal trend towards increased 
vitamin D status in the first year of life has also been found in a number of comparable studies (Challa 
et al., 2005; Grant et al., 2014; Kim et al., 2010; Narchi et al., 2011).  Of course, this may be influenced 
by season, and an imbalance in season of recruitment was seen in chapter 3.  However, a physiologic 
increase in the circulation of vitamin D binding proteins, a key determinant of 25OHD concentrations 
is also possible (Carpenter et al., 2013).  Either way, these findings reveal the importance of a placebo 
group for nutritional studies of this nature, something lacking in many similar trials.  An association 
between vitamin D and gestational/post-gestational age also appears to exist beyond that explained 
by the other variables in our model.  This suggests that there is some longitudinal variation in 25OHD 
metabolism directly related to stage of pregnancy.  While it remains possible that this association is 
partially explained by other variables not our model, this finding is consistent with our current limited 
understanding of vitamin D metabolism during pregnancy.   Other longitudinal pregnancy studies have 
shown a similar decrease in 25OHD status by the end of pregnancy (Holmes et al., 2009; Zhang et al., 
2014), and our data is almost identical to Lundqqvist et al. where this was found (Lundqvist et al., 
2016).  Similarly,  Milman et al found an increase till 32 weeks,  followed by a decrease through to 
delivery(Milman et al., 2011).  A number of physiological changes in pregnancy may account for this, 
including genetic variations in the VDR(depending on the population studied), or variations in vitamin 
D binding proteins (VDBP), which, as in infancy (above), have been shown to also increase in pregnancy 




increasing 1,25-dihydroxyvitamin D production, which is seen at this time of peak foetal calcium need 
(Hollis et al., 2011; Turner et al., 1988).  Analysis issues may also contribute, for instance the detection 
or not of the C3-epimer of vitamin D (Yazdanpanah et al., 2013), which has also been shown to increase 
in pregnancy (Park et al., 2016).  
 
5.1 Strengths and limitations 
Study design is a key strength of the three studies of differing methodology that make up this thesis.  
This is highlighted firstly in chapter 2, with the national, prospective nature of the rickets surveillance 
study, using the established infrastructure of the NZPSU.  The NZPSU represents 92% of the 
paediatricians registered with the NZ Medical council, and has a >90% response rate (B. J. Wheeler et 
al., 2015).  For chapter 3, the randomised, double-blind, placebo-controlled trial design, as well as 
environment with little other concurrent infant supplementation/dietary fortification are major 
strengths, and separates this study from the majority of the existing trials on high-dose maternal 
vitamin D supplementation (Basile et al., 2006; Hollis & Wagner, 2004; Oberhelman et al., 2013; Saadi 
et al., 2009).  Thirdly, the longitudinal data presented in chapter 4, which includes both infants and 
mothers from three time points in pregnancy to week 20 postnatal is a strength and point of difference 
from most descriptive studies of vitamin D status during pregnancy or lactation.  Again, the New 
Zealand context of negligible dietary fortification, and minimal supplementation are additional 
advantages of descriptive studies of vitamin D status in New Zealand.    
The high rates of exclusive and concurrent breastfeeding at completion of both the RCT and 
longitudinal descriptive study are also important strengths, given that the first 20 weeks of lactation 
were particular focuses of both these projects.  This is a point of difference from other studies 
conducted during lactation (Grant et al., 2014; Hollis & Wagner, 2004; Hollis et al., 2015; March et al., 
2015; Oberhelman et al., 2013; Saadi et al., 2009).  In addition, the robust and detailed data collection 
from the three studies is a strength, this includes the detailed reporting of rickets by New Zealand 
paediatricians, as well as the detailed collection of data for chapters three and four on skin colour (by 
objective spectrophotometry), supplement use, season, and other sociodemographic factors.  Vital 
factors such as season have been overlooked or restricted in some previous longitudinal studies (Cross 
et al., 1995; Ritchie et al., 1998; Zhang et al., 2014).    
As with all research, the work described in this thesis has limitations.  For the rickets surveillance study 
the biggest weakness lies in possible under-reporting or under-diagnosis of cases of VDDR.  This is 




experienced two catastrophic earthquakes in the first year of reporting, and there did appear to be 
smaller numbers of cases reported from this region.  Under diagnosis may be reflected in the low 
numbers of incidentally diagnosed rickets.  In the Australian data 80% of cases were found on 
“screening” (Munns et al., 2012), although frequency of incidental cases in the Canadian data, was 
identical to my NZPSU study (Ward et al., 2007).   
For the projects detailed in chapters 3 and 4, it is unknown how generalizable the results are to other 
ethnicities and latitudes.  Given that the majority of participants were of “low” risk light-skinned 
European ethnicity, the findings of these studies are likely to be similar or more profound in those 
with darker skins or non-European ethnicity.  A further limitation, is ideally additional analysis of 
breast milk and of blood for additional vitamin D metabolites and binding proteins would have been 
conducted to give a more complete picture of vitamin D status and metabolism.  Unfortunately 
funding did not allow for this.  However, 25OHD was the primary outcome of interest for both our RCT 
and longitudinal study.  In addition, measurement of PTH, and also 25OHD status in infants are 
important strengths and points of difference in the longitudinal study (chapter 4).       
Finally, for chapters 3 and 4, type 2 error remains a possibility due to limitations in sample size, and 
for the RCT, distribution by season.  This is one explanation for the clinically (15.8nmol/L) but not 
statistically significant (p=0.13) change in 25OHD status compared to placebo in the 100,00 IU group 
of the RCT in the primary analysis, and why a statistically significant change was only found after 
adjustment for season, skin colour, and supplement intake.      
  
5.2 Future directions 
The RCT detailed in chapter 3 found that maternal vitamin D supplementation in lactating women 
appears safe and may improve infant status.  This suggests that further studies examining maternal 
supplementation strategies for dual supplementation of lactating mothers and their infants is required 
before this could be recommended as a public health strategy.  In particular, given the data we now 
have, future larger studies could look at varying dosage regimens (daily vs intermittent e.g. weekly, 
fortnightly, monthly) as alternative infant supplementation options to the currently recommended 
daily infant strategy, as well as confirm, or not, our findings and effect size.  Combining these with a 
third trimester maternal supplementation strategy similar to Grant et al. (Grant et al., 2014) or March 
et al. (March et al., 2015) is also likely to provide additional efficacy.  This combined approach is likely 




While that is occurring, efforts to increase awareness of New Zealand’s current targeted maternal and 
infant vitamin D supplementation policy are required, as highlighted in the rickets cases diagnosed in 
chapter two.  At the same time advocacy for consideration of universal supplementation, at least at 
southern latitudes, is also required.  Once these initiatives to increase awareness and supplementation 
have occurred, then a repeat of our prospective rickets study via the NZPSU would be of value – to 
measure success or not of public health policy implementation in this area. 
In addition, I have now obtained a grant for a study investigating subsequent bone outcomes (in our 
RCT cohort) that may be more important than the surrogate 25OHD status that we have measured in 
these studies.  When vitamin D status during pregnancy or infancy is linked to concrete health 
outcomes, this will provide stronger evidence/support for promoting maternal and infant 
supplementation strategies.  To this end, in collaboration with the colleagues from the University of 
Otago Dental School, we plan a histological, molecular composition, and clinical follow up study to 
examine exfoliated teeth and dental caries/enamel defects in the children from the longitudinal 
cohort study detailed in Chapter 4.  These various dental outcomes will then be compared to infant 
cord vitamin D status and maternal pregnancy status, measures taken over a time course that reflects 















In conclusion, this thesis has examined several aspects of vitamin D status and pathology spanning 
pregnancy, lactation, and childhood.  It has demonstrated that in New Zealand, vitamin D deficiency 
during pregnancy, lactation and childhood remains an important health concern.  In Dunedin, at 45°S, 
both infant and maternal deficiency during pregnancy and lactation is very common, and sometimes 
severe.  Severe deficiency can lead to childhood rickets, and this thesis has demonstrated that rickets, 
an important bone pathology that can be easily prevented with vitamin D supplementation, is still 
occurring In New Zealand, with a higher incidence in children with mothers from India and Africa, and 
in children younger than three years, who are currently or previously breastfed.  While infancy and 
breastfeeding are risk factors for rickets, high-dose monthly maternal supplementation may also hold 
promise as an alternative dual maternal and infant supplementation strategy.  Further research is now 
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Dept. Women’s Children’s and Health research grant 
HEHA  







2. Background Information and Scientific Rationale 
 
Vitamin D is critical for calcium homeostasis and for mineralization of the skeleton.  
The most severe consequence of vitamin D deficiency in childhood is rickets (a 
mineralization defect at the epiphyseal growth plates) and osteomalacia (a 
mineralization defect of bone tissue). These effects can be associated with pain, 
fractures, skeletal deformity, growth retardation, dental defects, delayed 
developmental milestones and, in severe cases, seizures. Deficiency in children, 
without rickets, is also associated with low bone mineral density (Cheng et al., 2003) 
which has potential long-term implications particularly in adulthood.  It has been 
recognised that Vitamin D plays a major role in the immune system.  Low levels during 
foetal life, early infancy and adulthood potentially have a major effect on response to 
infection, the development of autoimmune disease as well as cardiovascular disease, 
and possibly cancer (M. F. Holick, 2004; Urashima et al., 2010).   
Vitamin D is unique among vitamins as its main source is not dietary, but direct 
synthesis in the skin following exposure to UVB radiation, from sunlight.  UVB 
radiation exposure varies based on latitude, skin colour, sunscreen use and 
clothing(McKenzie et al., 2009).   Changes in human lifestyle including sun avoidance 
practices, indoor occupations and recreation, added to NZ’s geographical location at 
35ºS to 47ºS, mean that children and adults cannot depend on adequate skin 
exposure to sunlight for vitamin D synthesis, especially during winter 
months(McKenzie et al., 2009; Rockell et al., 2008).  At latitude 45 ºS the Otago region 
is particularly at risk. 
Dietary intake is a secondary source, but without additional supplementation there is 




currently has no mandatory food supplementation.  Compounding this, human milk, 
which is advocated as the ideal fluid source for infants, has been criticised as being 
generally low in vitamin D and this has led to recommendations for universal 
supplementation to breast feeding infants in some countries(Wagner et al., 2008).   
One of the main reasons breast milk may not be a rich source of vitamin D is that 
many breast feeding mothers are themselves vitamin D deficient(Judkins & Eagleton, 
2006; Nozza & Rodda, 2001).  Preliminary work from the United States suggests that 
daily supplementation of the breast feeding mother with high dose vitamin D can 
safely lead to not only improved vitamin D levels for her, but also in her milk and 
subsequently her nursing infant(Hollis & Wagner, 2004).   
This suggests that an attractive alternative to universal supplementation of breast fed 
infants may be their indirect supplementation via effective supplementation of their 
mothers and hence their breast milk.  This would support current WHO 
recommendations on the importance of breast feeding and also avoid the issue of 
direct supplementation of exclusively breast-fed infants which is controversial and 
poorly complied with by families (Taylor et al., 2010).   
We propose, to investigate for the first time, the effect of high dose intermittent 
maternal vitamin D supplementation e.g. monthly on vitamin D levels of both the 
mother and nursing infant This will be a safe (Hollis & Wagner, 2004; Vieth, 1999), 
easy and potentially more acceptable alternative to both daily maternal and/or infant 
dosing.  In NZ we have a logical option in cholecalciferol 50,000 IU tablets (vitamin 
D3).  Giving this fortnightly or monthly will be safe for mothers and provide a similar 
monthly vitamin D dose to that already shown to be of benefit in raising vitamin D 
levels in mothers, maternal breast milk and indirectly in the nursing infant.   
 
 
3. Study Hypothesis and Objectives 
 
3.1 Overall Goals: 
To inform policy of effective and feasible interventions to combat vitamin D deficiency 
in exclusively breast fed infants.  The testing of our hypotheses will allow policy 
makers to determine the value of providing high dose intermittent maternal vitamin D 




during periods of exclusive breastfeeding, thus encouraging and supporting true 
exclusive breast feeding.   
3.2 Hypothesis:  
 
It is proposed that monthly maternal supplementation with Cholecalciferol may 
improve the vitamin D status of the exclusively breast fed baby, the human milk and 
the lactating mother.  We, therefore hypothesize that the serum 25OHD level of the 
exclusively breast fed infant and mother will be greater when supplemented with 
monthly 100,000IU vitamin D > 50,000IU vitamin D > placebo.   
 
3.2 Objectives:   
The main objective of this study is to evaluate the impact of maternal monthly vitamin 
D supplementation in the form of Cholecalciferol D3 on the 25OHD status of her 
exclusively breast fed infant.  Secondly we will evaluate the maternal 25OHD status, 
the Cholecalciferol D3 status of human milk and a variety of bone markers.     
3.3 Primary Outcome Measure: 
Change in Infant 25OHD (nmol/L) at 20 weeks /proportion achieving serum 25OHD 
>50 
3.4 Secondary Outcome Measures: 
  Change in Maternal 25OHD (nmol/L) at 20 weeks /proportion achieving serum 25OHD 
>50 
 Change in other bone/vitamin D markers at 20 weeks (PTH, Ca, P, ALP) 
Change in Breast milk vitamin D3 at 20 weeks 
4. Subject Selection 
4.1 Research Site: 
Dunedin and its surrounds is the single site for this study.  Home visits will comprise 
the bulk of the investigator/subject contact.  Some contact will be had within two 




1800 deliveries/year); and the paediatric outpatient department (as a potential site 
for phlebotomy).  
4.2 Number of Subjects/Power Calculation: 
Calculated on basis of detecting a 15 nmol/L difference in mean serum 25(OH)D at 
study end [approximately 90% of the observed decline from the 2002 National 
Children’s Nutrition Survey data, while controlling for baseline 25OHD levels]. To have 
80% power to detect such an effect with a standard deviation of 20 nmol/L(Rockell et 
al., 2005), 28 children would be required in each arm. Allowing for an estimated 20% 
loss to follow-up, 105 families will be recruited at baseline.     
4.3 Recruitment: 
Recruitment will occur via a variety of avenues. 
4.3.1 With the receipt of maternal booking letter (sent via the DHB to confirm 
booking at Queen Mary), an introduction to the study will be sent out.  This 
has our contact details but is intended as only a warning of future contact. 
4.3.2 Identification of potential participants from antenatal registration.  A weekly 
list of new registrations will be obtained from the Queen Mary IT staff (Darren 
Klemp (Darren.klemp@southerndhb.govt.nz).  At 20-24 weeks gestation - 
Potential participants will then be contacted by mail, and offered participation 
by an opt out (from January 2012, was opt in prior to this) design (to contact 
us by email, phone to participate/for further information).   Families who do 
not opt-out will be contacted by phone a week later to discuss. 
4.3.3 Directly approaching LMCs via email, breast feeding education sessions, and in 
person.  LMCs may then recruit or refer directly 
4.3.4 Direct recruitment from Dr Adel Mikail and A.Prof. Mike Stitley’s antenatal 
clinics 
4.3.5 Pamphlets at breastfeeding antenatal classes  









4.4.1 Healthy pregnant women from Dunedin 
4.4.2 Planning to exclusively breast fed for 5 months 
4.4.3 Willing to take intermittent vitamin D supplementation 
4.4.4 Ability to obtain written informed consent 
 
4.5 Exclusion Criteria 
 
4.5.1 Unwilling to stop taking additional postnatal supplements that contain vitamin 
D   
4.5.2 Not intending to exclusively breast feed for at least 5 months 
4.5.3 Delivery prior to 37 weeks gestation 
4.5.4 Low or elevated calcium levels/urine Ca/Cr ratio at baseline  
4.5.5 Not willing to take vitamin D supplementation 
4.5.6 Health conditions potentially affecting vitamin D metabolism e.g. on 
anticonvulsants, malabsorption problems 
4.5.7 Potential subjects will also be excluded if they are planning to travel to a sunny 
climate during the study period. 
 
4.6 Premature Withdrawal 
Participants are free to withdraw from the study at any time.  If the subject 
prematurely withdraws, every effort will be made to collect all data up to and 
including the day of study discontinuation.    
 
5. Study Supplementation 
5.2 Description and formulation 
The study uses Cholecalciferol 50,000 IU (1.25gram) tablets (Cal.D.Forte).  This is a 
white Sugar coated 8mm biconvex tablet.  This is manufactured along with identical 
placebo tablet by Optimus Healthcare limited, Auckland.  Tablets come in individual 
bottles.  Pharmacy will allocate tablets following randomisation. 





All supplementation is provided monthly.  There are three arms to the study:  Placebo, 
50,000 IU and 100,000IU given once per month.  Dosing starts at 1 month postnatal 
and continues for 4 months total.  Two capsules will be taken per month comprising 




Placebo is a white sugar coated tablet.  It is identical in size and shape to the 
treatment arm.  It is also manufactured by Optimus Healthcare limited.  
 
5.5 Safety and Activity 
 
Vitamin D can be toxic in large doses.  This can cause a variety of adverse effects 
largely due to hypercalcaemia.  The doses provided in this study (1666 IU & 3333 
IU/day) are less than upper safe dosing levels as set by the Institute of Medicine(A. 
Catharine Ross & Institute of Medicine (U. S.). Committee to Review Dietary Reference 
Intakes for Vitamin D and Calcium., 2011) (4000 IU/d) and well under expected toxic 
doses as suggested by the literature on this topic. There are no documented 
overdoses in the literature with doses under 10,000 IU/day(Vieth, 1999).   
 
Monitoring for toxicity will be undertaken.  This is primarily looking for manifestations 
of hypercalcaemia.   Maternal urine and serum monitoring will be undertaken from 
the first antenatal assessment, prior to the first dose of study supplementation, and at 
completion of the study (20 weeks).   
 
Hypercalciuria or hypercalcaemia during intervention will be indications to stop study 
intervention and to investigate for possible vitamin D toxicity.  Hypercalciuria prior to 
intervention will be repeated to confirm.   
 
6. Study Procedures 
  
6.1 Study Time Schedule: (See pages iii/iv/v above) 
 




Women are first visited at recruitment to get baseline data.  This is via home visit or at 
hospital at preference of women.  Phone call reminders antenatally are given prior to 
blood tests at 28 and 36 weeks (a week prior).   
Following delivery, phone contact is made at 3 week postnatal.  Congratulations are 
given and arrangements made for 4 week home visit.  Randomisation will occur at this 
time if all is on track (or exclusion from study if not breast feeding or any other 
exclusion criteria met). 
Further monthly reminder phone calls will occur, pre-monthly dose.  Final visit at 20 
weeks (phone call 1 week prior to arrange).   
6.3 Randomisation: 
Following delivery, breast feeding mothers will be randomly allocated to one of the 
three arms of the trial by research support at the Dunedin Public Hospital Pharmacy.    
Randomisation will be done via randomisation list provided by Peter Herbison 
(statistician).  This has been provided to pharmacy research unit.  Participants will be 
block randomised in groups of 15.  This is to ensure equal distribution by season.  All 
investigators (including statistician) will be blinded to intervention. All will receive 
monthly medication in blister packs appropriate to one of the three arms of the 
intervention e.g. placebo/placebo, placebo/50,000 IU Cholecalciferol or 2 x 50,000 IU 
Cholecalciferol.   
6.4 Socio-Demographic information: 
Socio-demographic data is collected by questionnaire, at baseline enrolment (maternal 
only), and at 4 and 20 weeks postnatal (both mother and baby).   Questionnaire will be 
conducted and completed as a joint process with research team during home visit.  (See 
appendices 1, 2 and 3 for Questionnaires)   
6.5 Concomitant Medications: 
Information on all concomitant medications taken by either mother or infant will be 
documented.  Postnatal supplements containing vitamin D are required to be stopped 
for the duration of the study.  The investigators are happy to assist in arranging for 




maternal or infant vitamin D is an exclusion criterion.  See above for further 
medication based exclusion criterion.   
6.6 Blood/Urine Collection and Analysis: 
Order of testing priority: 
1) 25OHD  2) ALP/Ca/P/Ferritin  3) PTH   
 
For each blood test: (minimum volume whole blood for all tests ~ 5ml) 
-Mother + cord = 8ml red top 
-Infant  
Human Nutrition Lab: 
25OHD  - 0.5ml serum (~1ml whole blood) - LCMS 
PTH  - 0.5ml serum    - Chemilum 
 
Southern Community Labs: 
ALP/Ca/Phos/ Ferritin - 0.5ml serum  
Maternal urine for Calcium creatinine ratio will be collected prenatally at 28 and 36 
weeks, and postnatally at 4 and 20 weeks.  To avoid falsely elevated results we will 
follow a protocol from the Canterbury Health Laboratory titled - “Collecting Overnight 
Fasting Urine for Hydroxyproline and Calcium Creatinine Ratios” (see appendix 7).  
Appendix 8 details our lab request form.   
Maternal bloods are prospectively collected for the first phase of the study at 28  and 
36 weeks gestation.  As we strive to recruit most participants prior to 28 weeks our 
wish is >50% of total participants will be involved in this first phase of the study.  As 
part of this consent is obtained for access to antenatal 1st trimester booking bloods.  
These are collected prior to recruitment and are stored in freezer space within SCL for 




more formal storage system.  Currently we will go through this bag 1 year from the 
booking of each patient and remove our sample prior to them being destroyed.  To 
more formalise this we are exploring the option of making an additional storage bag 
labelled with our study into which participant booking bloods can be placed once 
recruited to avoid any risk of destruction.   
6.7 Breast milk collection:  
Expressed breast milk will be collected prior to monthly intervention at 4 and 20 
weeks.   
Milk will be collected with a “Medela™ Lactina plus” hospital grade breast pump 
(adjustable speed) in most instances.  We have two units available.  Those women with 
their own pump may use their own equipment (Dunedin hospital lactation consultants 
in their experience predict up to 50% of women may have their own equipment).  
Medela disposable sterile expressing sets ($212 excl. GST/30 units or $7.10/unit) will be 
allocated to each woman.  These can be used for both episodes of expressing.  For the 
minority of women requiring a larger cup size, the hospital lactation service is happy to 
provide this (personal communication with Anne Jenkins and Stefanie Kalmafoff - 
29/6/11). 
 
Expressed milk collection is recommended an hour after first morning feed (this is the 
time when milk supply is at its peak).  Volume for collection is 100ml.   As the average 
volume expressed in the morning following as feed is approx. 30-50ml, milk will need 
to be collected over two mornings in most cases and then frozen (some women will 
get 80-100ml in one go).  Pump should be used at its lowest suction setting initially 
and then suction increased based on need and comfort.    
 
Milk will be frozen and stored in pre-provided plastic 120ml specimen containers.  
Containers will be labelled with study ID and date collected.  Milk can be stored in 
subjects’ freezer till pick up or drop off arranged.  Frozen specimens will be 
transferred to freezer space at department of Human Nutrition laboratory as 
available.  The samples are to only be <24hours old prior to freezing and transported 




The LC and Queen Mary are happy for a minority of women to use hospital pumps, in 
hospital, if requested by study participants or our machines are in use/under repair.  A 
pump on an as available basis for short periods may also be available from the 
hospital LC team if the need arises (no formal provision for this has been made).  
Pumps can also be hired directly from Fisher & Paykel NZ (direct communication from 
Sandra Mackay (Sandra.mackay@fphcare.co.nz)    
 
Lactation support: 
We will provide a lactation support and referral service to all women participating in 
the study.  Lactation services available for referral or self-referral are as follows.   
 
Following delivery (while still inpatient in Queen Mary): 
 Women will be advised to request contact with the lactation consultants (LC) before 
discharge as part of the standard service.  Women are advised to inform LC that they 
are part of study.  Local LC have been briefed on study details.  Specific advice is 
offered at this time regarding: 
- Lactation advice and support 
- Pumping and an opportunity to explore the hospital Medela™ pump 
During the first 6 weeks postnatal there are three options for support for lactation:   
- Lead Maternity Carer (LMC) support is available, and regularly provided as 
part of standard postnatal care over the first 6 weeks.  We can advocate 
for mothers or advise they contact their LMC. 
- During the first 6 weeks the hospital LC team is contracted and available 
by referral and drop in (may be a wait) 
- Plunket breast feeding support person, Jill Moore, is available for 
community support. 
From week 7 to month 5 there are two options for lactation support: 
- Plunket breast feeding support person, Jill Moore, is available in the 
community.  We can refer or advise mothers to self refer.   
Dr Wheeler (PI) and Shirley Jones (Research Nurse) have been educated on pump 




Early Cessation of Breast feeding: 
Women will be encouraged, and provided with all available support, to continue 
exclusively breast feeding till at least 20 weeks.  If for any reason a woman ceases to 
breast fed we will request that they inform us of this.  All future data and sampling (other 
than breast milk) will be collected as planned.  Date of breast feeding cessation will be 
recorded.     
1.1. Skin Colour Assessment: 
Changes in skin colour are a marker of sun exposure during the course of the study.  This is 
an important confounding factor in final 25OHD outcomes.  Participant skin colour will be 
determined by spectrophotometer (CM2006d, Minolta Co. Ltd, Osaka, Japan).  Maternal 
measures will be taken initial enrolment to study, 4 weeks post natal and at completion of 
the study (20 week assessment).  Baby will also have measures taken at 1 and 5 months.  
Skin colour measurements are taken from the medial aspect of the upper arm (target 
sample – natural skin colour)) and dorsal aspect of forearm (sample – sun exposed surface).  
A calculation is made (appendix 9) and this number is then converted to a final skin colour 








































Appendix 10. RCT - Consent form 
The vitamin D and breast feeding study  
Intermittent maternal vitamin D supplementation to prevent 
vitamin D deficiency in the breast feeding infant and lactating 
mother  
CONSENT FORM FOR PARTICIPANTS 
 
I have read the Information Sheet concerning this project and understand what it is about.  All 
my questions have been answered to my satisfaction.  I understand that I am free to request 
further information at any stage.  I know that: 
1. My participation in the project is entirely voluntary; 
 
2. I am free to withdraw from the project at any time without any disadvantage; 
 
3. Personal identifying information will be destroyed at the conclusion of the project but 
any raw data on which the results of the project depend will be retained in secure storage 
for 10 years after participants turn 16 years old (i.e. aged 26 years). 
 
4. I am aware that I/my child may experience pain during the drawing of blood, and in 
some cases minor bruising may occur but this will generally disappear in about one to two 
days; 
 
At the end of the study I would like left over biological specimens: (circle your preferred 
option) 
 
RETURNED TO ME / DESTROYED  /  TRADITIONAL BLESSING AND DESTROYED 
 
5. In the future, if the PI would like to examine your samples (blood, milk or urine) 
for other nutrition research purposes outside of those stated in this vitamin D 





_____ Option A I consent to my sample being used in research outside the purposes 
stated here as long as the research is approved by the University of Otago Ethics 
Committee and is supported by the Māori Research Consultation Committee. 
 
_____ Option B. I wish to be contacted for permission to use my sample for research 





_____ Option C. I do not wish my samples used outside of the stated purposes.   
 
 
6. I am aware that I will receive no payment for participation in this study 
 
7. The results of the project may be published and will be available in the University of 
Otago Library (Dunedin, New Zealand) but every attempt will be made to preserve my 
anonymity. 
 
I agree to take part in this project.      YES/NO 
 
I allow access to my antenatal booking bloods for study sampling.  YES/NO 
 





.............................................................................             ............................... 
       (Signature of participant)      (Date) 
 
              
 ………………………………………………………………………… 












































Dear LMC Name 
I would like to inform you of our research study.  We believe Breast Milk is the ideal food for 
children less than 6 months.  Our research project is aimed at improving both maternal and 
infant vitamin D status during periods of exclusive breast feeding, using monthly maternal 
vitamin D supplementation. By providing vitamin D supplementation to the mother, we can 
increase the vitamin D levels in her breastmilk. If we can provide evidence that this simple 
technique works then we strengthen our goal of exclusive breast feeding and can offer this as 
an alternative option to the currently available approach, which is infant supplementation.   
 
Full details of the study are provided in the enclosed information sheet.  As a brief outline, 
recruitment will take place in the antenatal period and will use a blinded randomised trial with 
three arms (50,000 IU or 100,000IU vitamin D administered monthly or placebo). This treatment 
will commence at 1 month following birth and be complete at 5 months.   Mothers will be visited 
at home or in our clinic (depending on maternal preference) at 1 & 5 months to record baby 
growth/general health, complete a questionnaire, have a skin colour assessment and have 
samples of blood, urine and breast milk collected.  At the final meeting a blood sample is 
required from the baby – either a venous sample or via heel prick.  We will also appreciate your 
assistance to take a cord blood sample at delivery.   
 
There is a second antenatal component to our study where we will be collecting maternal 
bloods alongside the standard antenatal collections, at 28 weeks (polycose screening) and 36 
weeks (iron status screening).  Consent will also be obtained to sample stored booking bloods. 
For women currently in the third trimester this will not be an option, however, we still wish to 
The Vitamin D study 
Principal Investigator: Dr Ben Wheeler 
Department of Women’s & Children’s Health,  
PO BOX 913, Dunedin, New Zealand 
Research Nurse: Shirley Jones  
Telephone: 64 03 474 7644  email: ben.wheeler@otago.ac.nz 





offer them access to the main study above.  Overall our hope is at least 50% of women will be 
available to participate.  The aim of this second study is to increase our understanding of vitamin 
D metabolism and bone health during pregnancy. 
  
The University of Otago supports the need for high quality research in order to prevent health 
problems.  Thank you for taking the time to read this letter and the enclosed brochure. If you 
have any questions or have any women who you feel may be interested in the above study 
please contact myself or my Research Nurse; Shirley Jones at the above contact details. We 
will also be inviting women by letter once they have booked into Queen Mary so they may be 
aware of the study.   We realise that you will have a busy schedule ahead but appreciate your 




Dr Ben Wheeler 
Paediatrician / Senior Lecturer 




























I would like to inform you of our research study.  We believe Breast Milk is the ideal food for 
children less than 6 months.  Our research project is aimed at improving both the mother’s 
and babies vitamin D status during periods of exclusive breast feeding, using monthly 
maternal vitamin D supplementation. By providing vitamin D supplementation to the mother, 
we can increase the vitamin D levels in her breastmilk. If we can provide evidence that this 
simple technique works then we strengthen our goal of exclusive breast feeding and can offer 
this as an alternative option to the currently available approach, which is supplementation to 
baby.   
 
Full details of the study are provided in the enclosed information sheet.  As a brief outline, 
recruitment will take place during your pregnancy and you will be randomly placed in one of 
the 3 options (Vitamin D in two different monthly doses or placebo). This treatment will 
commence at 1 month following birth and be complete at 5 months.   Mothers will be visited at 
home or in our clinic (depending on your preference) at 1 & 5 months to record baby’s 
growth/general health, complete a questionnaire, have a skin colour assessment and you will 
have samples of blood, urine and breast milk collected.  At the final meeting (Month 5) a blood 
sample is required from the baby – either a venous sample or via heel prick (like the standard 
newborn screening sample).  We will also need a cord blood sample from your placenta 
following delivery.  Your Midwife/Obstetrician will organise and collect this for you.   
 
There is a second pre-delivery component to our study where we will be collecting your blood 
alongside the standard pre-delivery collections, at 28 weeks (polycose screening) and 36 weeks 
The Vitamin D study 
Principal Investigator: Dr Ben Wheeler 
Department of Women’s & Children’s Health,  
PO BOX 913, Dunedin, New Zealand 
Research Nurse: Shirley Jones  
Telephone: 64 03 474 7644  email: ben.wheeler@otago.ac.nz 





(iron status screening).   This part of the study is optional. We also wish to obtain a sample of 
your stored booking bloods taken at the start of your pregnancy. Overall, our hope is at least 
50% of women will be available to participate in this second study.  The aim of this second study 
is to increase our understanding of vitamin D metabolism and bone health during pregnancy. 
  
The University of Otago supports the need for high quality research in order to prevent health 
problems.  Thank you for taking the time to read this letter and the enclosed brochure.   
 




Dr Ben Wheeler 
Paediatrician / Senior Lecturer 



















Dear Dr  
 «MotherName» «Surname» 
DOB: «DOB» 
    «Address_1» «Address_2» «Address_3» 
The «Surname» family have agreed to be part of a randomised controlled trail looking at 
intermittent supplementation of vitamin D to lactating mothers.  The trial has three arms; 
50,000 IU, 100,000 IU or placebo administered monthly. The aim of the study is to assess if 
intermittent vitamin D supplementation prevents vitamin D deficiency in the mother and breast 
feeding infant as an alternative to daily infant supplementation.  Maternal bloods will be 
collected along with standard antenatal collection at booking, 28 and 36 weeks.  Further 
samples including blood, urine and breast milk will be taken at 1 month and 5 months.  Bloods 
for baby include: cord blood, and a venous sample at 5 months.   
 
We would appreciate if during your normal post delivery care you refrain from giving any 
vitamin D supplements.  Please let us know if you feel these will be clinically indicated over and 
above what we are doing.     
 
We will also contact you if any abnormal results occur during the course of the study.   
 
We look forward to having «MotherName» and her baby assisting us in our research.  If you 




Dr Ben Wheeler 





Appendix 15. RCT – Recruitment questionnaire – baseline 
      The Vitamin D and breastfeeding study 
 
University of Otago 
Departments of Women’s and Children’s Health 









The answers from all women surveyed will be gathered together, and no 
individual answers will be published or passed on. If you do not wish to 
answer any of the questions, leave them blank. 
 
 Please note that all questions relate to your RECENT PREGNANCY, not 
previous pregnancies. 
 
 Most answers require a tick in a box, for example: 
 ☐ yes 
  no 
 ☐ not sure 
 Some questions require a written answer in the space provided. 





Study Recruitment Questionnaire     Date: 
_______________ 




Home address: ________________________________________________   
Tel: ____________________________________ 
Midwife:  ____________________  Phone: ____________________ 
G.P. ____________________  Practice: ____________________ 
 
1.  What was your age at your last birthday? ___________________ 
2. What is your height?    ___________________ 
3. What is your current weight?   ___________________ 
4. What was your weight before pregnancy? ___________________ 
5.  How many times have you been pregnant?  
 ☐ once, including my recent pregnancy 
 ☐ more than once (Please specify number of times) ___________________ 
6.  How many birth children do you have?   ___________________ 
7. How many weeks pregnant are you?   ___________________ 
8. What is your estimated due date?    ___________________ 
9.  Are you experiencing any pregnancy complications?  
☐ No 





________________   
10.  Which country were you born in? ________________________ 





11.  Which ethnic group do you belong to?  
Please tick the box or boxes that apply to you. 
 ☐ New Zealand European  
 ☐ Māori  
 ☐ Samoan 
 ☐ Cook Island Maori  
 ☐ Tongan 
 ☐ Niuean 
 ☐ Chinese 
 ☐ Indian 
☐ other such as Dutch, Japanese, Tokelauan (Please specify) 
________________________________________________________ 
12. Which ethnic group does the father of your baby belong to? 
Please tick the box or boxes that apply to him. 
 ☐ New Zealand European  
 ☐ Māori  
 ☐ Samoan 
 ☐ Cook Island Maori  
 ☐ Tongan 
 ☐ Niuean 
 ☐ Chinese 
 ☐ Indian 
☐ other such as Dutch, Japanese, Tokelauan (Please specify) 
________________________________________________________ 
13.  Which country was the father of your baby born in? 
______________________ 





14.  What is your marital status? 
 ☐ married 
 ☐ de facto (living with a partner) 
☐ separated / divorced 
 ☐ widowed 
 ☐ in a relationship, but NOT living with a partner 
 ☐ single 
 
15.  What is the highest education qualification you have completed? 
 ☐ left before high school 
 ☐ some high school 
 ☐ completed high school to year 12 (Sixth Form Certificate) 
 ☐ completed high school to year 13 (University Bursary) 
 ☐ further training (for example, apprenticeship) 
 ☐ tertiary (diploma or degree) 
 ☐ postgraduate qualification (Master’s or PhD) 
 ☐ other (Please specify) ___________________________________ 
 
SUN EXPOSURE INFORMATION: 
17.  Do you wear any veiling?       
      ☐ No 
☐ Yes, please tick the appropriate category below (tick one only):   
☐ consistently covered – covered up, including arms, hair and neck, 
when  outdoors 





☐ uncovered – did not generally cover up arms, hair and neck when 
outdoors   
18.  In the LAST MONTH, on average, how many hours are you outside per 
day between 10 AM and 4 PM… on WEEKDAYS (Monday to Friday)? 
 
☐ 30 minutes or less 
☐ 31 minutes to 1 hour 
☐ 2 hours 
☐ 3 hours 
☐ 4 hours 
 
☐ 5 hours 
☐ 6 hours 
 
19.  In the LAST MONTH, on average, how many hours are you outside per 
day between 10 AM and 4 PM… on WEEKENDS (Saturday & Sunday)? 
 
☐ 30 minutes or less 
☐ 31 minutes to 1 hour 
☐ 2 hours 
☐ 3 hours 
☐ 4 hours 
 
☐ 5 hours 
☐ 6 hours 
For the following question, think about what you do when you are outside during the  
LAST MONTH 
 
               NEVER  RARELY   SOMETIMES   OFTEN  
ALWAYS 
 
20. How often do you wear SUNSCREEN?...  ☐    ☐  ☐       ☐         
☐ 
 
21. How often do you wear a SHIRT WITH  
      SLEEVES tha cover your shoulders?...   ☐    ☐  ☐       ☐         
☐ 
 






23. How often do you stay in the SHADE  
      or UNDER AN UMBRELLA? …     ☐    ☐  ☐       ☐         
☐ 
 
24. How often do you wear SUNGLASSES? ☐    ☐  ☐       ☐         
☐ 
 
25. How often do you spend time in the  




























VITAMIN AND MINERAL SUPPLEMENT INFORMATION 
26.  Are you taking any vitamin or mineral tablets?  
☐ No 
☐ Yes, please specify which vitamin or mineral tablet(s) you are taking? 
Please answer in the table below. Use a separate row for each tablet you took, 





   On how many DAYS PER WEEK have you taken it:  






















EXAMPLE 1:        







   
EXAMPLE 2:        
Thompson’s   1 5 5 0 0 0 






   
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        





18.  Do you have any medical conditions (including allergies)?   
☐ No 





________________       
19.  Are you on any medications currently?    
☐ No 







20.   BEFORE you became pregnant, did you smoke cigarettes? 
 ☐ yes, but I stopped because I was trying to become pregnant  
 ☐ yes 
 ☐ no, I don’t smoke cigarettes (Please go to question XX) 
 
33.  Since you have become pregnant, have you smoked cigarettes? 
 ☐ yes, but I stopped when I knew I was pregnant 
 ☐ yes  
 ☐ no  






Appendix 16. RCT – Recruitment questionnaire – after delivery 
The Vitamin D and breastfeeding study 
(2nd Visit) 
 
University of Otago 
Departments of Women’s and Children’s Health 








The answers from all women surveyed will be gathered together, and no 
individual answers will be published or passed on. If you do not wish to 
answer any of the questions, leave them blank. 
 
 Please note that all questions relate to your RECENT PREGNANCY, not 
previous pregnancies. 
 
 Most answers require a tick in a box, for example: 
 ☐ yes 
  no 
 ☐ not sure 
 Some questions require a written answer in the space provided. 
                                                     









Home address: ____________________________________ 
Tel: ____________________________________ 
 
1.  What was your age at Delivery?  ___________________ 
2. What is your height?    ___________________ 
3. What is your current weight?   ___________________ 
   
4.   Did you experience any pregnancy/birth complications?  
☐ No 







SUN EXPOSURE INFORMATION:  Mother 
5.  Do you wear any veiling?       
      ☐ No 
☐ Yes, please tick the appropriate category below (tick one only):   
☐ consistently covered – covered up, including arms, hair and neck, 
when  outdoors 
☐ inconsistently covered – did not usually cover fully in her own 
backyard/garden 
☐ uncovered – did not generally cover up arms, hair and neck when 




6.  In the LAST MONTH, on average, how many hours are you outside per 
day between 10 AM and 4 PM… on WEEKDAYS (Monday to Friday)? 
 
☐ 30 minutes or less 
☐ 31 minutes to 1 hour 
☐ 2 hours 
☐ 3 hours 
☐ 4 hours 
 
☐ 5 hours 
☐ 6 hours 
 
7.  In the LAST MONTH, on average, how many hours are you outside per 
day between 10 AM and 4 PM… on WEEKENDS (Saturday & Sunday)? 
 
☐ 30 minutes or less 
☐ 31 minutes to 1 hour 
☐ 2 hours 
☐ 3 hours 
☐ 4 hours 
 
☐ 5 hours 
☐ 6 hours 
For the following question, think about what you do when you are outside during the  
LAST MONTH 
 
               NEVER  RARELY   SOMETIMES   OFTEN  
ALWAYS 
 
8 How often do you wear SUNSCREEN?  ☐    ☐  ☐       ☐         
☐ 
 
9. How often do you wear a SHIRT WITH  
      SLEEVES tha cover your shoulders?...   ☐    ☐  ☐       ☐         
☐ 
 
10. How often do you wear a HAT?...    ☐    ☐  ☐       ☐         
☐ 
 




      or UNDER AN UMBRELLA? …     ☐    ☐  ☐       ☐         
☐ 
 
12. How often do you wear SUNGLASSES? ☐    ☐  ☐       ☐         
☐ 
 
13. How often do you spend time in the  




























VITAMIN AND MINERAL SUPPLEMENT INFORMATION 
14.  Are you taking any vitamin or mineral tablets?  
☐ No 
☐ Yes, please specify which vitamin or mineral tablet(s) you are taking? 
Please answer in the table below. Use a separate row for each tablet you took, 
fill in as many rows as you need to, and please tell the interviewer if you need 
more space. 
  
   On how many DAYS PER WEEK have you taken it:  






















EXAMPLE 1:        







   
EXAMPLE 2:        
Thompson’s   1 5 5 0 0 0 






   
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        




13. MEDICAL HISTORY: 
15.  Do you have any medical conditions (including allergies)?   
☐ No 





________________       
16.  Are you on any medications currently?    
☐ No 







17. Since you have become pregnant, have you smoked cigarettes? 
 ☐ yes, but I stopped when I knew I was pregnant 
 ☐ yes  
 ☐ no 
 ☐ not sure 
 
18. Since you delivered have you smoked cigarettes? 
☐ yes  







Babies Study Recruitment Questionnaire    Date: 
_______________ 
Babies Study ID:   _________________ 
 
1. Infant name: 
4. Infant Date of Birth:      ___________________ 
5. What was your estimated due date?  ___________________ 
6. Infant Gestational Age (e.g. 40 weeks)? ___________________ 
7. Birth Weight (kg):     _______ 
8. Birth length:     _______ 
9. Birth Head Circumference:   _______ 
9. Current Age:      ___________________ 
10.  Current weight:     ___________________ 
11. Current Length:     ___________________ 
12. Current Head Circumference:  _______ 
13. Exposure to formula? 
☐ No 






SUN EXPOSURE INFORMATION:  Baby 
 
14. In the LAST MONTH, on average, how many hours is your baby outside 
per day between 10 AM and 4 PM… on WEEKDAYS (Monday to Friday)? 
 
☐ 30 minutes or less 
☐ 31 minutes to 1 hour 




☐ 3 hours 
☐ 4 hours 
 
☐ 5 hours 
☐ 6 hours 
 
15.  In the LAST MONTH, on average, how many hours is your baby outside 
per day between 10 AM and 4 PM… on WEEKENDS (Saturday & Sunday)? 
 
☐ 30 minutes or less 
☐ 31 minutes to 1 hour 
☐ 2 hours 
☐ 3 hours 
☐ 4 hours 
 
☐ 5 hours 
☐ 6 hours 
 
The following question refers to sun exposure habits for your baby:  
when outside during the LAST MONTH 
 
 
               NEVER  RARELY   SOMETIMES   OFTEN  
ALWAYS 
 
16. How often do you use SUNSCREEN?...  ☐    ☐  ☐       ☐         
☐ 
 
17. How often does he/she wear a SHIRT WITH  
      SLEEVES that covers shoulders/arms? ☐    ☐  ☐       ☐         
☐ 
 
18. How often do you use a HAT?...    ☐    ☐  ☐       ☐         
☐ 
 
19. How often does he/she stay in the SHADE  
      or UNDER COVER? …      ☐    ☐  ☐       ☐         
☐ 
 











________________       
 
21.    Is you baby on any medications/supplements currently (or at any time 
since delivery?   
☐ No 






















Appendix 17. RCT – Recruitment questionnaire – final visit 
The Vitamin D and breastfeeding study 
 
University of Otago 
Departments of Women’s and Children’s Health 








The answers from all women surveyed will be gathered together, and no individual answers 
will be published or passed on. If you do not wish to answer any of the questions, leave them 
blank. 
 Please note that all questions relate to your RECENT PREGNANCY, not previous 
pregnancies. 
 Most answers require a tick in a box, for example: 
 ☐ yes 
  no 
 ☐ not sure 




Study Recruitment Questionnaire     Date: 
_______________ 




Home address: ________________________________________________   
Tel: ____________________________________ 
Midwife:  ____________________  Phone: ____________________ 
G.P. ____________________  Practice: ____________________ 
 
1.  What was your age at your last birthday? ___________________ 
2. What is your height?    ___________________ 
3. What is your current weight?   ___________________ 
4. What was your weight before pregnancy? ___________________ 
5.  How many times have you been pregnant?  
 ☐ once, including my recent pregnancy 
 ☐ more than once (Please specify number of times) ___________________ 
6.  How many birth children do you have?  ___________________ 
7. How many weeks pregnant are you?   ___________________ 
8. What is your estimated due date?    ___________________ 









_____________________________________   
10.  Which country were you born in? ________________________ 
If you were NOT born in New Zealand, in what year did you arrive? ____________ 
 
11.  Which ethnic group do you belong to?  
Please tick the box or boxes that apply to you. 
 ☐ New Zealand European  
 ☐ Māori  
 ☐ Samoan 
 ☐ Cook Island Maori  
 ☐ Tongan 
 ☐ Niuean 
 ☐ Chinese 
 ☐ Indian 
☐ other such as Dutch, Japanese, Tokelauan (Please specify) 
________________________________________________________ 
12. Which ethnic group does the father of your baby belong to? 
Please tick the box or boxes that apply to him. 
 ☐ New Zealand European  




 ☐ Samoan 
 ☐ Cook Island Maori  
 ☐ Tongan 
 ☐ Niuean 
 ☐ Chinese 
 ☐ Indian 
☐ other such as Dutch, Japanese, Tokelauan (Please specify) 
________________________________________________________ 
13.  Which country was the father of your baby born in? ______________________ 
If he was NOT born in New Zealand, in what year did he arrive? ____________ 
 
14.  What is your marital status? 
 ☐ married 
 ☐ de facto (living with a partner) 
☐ separated / divorced 
 ☐ widowed 
 ☐ in a relationship, but NOT living with a partner 
 ☐ single 
 
15.  What is the highest education qualification you have completed? 
 ☐ left before high school 




 ☐ completed high school to year 12 (Sixth Form Certificate) 
 ☐ completed high school to year 13 (University Bursary) 
 ☐ further training (for example, apprenticeship) 
 ☐ tertiary (diploma or degree) 
 ☐ postgraduate qualification (Master’s or PhD) 
 ☐ other (Please specify) ___________________________________ 
 
SUN EXPOSURE INFORMATION: 
17.  Do you wear any veiling?       
      ☐ No 
☐ Yes, please tick the appropriate category below (tick one only):   
☐ consistently covered – covered up, including arms, hair and neck, when  outdoors 
☐ inconsistently covered – did not usually cover fully in her own backyard/garden 
☐ uncovered – did not generally cover up arms, hair and neck when outdoors   
18.  In the LAST MONTH, on average, how many hours are you outside per day between 
10 AM and 4 PM… on WEEKDAYS (Monday to Friday)? 
 
☐ 30 minutes or less 
☐ 31 minutes to 1 hour 
☐ 2 hours 
☐ 3 hours 





☐ 5 hours 
☐ 6 hours 
 
19.  In the LAST MONTH, on average, how many hours are you outside per day between 
10 AM and 4 PM… on WEEKENDS (Saturday & Sunday)? 
 
☐ 30 minutes or less 
☐ 31 minutes to 1 hour 
☐ 2 hours 
☐ 3 hours 
☐ 4 hours 
 
☐ 5 hours 
☐ 6 hours 










               NEVER  RARELY   SOMETIMES   OFTEN  ALWAYS 
 
20. How often do you wear SUNSCREEN?...  ☐    ☐  ☐       ☐         ☐ 
 
21. How often do you wear a SHIRT WITH  
      SLEEVES tha cover your shoulders?...   ☐    ☐  ☐       ☐         ☐ 
 
22. How often do you wear a HAT?...    ☐    ☐  ☐       ☐         ☐ 
 
23. How often do you stay in the SHADE  
      or UNDER AN UMBRELLA? …     ☐    ☐  ☐       ☐         
☐ 
 
24. How often do you wear SUNGLASSES? ☐    ☐  ☐       ☐         ☐ 
 
25. How often do you spend time in the  








VITAMIN AND MINERAL SUPPLEMENT INFORMATION 
26.  Are you taking any vitamin or mineral tablets?  
☐ No 
☐ Yes, please specify which vitamin or mineral tablet(s) you are taking? 
Please answer in the table below. Use a separate row for each tablet you took, fill in as many 





















   On how many DAYS PER WEEK have you taken it:  






















EXAMPLE 1:        







   
EXAMPLE 2:        
Thompson’s   1 5 5 0 0 0 
Vitamin C        
YOUR ANSWER(S):        
        
        
        
        
        
        
        




14. MEDICAL HISTORY: 
18.  Do you have any medical conditions (including allergies)?   
☐ No 
☐ Yes, please specify: 
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________      
19.  Are you on any medications currently?    
☐ No 




20.   BEFORE you became pregnant, did you smoke cigarettes? 
 ☐ yes, but I stopped because I was trying to become pregnant  
 ☐ yes 
 ☐ no, I don’t smoke cigarettes (Please go to question XX) 
 
33.  Since you have become pregnant, have you smoked cigarettes? 
 ☐ yes, but I stopped when I knew I was pregnant 
 ☐ yes  
 ☐ no 
 ☐ not sure 
